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In Africa, Prostate cancer (PCa) is the most frequently diagnosed solid organ tumour in males 
and use of prostate specific antigen (PSA) is presently fraught with diagnostic inaccuracies. Not 
least, in a multi-ethnic society like South Africa, proteome differences between African, 
Caucasian and Mixed-Ancestry PCa patients are largely unknown. Hence, discovery and 
validation of affordable, non-invasive and reliable diagnostic biomarkers of PCa would expand 
the frontiers of PCa management. We have employed two high-throughput proteomics 
technologies to identify novel urine- and blood-based biomarkers for early diagnosis and 
treatment monitoring of prostate cancer in a South African cohort as well as elucidate proteome 
differences in patients from our heterogeneous cohort. We compared the urinary proteomes of 
PCa, Benign Prostatic Hyperplasia (BPH), disease controls comprising patients with other 
uropathies (DC) and normal healthy controls (NC) both by pooling and individual discovery 
shotgun proteomic assessment on a nano-Liquid chromatography (nLC) coupled Hybrid 
Quadrupole-Orbitrap Mass Spectrometer platform. In-silico verification of identified biomarkers 
was performed using the Human Protein Atlas (HPA) as well as SRMAtlas; and verified 
potential biomarkers were experimentally prevalidated using a targeted parallel reaction 
monitoring (PRM) proteomics approach. Further, we employed the CT100+ antigen microarray 
platform to assess the differential humoral antibody response of PCa, DC and BPH patients in 
our cohort to a panel of 123 tumour-associated cancer antigens. Candidate antigen biomarkers 
were analyzed for ethnic group variation in our cohort and potential cancer diagnostic and 
immunotherapeutic inferences were drawn. Using these approaches, we identified 5595 and 9991 
non-redundant peptides from the pooled and individual experiments respectively. While nine 
proteins demonstrated ethnic trend, 37 and 73 proteins were differentially expressed by pooled 
and individual analysis respectively. All 32 verified biomarkers were prevalidated with parallel 
reaction monitoring. Good PRM signals for 12 top ranking biomarker was observed, including 
PSA and prostatic acid phosphatase. We also identified 41 potential diagnostic and 
immunotherapeutic antigen biomarkers. Proteogenomic functional pathway analyses of 
differentially expressed antigens showed similar enrichments of biologic processes. We 
identified herein novel urinary and blood-based potential diagnostic biomarkers and 




CHAPTER 1: GENERAL INTRODUCTION 
 
1.1. Functional Anatomy of the Prostate Gland 
 
The prostate gland (PG) is a compound tubule-alveolar accessory exocrine organ 
of the male genitourinary system. Its name is derived from the Greek word 
“προστάτη”, which stands for “the one standing in front” 
(http://etymonline.com/?term=prostate) due to its position below the bladder in 
the pelvis (Fig. 1.1). It is typically the size of a walnut/chestnut in healthy 
individuals, and weighs about 7-16g with a mean of ca. 11g [1]. It secretes and 
stores a moderately alkaline fluid (seminal plasma) which provides about 50-
75% of the volume of the human semen (~3mL). This fluid is important for 
preserving the lifespan of the spermatozoa as well as liquefaction of the semen. 
The function and development of the PG is regulated by androgen hormones [2, 
3] such as dihydrotestosterone (DHT), testosterone,  
 
                     
Figure 1.1 Sagittal section of the male pelvis showing the position of the prostate gland (http://www.webmd.com/) 
 
dehydroepiandrosterone, and dihydrotestosterone (Fig. 1.2). 
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Anatomically, it is a cone shaped gland made up of smooth muscles, epithelium 
and connective tissue [4]. The PG base is located cephalad against the neck of 
the bladder and its apex is directed backward towards the urogenital diaphragm. 
Its posterior surface is separated from the rectum by the recto-vesical septum. 
The anterior aspect is bounded by the retro-pubic space (containing a venous 
plexus) which separates it from the pubic symphysis. The levator ani muscle and 
a venous plexus faces its lateral wall [4]. The prostatic urethra passes through the 
PG and the seminal vesicles and bulbourethral glands are proximally linked to it 
as well. The front of the PG shows the urethral crest, seminal colliculus and the 
prostatic sinus into which the prostatic duct opens.  
 
                                  
        Figure 1.2. Peripheral and central hormone effect on the prostate gland (prostatesupplementguide.com)  
 
The PG can be divided anatomically into lobes [5] viz. two lateral lobes that 
extends to all zones, a posterior lobe, an anterior lobe also referred to as the 
“isthmus” which is anterior to the prostatic urethra, and a median lobe which is 
posterior to the prostatic urethral and flanked by the two ejaculatory duct on 
either sides. The posterior lobe (PL) corresponds approximately to the peripheral 
zone, while the median (ML) and anterior (AL) lobes correspond to the central 
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and transitional zones respectively (Table 1.1). However, the lobar classification 
is not well delineated in adult prostate tissue. Hence, in recent times, zonal 
anatomic classification of the prostate gland has also emerged. Using the zonal 
anatomic model by McNeal [6], the PG is divided into 3 glandular zones with an 
anterior fibromuscular component without glandular components. The three 
major zones are: peripheral, central and transitional zones. The peripheral zone 
accounts for about 70% of the gland, while the central and transition zones 
account for about 25% and 5% respectively. Nearly 70-80% of prostate cancer 
(PCa) occurs in the peripheral zone and about 10-20% in the transitional zone. 
Only about 2.5% of PCa occurs in the central zone, and tend to be more 
aggressive. Most benign prostatic hyperplasia (BPH) occurs in the transitional 
zone which is known to grow throughout life.  
 
      
                                         Table 1.1 Lobes and zones of the prostate gland 
 
The role of numerous secreted components of the seminal plasma is unclear 
except for a few enzymes (including Kallikrein (KLK) 3, also known as 
prostate-specific antigen (PSA)) which are known to participate in the seminal 
plasma enzymatic clotting and lysis cascade [7]. PSA is a serine protease which 
is known to cleave the clotting protein semenogelin (I & II) [7], which is an 
important component of the seminal coagulum. Prostatic fluids have also been 
found to contain prostaglandins, zinc, potassium, citric acid and several proteins 
and poly-/oligo-peptides [8]. These substances have been found to possess 
antimicrobial properties as well as improve sperm motility and viability.  
Inadvertent resection of the bladder neck involving the distal urethral sphincter 
or the periprostatic neuro-vasculature may result in urinary incontinence and 
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impotence respectively [9]; albeit the PG is not an essential organ to life and can 
be totally resected during radical prostatectomy without life-threatening 
implications [10]. 
Histologically, there is no characteristic separation of acinar and ductal 
structures as found in most other glands of the body. The normal prostatic 
epithelium is typically divided into two cellular layers comprising of an 
androgen dependent secretory luminal layer and an androgen independent basal 
epithelial layer [11]. These two layers are scantily interspersed by a small 
population of cells called the transit-amplifying or neuroendocrine (NE) cells 
[12] which have sensory and endocrine attributes and are hypothesized to 
originate embryologically from prostatic stem cells and are able develop into 
luminal or basal cells and hence are involved in growth and differentiation of the 
PG. Aggressive prostate cancer (PCa) growth or progression can lead to 
differentiation of PCa cell into a more androgen-refractory “NE-like” phenotype 
[13, 14]. This malignant phenotype promotes anti-apoptotic properties by 
perturbation of survivin as well as neoangiogenesis via vascular endothelial 
growth factor (VEGF) augmentation [15].  Under benign conditions, the basal 
epithelial layer separates the luminal layer from the basement membrane and the 
absence of basal layer is highly suspicious of malignant invasion of cancer cells. 
In addition, the adult PG demonstrates a branching acinar-ductal system within a 
dense fibro-muscular connective tissue stroma.  
Immunohistochemically, the luminal layer is positive for PSA, prostatic acid 
phosphatase (ACPP), androgen receptor (AR), vimentin, CK8, and CK18 [16]; 
while the basal layer is negative for all these immunohistochemical markers and 
NE cells are positive for ACPP and chromogranin-A. In addition, distinct cell 
types with unique immunohistochemical properties in comparison with benign 
or normal prostatic epithelium are found during cancer development in the PG. 
Embryogically, the dual origin of the PG stems from the fact that contiguous 
structures such as the ejaculatory ducts, seminal vesicle, epididymis, and vas 
deferens; as well as the central zone of the PG are hypothesized to originate from 
the mesodermal Wolffian duct, while the rest of the PG is derived from 
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endodermal invagination into surrounding mesenchyme [17]. The primordium 
for the future PG, the urogenital sinus (UGS) develops around the 9-11th week of 
embryonic life and the primitive testis stimulates endodermal bud ingrowths into 
the UGS [18]. Androgens then cause the UGS epithelium to differentiate into 
prostatic ducts around the 13th week [19], while peri-ductal smooth muscles are 
formed by the urogenital mesenchyme. Around the 20-30th week of gestation, a 
solid bud which is made of central spindle cells and peripheral columnar cells 
appears at the distal end of the ducts. Between 30-35th weeks of gestation the 
gland undergoes tubulo-alveolar differentiation and develops a lobular 
architecture [19, 20]. There is a resting phase for PG enlargement after birth, 
albeit budding morphogenesis and ductal proliferation does not cease; androgen 
dependent glandular enlargement and maturation is resumed again in the peri-
pubertal teenage years.  
1.2. Basic Concepts in Cancer 
 
Cancer is a multifactorial disease which has a variable incidence, mortality, and 
prevalence rate in different populations globally. Chemical carcinogens such as 
beryllium, arsenic, benzene, asbestos, cadmium, chromium, nickel, ethylene 
oxide, radon and vinyl chloride have been shown to demonstrate reasonable 
evidence of involvement in cancer development [21, 22].  
Cancers can also be inherited in an autosomal dominant manner [23]. A few 
examples of inherited cancer syndromes include: Li Fraumeni Syndrome (p53), 
retinoblastoma (Rb), hereditary non-polyposis colon cancer (MSH2, MSH6, 
MLH1), Familial adenomatous polyposis coli (APC) and breast cancer (BRCA1 
and BRCA2). Autosomal recessive inheritance of DNA repair defects includes: 
Bloom syndrome, Fanconi anaemia, xeroderma pigmentosum and ataxia-
telangiectasia [23].  
Normal growth regulatory genes are typically proto-oncogenes, tumour 
suppressor genes, DNA repair genes and Apoptotic genes [23]. Tumour 
suppressor genes can be promoters (e.g. p53 and Rb) or caretaker genes which 
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preserve the integrity of the genome and prevent the development of mutator 
phenotypes. Two landmark papers that described the major hallmarks of cancer 
were published by Hanahan and Weinberg in 2000 and 2011. Their earlier paper 
described the six major hallmarks of cancer cells which were: limitless 
replicative potential, evading apoptosis, insensitivity to anti-growth signals, self-
sufficiency in growth signals, sustained angiogenesis, and tissue invasion/ 
metastasis [24]. In their second paper, four additional emerging hallmarks of 
cancer cells were added viz. deregulating cellular energetics, avoiding immune 
destruction, tumour-promoting inflammation and genome instability/ mutation 
[25]. Clearly these 10 hallmarks (Fig. 1.3) do not occur in all cancer cell types at 
all times [26] and changes in the tumour microenvironment and potential for 
stromal metabolic reprogramming of tumour cells needs to be carefully 
considered [27].  
Another important consideration is intra-tumour heterogeneity (ITH) or inter-
biopsy heterogeneity which suggests that multiple genetic mutation and 
phenotypes of cancer can be found in the same cancerous lesion. This was well 
demonstrated by Gerlinger et al [28] using multi-region sequencing of renal 
cancer biopsies. ITH in clonal expansion of cancer stem cells was shown by 
these authours to follow a Darwinian evolution pattern. Cancer progression and 
development of ITH is dependent on factors like growth rate, invasiveness, 
hormones, metastatic potential, karyotype and responsiveness to anticancer 
drugs. An important theory for cancer cell expansion is the “cancer stem cell” 
theory, which presupposes that only a fraction of the cancer cells, known as stem 
cells drive tumour expansion [29]. Cancer biology is indeed enigmatic and 
multiple pathways and processes are involved in its pathogenesis. 
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Figure 1.3. Ten essential hallmarks of Cancer are: limitless replicative potential, evading apoptosis, insensitivity to anti-
growth signals, self-sufficiency in growth signals, sustained angiogenesis, tissue invasion/ metastasis, deregulating 
cellular energetics, avoiding immune destruction, tumour-promoting inflammation and genome instability/mutation. 
Although all ten do not occur in all cancer cell types at all times.  (adapted from [25]) 
 
1.3. Prostate Cancer 
Analogous to cancer at any other site in the body, prostate cancer (PCa) is an 
uncontrolled, abnormally disordered malignant growth of tissue in the PG, which 
is found only in men. It could be a small growth limited to the PG in which case 
it is referred to as localized; or it could gradually enlarge and invade adjacent or 
distant structures (Fig. 1.4). Early detection and treatment of PCa while it is still 
localized is important for better disease outcome. Some prostate cancers grow 
very slowly and may not be problematic for many years after its diagnosis, while 
some may run a very aggressive course and spread to other organs shortly after 
detection. Factors responsible for indolent or aggressive phenotypes of PCa are 
poorly understood. The risk of developing PCa significantly increases after the 
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age of 40 years [30]. Even without any form of treatment, PCa often runs a 
protracted natural history and many men die with it rather than from it [31]. 
 
             
                                  Figure 1.4. Stages of progression of prostate cancer (www.cancer.gov) 
1.3.1. Prostate Cancer Epidemiology 
 
PCa is a leading cause of death in elderly males globally. Over a million new 
cases are reported annually according to the GLOBOCAN/ IARC 2012 
databases, second only to lung cancer. According to this database, PCa is the 
fifth leading cause of cancer death in men globally, accounting for up to 307,000 
deaths annually [32]. It was reported by this global cancer statistics database to 
have the highest incidence (59,493), mortality (42,802) and 5 year prevalence 
rate (155,028) in Africa.  
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This high incidence, mortality and 5-year prevalence trend is similar whether 
you look at sub-Saharan Africa, Southern Africa or the Republic of South Africa 
(http://globocan.iarc.fr/). In contrast to the situation in the developed world, 
where high incidence and low mortality reflect the efficacy of the early diagnosis 
and prompt treatment; most of cases are diagnosed at advanced stages in Africa 
and the incidence and mortality rates are almost at similar levels in Middle, 
Western, and Eastern Africa (Fig. 1.5).   
                




Possibly due to a relatively higher level of development and infrastructure in 
South Africa, PCa incidence is quite high compared to the rest of Africa (Fig. 
1.6); but unfortunately, mortality rates in this region are high as well (Fig. 1.7).  
 
 
Figure 1.6. Map of Global Incidence of PCa (http://globocan.iarc.fr/) 
 




The fact that South Africa has a high incidence rates of PCa similar to those in 
North America, Western Europe and Australia (Fig. 1.6) but a high mortality 
rate comparable to most other sub-Saharan African countries (Fig. 1.7) may 
indicate that despite having a relatively better diagnostic infrastructure; 
manpower and resources are lacking to manage the huge burden of diagnosed 
PCa cases.  
1.3.2. Aetiological/ Risk factors 
 
Even though the main causative factors for prostate carcinogenesis are poorly 
understood, several aetiologic and risk factors have been suggested to be closely 
associated with PCa development. Three important non-modifiable risk factors 
suggested for PCa are positive family history of PCa, age and racial profile. On 
the other hand, modifiable risk factors include obesity, smoking, alcohol 
consumption, androgens, diet, and diabetes mellitus, inter alia. Men over the age 
of 40 and men of African descent are at greater risk of developing PCa compared 
to their Caucasian counterparts. Men of Asian origin have the least risk of 
developing PCa, albeit their risk increases when they migrate to North America 
[33], as most North American diets are richer in meat and animal fat compared 
with fruit and vegetables.  
Large studies have shown that red meat consumption and total fat intake 
significantly increases the risk of developing PCa [34]. Dietary consumption of 
red tomatoes rich in antioxidant carotenoid lycopene [35]; cruciferous vegetables 
rich in isothiocyanate sulforaphane, which has chemoprotective properties [36]; 
and other antioxidant nutrients such as vitamin E [37] and selenium [38] have 
been found to correlate with reduced PCa risk. High consumption of soy 
products rich in isoflavinoids in eastern Asia has been suggested to be 
responsible for reduction in PCa risk compared to the western world [39]. Body 
mass index has been show to correlate with risk of advanced PCa, albeit no 
correlation was found for localized disease [40]. Many other studies have 
investigated the effect of various diets on PCa risk including green tea [41], fish 
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[42] and dairy products [43], inter alia. Even though PCa has been shown not to 
be related to alcohol consumption by some studies [44], binge drinking was 
shown to increase its risk [45]. Smoking, which exposes individuals to 
polycyclic aromatic hydrocarbons has been demonstrated to increase the 
mortality risk in PCa by 14% in a meta-analysis of twenty-four cohort studies 
[46].  
Many studies have indicated that there is an inverse relationship in the risk of 
developing PCa and type II diabetes mellitus, despite the presence of 
hyperinsulinemia [47]. Hereditary and genetic factors have been suggested to 
play a role in PCa development. An inherited PCa susceptibility gene locus on 
1q24–25 (HPC1) has been well researched. Some other susceptibility genes that 
have received PCa research attention include MSR1 (8p22), RNASEL (1q25), 
CYP17, ELAC2, Androgen Receptor (AR) and steroid-5-α-reductase type II 
(SRD5A2) [48]. Hypermethylation of CpG island surrounding GSTP1 gene has 
been suggested to result in somatic defects in PCa leading to loss of “caretaker” 
effect of GSTP1 in PCa [49]. Other genes widely studied for somatic defects in 
PCa include PTEN, CDKN1B, and NKX3.1.  
Inflammatory prostatitis, including those that result from sexually transmitted 
infections (regardless of infective agent) have been reported to increase the risk 
of developing PCa [50, 51].  
1.3.3. Histopathology of Prostatic Diseases and Prostate Cancer 
 
Pathologic processes that affect the PG can be broadly divided into three viz 
inflammatory processes, benign hyperplastic processes, and malignant tumours. 
Inflammatory processes include acute or chronic prostatitis, granulomatous 
prostatitis and chronic non-bacterial prostatitis. Acute bacterial prostatitis can be 
causes by Escherichia Coli (E.Coli), Staphylococci, Enterococci and other gram 
negative rods that cause urinary tract infections [52]. Granulomatous prostatitis 
can be caused by fungal or mycobacterial infection in immunocompromised 
patients. Non-bacteria prostatitis can be caused by bicycle riding, backflow of 
13 
 
urine into the prostate, irritation from chemicals, nerve problems and viruses. 
Benign hyperplastic processes include benign nodular hyperplasia and benign 
prostatic hyperplasia (BPH). The major suggested aetiologies for benign 
hyperplastic processes, demonstrated in canine PGs involves imbalance between 
the normal ratio of oestrogen and androgens [53], which leads to autocrine 
stimulation of stroma cells and paracrine stimulation of neighbouring epithelial 
cells by testosterone.  
Prostatic tissue that begin to demonstrate signs of cellular atypia are potentially 
malignant or precancerous and are generally referred to as prostatic 
intraepithelial neoplasia (PIN), which can either be low (LGPIN) or high grade 
(HGPIN). Generally speaking, potential for cancer development in LGPIN and 
high HGPIN are low and high respectively, albeit PIN is a well-established 
precursor of PCa [54]. Invasive carcinomas of the prostate are the commonest 
malignant lesions of the prostate; and acinar adenocarcinomas constitutes ca. 90-
95% of all adenocarcinomas [55].  
Common acinar variants include pseudohyperplastic, oncocytic, mucinous, 
foamy, atrophic, lymphoepithelioma-like and signet ring; while non-acinar 
variants include squamous and adenosquamous carcinomas, urothelial 
carcinomas, sarcomatoid carcinomas, basal cell carcinomas, neuroendocrine 
carcinomas, and ductal carcinomas [55].  
Carcinomas of the prostate can be diagnosed as an unexpected finding during 
autopsy in which case it is referred to as latent; can be an incidental finding after 
endoscopic trans-urethral resection of prostate (TURP) for a BPH; can present 
with evidence of metastasis without a discernible primary lesion in which case it 
is called occult; and it can be clinically evident and detectable by routine 
investigation. 
1.3.4. Histologic Classification and Grading of Prostate Cancer 
 
Grading and classification of disease enables clinicians to understand the 
severity or aggressiveness of disease and allows for international standardization 
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of nomenclature. In addition, it aids in the determination of the best treatment 
option for disease. The Gleason’s grading is the most widely used grading 
system for PCa, and more recently, the World Health Organization (WHO) has 
developed an international histologic classification system for tumours of the 
prostate.  
1.3.4.1. Gleason’s Grading and Scoring System 
 
Based on architectural features of hematoxylin and eosin (H&E) slides under the 
light microscope at low power magnification, Donald F. Gleason developed a 
grading system for PCa in 1966 using a small cohort of PCa patients; and this 
was further revised in 1974 and 1977 using a larger cohort [56]. In this grading, 
PCa samples fell into one of five grades (1-5). Increasing grade corresponded to 
severity of malignancy and degree of differentiation (Fig. 1.8).  
Nine architectural patterns of PCa were merged into 5 major groups [57]. The 
Grade 1 is the best differentiated, while grade 5 is the worst differentiated 
histopathologically; and other grades fall in between these extremes. Gleason 
score is derived from this grading system by adding the Gleason grades of the 
most common and the second most common patterns found in a tumour sample.  
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                                             Figure 1.8. Gleason’s grading system for prostate cancer (adapted from [57]) 
1.3.4.2. WHO Histologic Classification 
 
In 2004, the WHO histologically classified tumours of the prostate to include 
various primary and metastatic tumours. Different classes of tumours were 




Figure 1.9. World Health Organization’s histological classification of tumours of the prostate 2004 (www.iarc.fr) 
1.3.5. Clinical Staging of Prostate Cancer 
 
Beside the use of pathological staging/grading, clinical staging which is often 
employed by clinicians, can be used to predict the outcomes and to formulate the 
appropriate treatment for various stages of disease. Older methods of clinical 
staging such as Jewett and Whitmore scheme (a.k.a ABDC) is still in use by 
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some clinicians. Currently, the most common clinical staging system for PCa 
developed by the WHO is the TNM staging system. “T” stands for the primary 
tumour, while “N” stands for nodal involvement, and “M” stands for distant 
metastasis. A summary of the TNM classification is shown in Figure 1.10. 
 
                                         Figure 1.10. TNM staging of prostate cancer (www.iarc.fr) 
 
As shown, various combinations of the T, N and M components have been used 
to classify PCa into clinical stages I to IV. The American Joint Committee on 
Cancer (AJCC) has revised the TNM staging, putting into consideration the 
Jewett-Whitmore staging, Gleason score and Prostate-Specific Antigen (PSA) 
level (Table. 1.2). This classification was advanced to create a multiparametric 




                               Table 1.2. AJCC staging of Prostate Cancer (http://prostatecancerinfolink.net/) 
 
1.3.6.  Diagnosis of Prostate Cancer 
 
An accurate diagnosis of PCa depends on a combination of good clinical history 
taking and appropriate investigations. The major clinical investigations that have 
aided the diagnosis of PCa tremendously are digital rectal examination (DRE), 
trans-rectal ultrasound (TRUS), biopsy, and measurement of blood levels of 
PSA. A DRE is done routinely as part of medical screening in men. The 
physician inserts a lubricated finger through anus of the patient being examined 
to palpate the posterior lobe of the prostate for lumps, hardness or any 
irregularities (Fig. 1.11).  
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                 Figure 1.11. Digital rectal examination of the prostate gland (http://www.prostatespecialist.co.uk/) 
 
TRUS uses an ultrasound probe to examine the PG and adjacent tissue tissues 
through the wall of the patient’s anus (Fig. 1.12). Both procedures involve 
insertion of either the lubricated finger or the ultrasound transducer into the anus 
of the patient. Biopsy procedures are carried out either trans-rectally, through the 
urethra, or the perineum (under ultrasound guidance); although trans-rectal route 
is the commonest. Needle cores are used to take multiple samples from different 
aspects of the PG for histopathologic diagnosis. Between 8 and 10 needle cores 
are recommended for adequate sampling of the PG. Biopsy procedures can be 
complicated by rectal bleeding, hematuria, prostatitis, hematospermia and 
epididymitis [58]. Serum PSA level measurement has been an important 
adjunctive biochemical test for the diagnosis of PCa. Generally, levels of PSA 
exceeding 4.0ng/mL may indicate the presence of PCa in a patient [59].  
20 
 
                     
           Figure 1.12 Trans-rectal ultrasound for prostate examination (http://www.eastcoasturology.com.au/) 
 
1.3.7. Treatment of Prostate Cancer 
 
Low risk (typically Gleason score 2-6, PSA level <10.0) or clinically localized 
PCa treatment options may be palliative or curative. Palliative measure may 
include watchful waiting and hormonal therapy; while curative measure includes 
active surveillance, radical prostatectomy and radical radiotherapy. Radical 
radiotherapy may include interstitial brachytherapy, intensity-modulate radiation 
therapy (IMRT), external beam therapy, proton beam therapy and 3D conformal 
radiation therapy. Active surveillance involves repeated biopsy and monitoring 
of PSA level particularly in PCA patients with a short PSA doubling time [60, 
61].  PSA doubling time is the number of months it would take for PSA level to 
increase by two-fold [60]; and PSA doubling time of < 12 months is regarded as 
high risk [62]. Even though often used interchangeably with watchful waiting 




Intermediate risk PCa (typically Gleason score 7, PSA level 10-20) is clinically 
localized PCa with extensive involvement of greater than half of one lobe of the 
prostate gland, or even bilaterally without extraprostatic or seminal vesicle 
spread. In these cases, dosage of radiation and hormonal deprivation therapy 
(which may involve surgical castration/ orchiectomy or chemotherapy) is often 
escalated, and combination therapy is sometimes employed. Intermediate grade 
PCa can also be treated surgically by radical prostatectomy with pelvic lymph 
node dissection.  
High risk PCa (typically Gleason score 8-10, PSA level >20), which involves 
extensive prostatic with extracapsular and seminal vesicle involvement is treated 
by a combination of radiotherapy and androgen deprivation therapy. High risk 
PCa can also be surgically treated with radical prostatectomy provided there is 
no fixation of tumour. Other methods of PCa treatment include cryosurgery [63], 
immunotherapy/vaccine therapy [64], and bone directed therapy [65]. An 
overview of the treatment of various stages of PCa is provided below (Table. 
1.3).  
Progression of PCa is characterized by changing from an androgen dependent 
PCa to an androgen refractory or castration resistant phenotype [66]. A few 
drugs currently approved for the treatment of metastatic castration resistant PCa 
includes: Docetaxel a taxoid mitotic inhibitor; Abiraterone an androgen 
synthesis inhibitor; Carbazitaxel a microtubule inhibitor; and Sipuleuce-T, an 
autologous immunotherapeutic agent raised against prostatic acid phosphatase 
(PAP).  
Emerging drugs in phase III clinical trials for PCa treatment include: MDV3100 
(enzalutamide) which is an androgen receptor antagonist; Orteronel (TAK-700) 
which blocks androgen synthesis by inhibiting the 17,20-lyase enzyme; 
Dasatinib (srcKI) an Src family kinase (SFK) inhibitor; clusterin chaperone 




                         Table 1.3. Overview of PCa treatment (www.medscape.com) 
 
1.4. Biomarkers and Prostate Cancer 
 
Biomarkers are measurable biologic, chemical, or physical characteristics or 
objective indicators of a normal biologic state, progress of disease, or response 
to drug therapy [69]. They can be nucleic acids, proteins or metabolites 
measurable in blood or other body tissues. An ideal biomarker should be safe, 
highly specific, sensitive, accurate in its detection ability, easily measurable and 
consistent across ethnicity and gender. The currently reported biomarkers of PCa 
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are very limited in terms of test characteristics; and in general there is a paucity 
of good biomarkers for early detection or prognosis of PCa. Even though the 
classification of biomarkers is currently under ongoing debate, cancer 
biomarkers can be classified into the following domains; diagnostic, prognostic, 
predictive, chemoprevention, screening, risk stratification, and post-treatment 
surveillance [70].  
Pharmacologic classes of cancer biomarkers include; target verification, 
pharmacodynamics assay, treatment selection for clinical trial, surrogate end 
point in drug approval and early compound selection [70]. Several biomarkers 
have been used for detection and treatment monitoring of PCa. A few previously 
described biomarkers of PCa includes: PTEN, PI3K, PCA7 gene panel, PSGR, 
MME, PSCA, PCA3, TMPRSS2-ERG gene fusion, CD98, EPCA, CD276, 
prostate-specific membrane antigen (PSMA), caveolin-1, EN-1, and annexin A3 
[71]. Some traditional, and a few emerging biomarkers of PCa are briefly 
described below: 
Acid Phosphatase (ACPP):  This is one of the oldest biomarkers used for PCa 
diagnosis in serum, however the drawback of this biomarker is that ACPP is 
expressed by both normal and malignant prostatic tissues, as well as 
extraprostatic tissues [72].  
Prostate-Specific Antigen (PSA): Also known as kallikrein 3 (KLK3), PSA is 
the most widely used biomarker of PCa and has tremendously improved the 
diagnosis of PCa. However, recent evidence indicates that PSA falls short in its 
diagnostic ability in the lower reference ranges (2-10 ng/mL). Even though 
highly sensitive, it is not so specific and has led to a lot of false positives, false 
negatives and overtreatment of PCa patients. To improve the diagnostic ability 
of PSA, several related parameters such as PSA doubling time, PSA velocity, 
free-to-total PSA ratio and prostate health index (PHI) have been explored [73].  
Prostate cancer antigen 3 (PCA3): Otherwise known as DD3 or differential 
display clone 3, PCA3 is a noncoding mRNA which is found to be highly 
abundant in malignant prostatic tissues in comparison to benign [74]. It is the 
most widely used non-PSA based biomarker for prostate cancer diagnosis [75]. 
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The PCA3 assays was developed to detect the urinary level of RNA transcripts 
which are contained in cells shed into the urine during micturition [76]. One 
limitation of this test is that it is dependent on the urinary PSA transcript 
expression level. 
TMPRSS2-ERG gene fusion: Transmembrane Protease, Serine 2– ETS fusion 
genes are members of the ETS family of genes, noted to be highly expressed in 
malignant prostatic tissue and not expressed in benign prostatic tissues. It was 
hypothesized to be a good indicator for PCa aggressiveness, however its 
expression in only about 50% of all PCa patients in Western studies [77], makes 
it a better marker of disease heterogeneity rather than a predictive or prognostic 
marker. It suffers the same drawback as PCA3 in that it depends on urinary PSA 
transcript levels for meaningful interpretation of result. 
Alpha methylacyl-CoA racemase (AMACR): Is a highly sensitive and specific 
diagnostic biomarker often used in PCa tissues. Low levels of AMACR in 
biopsy tissues have been associated with biochemical recurrence and PCa 
metastasis [78]. 
1.5. Personalized/ Omics-based Approaches in Prostate Cancer 
 
Omics based approaches seek to use high-throughput techniques to answer 
biologic questions in a systems-oriented manner. It interrogates the full 
complement of biomolecules in a cell, tissue or body fluid and examines their 
interaction rather than in isolation. Examples of omics based approaches include 
genomics, proteomics, metabolomics, lipidomics, epigenomics and 
pharmacogenomics, inter alia. Many of these approaches have been used to 
develop useful biomarkers for PCa; and it is expected that biomarkers generated 
from omics based approaches would benefit personalized or individualized 
diagnosis and treatment of PCa in no small measure.  
For example, a recently described classification of the seven possible genotypes 
of prostate cancer [79] based on TMPRSS2:ERG translocations (Fig 1.13) may 
25 
 
represent a more useful molecular classification of PCa (in terms of therapeutic 
options) than histologic classification. 
 
Figure 1.13. Graphical circos plot representation of seven PCa genomes based on TMPRSS2-ERG translocation. The 
outer ring and inner rings depict the genomic location and chromosomal copy number respectively. In the inner ring, red 
and blue indicates copy number gain and loss respectively. Interchromosomal translocations are represented in purple, 
while intrachromosomal rearrangements are shown in green. This picture shows genomic organization based on the 
absence (bottom row) and presence (top row) of the TMPRSS2-ERG fusion genes (adapted from [79]). 
 
1.6. Proteomics and Prostate Cancer Biomarkers 
 
The field of proteomics encompasses omics-based high throughput techniques 
for large-scale identification of the full complement of proteins in an organism, 
tissue, cells or body fluid. The field is also potentially able to investigate the 
functional states of proteins including, post-translational modifications, protein-
protein interactions; and protein interaction with other biomolecules such as 
carbohydrates, lipids and other metabolites. Proteomics can provide insight into 
protein structures, alternative splicing events, as well as aiding genome 
annotation. It is important to note, that there can be variations to the proteome of 
a cell depending on the time point, stage of disease, diet and a host of other 
factors. Currently, proteomics has been employed to identify clear, reproducible 
cancer-related signatures for early detection, diagnosis, or prognosis between 
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disease and healthy cohorts of patient [80-85]. However, the lack of 
standardization of validation methods among researchers; as well as non-
concordant experimental outcomes from independent research groups [75], has 
underscored the urgent need for systematic validation of proteomics biomarkers 
[86-88]. Notably, the most common proteomics methodologies are mass 
spectrometry-based proteomics and protein microarray technology based 
proteomics. Using these methodologies, a gamut of proteomics biomarkers of 
PCa have already been identified [89-95], and some were demonstrated to 
potentially predict progression and aggressiveness of prostate cancer [96-98]. 
However, successful application of omics based approaches is heavily dependent 
on available bioinformatics and computational biology resources.  
1.7. Liquid Biopsy in Prostate cancer diagnosis 
 
Tissue biopsy and surgical procedures are invasive and can potentially be 
accompanied by various complications. To minimize these complications, 
liquid/fluid biopsy technology has become an emerging hot spot in cancer 
research; because it is a less invasive and can isolate biomarkers from body 
fluids such as urine, saliva, ascites, blood, semen, cerebrospinal fluid (CSF) and 
pleural effusion [99]. Examples of biomarkers that can be isolated by the liquid 
biopsy approach include: proteins, microRNA, circulating tumour nucleic acid 
(ctNA), circulating tumour cells (CTC), exosomes, and long noncoding RNA 
(lncRNA) [100-102].  
This method is highly beneficial for personalized treatment of patients, and 
provides access to important information, even with a small amount of test 
sample. It also permits frequent monitoring of treatment response without the 
added cost of repeated surgical procedures. An important caveat is that liquid 
biopsy requires sophisticated equipment such as ultracentrifuges, DNA-
sequencing machines, and diagnostic kits. Not least, results generated are 
sometimes not reproducible between different research groups as a result of 
tumour heterogeneity [103-106]. Liquid biopsy has been used for diagnosis of 
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various cancer types [107-111], as well as PCa [112, 113]. Additionally, this 
technique has been found useful in cancer patient stratification, monitoring and 
screening [114].  
1.8. Urine as a Biomarker Source 
 
As an ultrafiltrate of blood, urine possesses analogous protein profiles with 
blood and provides a usable catalog of proteins for interpretation of 
pathophysiologic events in the human body [115]. Sampling urine, as compared 
to blood or prostatic tissue biopsy is a less invasive approach for PCa diagnosis 
and treatment monitoring; and the service of a skilled personnel is not required 
for urine sample collection. In addition to this, urine is abundantly available and 
permits repeated sampling [116], unlike the blood which has a fixed total body 
volume of approximately  five liters [117].  
Using this approach, the risk of blood-borne infections like human 
immunodeficiency virus (HIV) and hepatitis are minimal. Notably, the urinary 
proteome is less complex compared with the blood proteome; and not least, there 
is very little or no possibilities of proteolysis since urinary proteins are quite 
stable, having undergone all the possible proteolysis during storage in the 
bladder [116]. Hence there is little or no benefit of using protease inhibitors 
during storage [116]. Despite the fact that urine is a very promising disease 
biomarker source, a caveat is that its composition is variable depending on the 
time of the day, dietary intake and the state of health of the individual. Many 
urinary biomarkers of various diseases have been previously described [118], 
albeit only a few of these biomarkers make it to clinical use. 
1.9. Blood as a Biomarker Source 
 
The human blood is the most vital body fluid that is involved in the transport of 
oxygen and essential nutrients to different organs, tissues and cells as well as 
transporting metabolic waste away from them. Considering the extensive contact 
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of the blood with body structures, it is an attractive source of biomarker 
discovery. In addition, the increased discohesive nature of cancerous tissues 
sometimes makes tumour cells more mobile and allows them to be transported in 
the blood stream as tumour markers. Even though limited in volume, it is the 
most frequently used sample for clinical diagnosis of many disease conditions.   
Blood samples have been used to identify biomarkers of many human diseases 
including: Alzheimer’s disease [119], Parkinson’s disease [120], breast cancer 
[121], preeclampsia [122], and prostate cancer [74]. Moreover, it is also known 
that tumour-associated autoantigens (TAA) from cancerous conditions are able 
to stimulate the humoral immune response leading to the generation of auto-
antibodies [123]; and this has been demonstrated to drive cancer-specific 
autoimmunity in different human cancers including renal [124], colorectal [125], 
lung [126], and prostate cancer [127-131]. These autoantibodies have been found 
to have potential theranostic utilities for cancer diagnosis, immunotherapy and 
therapeutic vaccine target development.  
 
1.10. Historical Perspectives on Prostate Cancer in Men of African Descent 
 
The currently accepted hypothesis is that aggressive phenotypes of PCa are more common in 
men of African descent; albeit underlying factors for such aggressiveness are poorly understood. 
Beyond various suggested sociocultural issues such as poor funding [132], insufficient 
manpower and skilled health personnel [133], poor access to healthcare [134], religious and 
cultural beliefs [135], lack of well-updated cancer registries [136], poor research and healthcare 
infrastructure [137], low educational level [138], prevalence of infection [139, 140], poor 
governance structures and fiscal policies [141]; the underlying genetic, hereditary and 
environmental basis of PCa aggressiveness in men of African descent still warrants further 
research.  
Migration patterns of people in Africa may provide a clue to the high burden and aggressiveness 
of PCa in this population. Historically, humans appear to have lived longest on the African 
continent and preserved fossils of early men discovered at the “cradle of humankind” which is a 
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world heritage site in South Africa [142-145], alludes to that theory. Ever since the human 
hunter-gatherer populations in the late Pleistocene epoch were replaced by the human farmer or 
agro-pastoralist populations in the Holocene epoch [146, 147], mankind continues to evolve 
genetically, based on environmental exposure and necessity for survival. Unlike the nomadic 
hunter-gatherers who had low resistance to infections due to poor exposure, farmers had the 
advantage of developing immunity to disease breakouts and epidemics in their crowded farming 
settlements [147].  
Hence, a deeper consideration of the complex ancestry of the culturally and linguistically diverse 
African male population would improve our understanding of disease pathogenesis in this 
population. Albeit, it appears plausible that a complex interplay inter alia, of genetics, infection 
and environmental factors underlies the pathogenesis and aggressive phenotypes of PCa found in 
men of African descent, resulting in a disproportionately high PCa burden in sub-Saharan Africa 
[148]. Western studies have revealed that African-Americans have up to 20% of their genetic 
makeup mixed with Caucasian ancestry [149]; however, literature on the ancestral 
characterization of the highly heterogeneous indigenous African populations is scarce. 
Considering that even within sub-Saharan African populations, disparities exist in incidence and 
mortality of PCa in different countries [150].  
Many of the indigenous Africans who presently live in South Africa have been predicted to 
originate from people of Southern Bantu ancestry who migrated downward from the original 
Bantu Homeland [151] which is approximately between eastern Nigeria and western Cameroon 
[152]. Various genetic and phenotypic events have been attributed to the Bantu expansion [153]. 
Even though hunter-gatherers were lighter in skin tone, have child-like bodies and were often 
monogamous in lifestyle; agro-pastoralist tended to be polygynous [154]. In fact, polygamy rate 
as high as 20-50% has been reported in marriages across sub-Saharan Africa [155]. In such agro-
pastoralist societies, intense competition for female partners could result in Darwinian style 
sexual selection [156] in which females would prefer stronger, bigger and more masculine males. 
This may explain why men of African descent are often quite robust anthropometrically [157-
160]; albeit there are other sexually selected attributes that makes a mate attractive in humans 
such as intelligence [161-163], hair color [164], personality [165], immune function [166], 
natural eye gaze [167], and facial appearance [168] , inter alia. 
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Hormonal influences are hypothesized to play a part in male body morphology and behavioral 
patterns [169-171]. Hunter-gatherer descendants were observed to have lower levels of androgen 
hormones dihydrotestosterone (DHT) and total testosterone as compared to agro-pastoralist 
descendants in a study carried out in the Southern African region [172]. Besides evidence from 
Africa, it has been shown that the Ache hunter-gatherer men from Paraguay have a lower 
salivary testosterone level in comparison to western values [173]. Also, the Tsimane hunter-
gatherer populations from lowland Bolivia were shown to demonstrate a spike in their 
traditionally low testosterone level as a result of the introduction of horticultural tasks into their 
daily routine [174]. Evolutionary population variations in testosterone level and PCa disparities 
has been well discussed in a synthesis by Alvarado et al [175] .  Young men of African descent 
have been reported to have a higher level of testosterone than their Caucasian counterparts [176] 
and Asian men have been reported to have a low level of 5α-reductase activity [177]. Also, 
variations have been reported in androgen receptor activity between Africans, Caucasians and 
Asians [178]. (A comprehensive table of androgen level racial variation is provided in Annexure 
V) These may suggest some of the possible reasons for high incidence and mortality of PCa 
among men of African descent worldwide. Many questions around PCa remain unanswered. For 
example, it is difficult to tell with any currently available diagnostic aid/test if PCa would be 




1.11. Biorepository development in Africa 
 
Most ground breaking projects in the field of molecular biology such as: the Human Genome 
Project (HGP) [180]; The Cancer Genome Atlas (TCGA) [181]; Human Proteome Project (HPP) 
[182]; and Chromosome Centric Human Proteome Project (CHPP) [183]; have benefitted 
immensely from specimen biorepositories. The National Cancer Institute has described a 
biorepository as human specimen collection including relevant data for the purpose of research, 
and subject to relevant processes, ethics and policies [184, 185]. There are various standards that 
must be met in order to create a good biorepository. These include: proper annotation of 
specimens (including clinical information); ensuring ethical conduct and patient confidentiality; 
regulated centralized access to samples; and data-driven, in-silico research enablement of 
information generated from samples. Despite the gamut of biorepositories established in the 
Americas, Europe, Asia and Australia [186-188], very few such biobanks have been established 
in sub-Saharan Africa [189].  
Most biorepositories in Africa are established within an investigator’s research group and most 
are yet to be standardized and centralized. There is a growing need for collaborative efforts 
amongst researchers in Africa to smoothen the task of standard biorepository establishment. 
Several challenges have plagued biorepository development and regulation in sub-Saharan 
Africa [189-192]; albeit modest progress has been made in a few sub-Saharan African countries. 
The emergence of the H3Africa consortium, has improved the centralization and standardization 
of biospecimen collection in Africa [192]. Standardization of sample annotation in various 





1.12. Statement of problem 
 
Low and Middle Income Countries (LMICs) receive only around 5% of the 
global spending on cancer, despite carrying up to 80% of the Global cancer 
burden [132]. The burden of PCa is on the increase both globally and 
particularly in South Africa. According to the International Agency for Cancer 
Research on Cancer (IARC) in 2012, there were 1.1 million and 9,957 new cases 
of PCa reported globally and in South Africa respectively; making PCa the most 
diagnosed cancer in South Africa. During this period, there were 307,000 and 
3,539 PCa deaths reported worldwide and in South Africa respectively; making 
PCa the second leading cause of cancer deaths in South Africa.  
Estimated age-standardized incidence and mortality rates per 100,000 in all ages 
is high in South Africa as compared to the rest of Africa. Men of African descent 
have been known to carry aggressive phenotypes [193-195] of the disease and 
factors responsible for this racial disparity in PCa are poorly understood. In 
addition, there is significant under-reporting of PCa cases due to background 
sociocultural issues within the South African population. Not least, it is unclear 
what factors underpin the progression of PCa, i.e. “which PCa lesions will 
remain indolent, and which ones would evolve to a more aggressive phenotype?” 
Factors that make androgen dependent tumours transform into androgen resistant 
phenotypes are poorly understood. In addition, it is unclear why metastatic 
phenotypes of PCa have a predilection for osseous tissues in comparison to other 
tissues [179]. Use of PSA for diagnosis of PCa can be fraught with false 
negative, false positives and overtreatment especially in the reference range of 2-
10ng/ml.  
It is unknown if there is a difference between the proteomes of the whites, blacks 
and mixed ancestry PCa patients in South Africa and putative urinary 
biomarkers are yet to be validated in any African cohort of PCa patients. Thus, 
further research is required to elucidate the biology and characteristics of PCa, 
particularly within a heterogeneous cohort of Southern African PCa patients; and 
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novel diagnostic and therapeutic biomarkers of PCa urgently need to be 
developed. 
1.13. Study Hypotheses 
 
 Based on proximity, PCa cells may secrete proteins into the genitourinary 
tract which may be detected in urine. 
 There may be a variation in the humoral autoantibody response generated 
to PCa by different ethnicities within the South African population. 
 There may be subtle differences in the proteomics profile of the different 
racial groups within the South African PCa patient cohort based on 
environmental exposure. 
 
1.14. Project Aim 
 
“Urinary and serological biomarker discovery and prevalidation for prostate 
cancer biomarkers in South African patients using proteomics techniques” 
 
1.15. Specific objectives 
 
 Analyse the urinary proteome of South African patients for PCa biomarker 
discovery. 
- Use mass spectrometry based methods to investigate the urinary 
proteomes of PCa patients in South Africa. 
- Identify potential urinary biomarkers of prostate cancer in our South 
African cohort. 
- Compare the urinary proteomics profile of the different racial groups in 
South Africa within our cohort. 
- Use in-silico methods to verify identified candidate biomarkers and 




 Analyse the serum autoantibody repertoire of South African patients for 
PCa biomarker discovery. 
- Use a novel cancer-testis antigen protein microarray platform based 
methods to investigate the blood proteomes of PCa patients in South 
Africa. 
- Identify potential serological biomarkers of prostate cancer in our 
South African cohort. 
- Compare the serological proteomics profile of the different racial 
groups in South Africa within our cohort. 




CHAPTER 2: GENERAL MATERIALS AND METHODS 
2.1. Prostate Cancer Biorepository Development 
 
The study was carried out in collaboration with the Urology Department at the Grootes Schuur 
Hospital (GSH), a tertiary teaching hospital connected to the University of Cape Town Medical 
School. GSH urology unit operates in two satellite hospitals which are the New Sommerset 
Hospital (NSH) and the Eerste Rivier Hospital (ERH). One of the major goals of the project is to 
develop for research purposes; a South African cohort of patients biodata and biospecimen, 
drawn from a wide background of patients including indigenous Africans, Caucasians and Mixed 
Ancestries.  
2.1.1. Study Staff 
 
Being a multi-departmental study, staff in all units involved in the study participated in the 
development of this biorepository. Academic staff included specialists and lecturers in Urology, 
Anatomic Pathology and Medical Biochemistry; as well as registrars in Urology, post-and pre 
doctoral research fellows at the International Centre for Genetic Engineering and Biotechnology 
(ICGEB). Non-academic staff included Nurses at GSH, Research Technicians at ICGEB, and 
Medical Records (MR) staff. The whole project was conducted under the coordination and 
oversight of the principal investigator (PI) and Group Leader of the Cancer Genomics Group 
(CGG) at ICGEB. 
2.1.2. Cohort Recruitment Workflow 
 
A high level of coordination and communication between study staff in the ICGEB laboratory 
and the hospital is needed. Phone calls, text messages, social media messaging and emails were 
used as means of communication between the urology team, medical record team and the CGC 
during weekly schedules. A summarized overview of the patient recruitment and sample storage 
process is presented below (Figure 2.1). Regular meetings were held between the leaders and 
members of the different teams on how to improve the cohort size, patient recruitment and 
sample collection process. Periodic reorientation meetings were held with the academic and non-
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academic staff to update them on the purpose of the study. Patient information was kept 
confidential and encrypted throughout the duration of the study.                                
 





2.1.3. Study Protocol and Ethical Consent 
 
Study protocol clearly stated the purpose and objectives of the study as well as criteria for patient 
selection. The protocol describes the method of participant selection and how their safety and 
confidentiality would be ensured throughout the duration of the study. Detailed explanation of 
how and for how long samples would be collected and stored is included in the protocol; as well 
as the potential benefit of the study. Study was carried out only after full ethical approval by the 
Health Research Ethics Committee of the Faculty of Health Sciences, University of Cape Town. 
The ethics approval number is #HREC 454/2012. Study was carried out following standard 
ethical guidelines as embodied in the declaration of Helsinki [196-198]. Consent forms were 
made available in local languages like Xhosa, Zulu, Afrikaans and English. 
2.1.4. Patient Selection 
 
All patients were initially seen at Grootes Schuur Hospital before some were referred to the 
satellite hospitals for surgery. Consecutive patients scheduled to undergo Transurethral resection 
of prostate (TURP) or prostatectomy are approached for enrollment after counseling by the 
nursing staff. After full explanation of the content of the consent form, patients were allowed to 
ask questions and sign the consent form thereafter. Patients who were unwilling to participate 
after going through the consent form were excluded from the study. Inclusion criteria for PCa 
patients in this study were; patients who were being diagnosed with PCa for the first time, who 
(1) have not been previously treated for PCa, (2) have not had surgical orchiectomy or hormonal 
treatment (3) do not have any comorbidities such as arterial hypertension or diabetes, and (4) do 
not have history of any other cancer at any site in the body. Patients who decline to participate in 
the study for religious, cultural or personal reasons and those who do not have adequate clinical 
information were excluded from the study. Other patients recruited for the study were patents 
diagnosed with benign prostatic hyperplasia (BPH), and those diagnosed with other uropathies 
(DC) such as urethral stricture, kidney stones and prostatitis. In addition, urine samples were 
collected from age matched normal healthy individuals as control cohort (NC) after proper 
consent taking. Indigenous Africans, Mixed Ancestry patients and Caucasian African patients 
with PCa were enrolled in this study. Clinicopathologic information for each enrolled patient was 
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accessed through the National Health Laboratory Services (NHLS) database at the hospital. 
Weekly tasks were scheduled around preexisting clinical activities in the Urology unit; and a 
draft timetable of the weekly activities of the team is as described in the table below (Table 2.1). 
Establishment of standardized guidelines for sample processing and data storage aided good 
annotation of the cohort. Also, access to the progress of the study and “opt out” option was 
provided for all participants without any penalties. 
  8am-10am 11am-12pm 1pm-2pm 3pm-4pm Later than 4pm 
Monday ICGEB calls registrar and medical records 
at GSH, ERH and NSH 
    Sample processing 
and storage at 
ICGEB   ICGEB goes to GSH to consent patients   
ICGEB goes to NSH to collect TURP/ Prostatectomy samples 
ICGEB goes to ERH to collect TURP/ Prostatectomy samples 
Sample processing and storage at ICGEB 
Tuesday ICGEB goes to GSH to collect TURP/ Prostatectomy specimen Sample processing 
and storage at 
ICGEB 
Sample processing and storage at ICGEB 
Wednesday ICGEB goes to GSH to collect TURP/ Prostatectomy specimen Sample processing 
and storage at 
ICGEB 
Sample processing and storage at ICGEB 
Thursday Sample database update Sample processing 
and storage at 
ICGEB 
Sample processing and storage at ICGEB 
Friday ICGEB calls registrar and Interns at NSH/ GSH Sample processing 
and storage at 
ICGEB 
ICGEB goes to GSH to consent ERH and GSH patients and collect urine and 
blood samples at GSH 
ICGEB goes to NSH to consent patients and collect urine and blood samples 
Sample processing and storage at ICGEB 
                          Table 2.1. Draft time table of patient recruitment, sample collection and sample storage in the study. 
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Upon notification on Fridays from the hospital that a suitable participant has been identified for 
treatment at ERH or NSH, delegated member of the CGG drive about 16 minutes down to NSH 
which is about 8.8 km away from GSH (Figure 2.2); to consent patients and collect blood and 
urine samples. On Mondays, tissue samples are collected from the NHS surgical theatre for these 
patients, by CGG members who drive down to NSH with a dry ice box.  
 
 
                            Figure 2.2. Distance from GSH to NSH is about 8.8km and about 16 minutes of driving (www.google.co.za/maps) 
Blood and urine samples from the ERH patients are usually collected on Friday at the GSH 
clinic. On Monday, to collect the surgical tissue specimen, the CGG member then drives down to 
ERH which is about 29.6 km from GSH and takes about 29 minutes to drive (Figure 2.3). 
Samples are collected and preserved in a dry ice box on the journey back to GSH. All collected 
samples are immediately stored at the recommended temperature after appropriate processing 





                          Figure 2.3. Distance from GSH to ERH is about 29.6km and about 29 minutes of driving (www.google.co.za/maps) 
 
2.1.5. Cohort Characteristics, Demographics and Physical Samples 
 
African, Caucasian, and Mixed Ancestry patients who met the inclusion criteria of this study 
were enrolled and their ages ranged between 30-80 years and the cohort is slightly dominated by 
mixed ancestry population. Only urine samples were collected from normal healthy individuals 
who were drawn from a healthy population. Patients that declined participation for personal, 
religious or cultural reasons were excluded. The physical samples that were generated for the 
biorepository were blood, urine, surgical tissue, and FFPE samples. Samples were processed as 
described below and quality checks were performed to ensure that samples were of adequate size 
and are in good condition. For example, blood, tissue and urine samples with inadequate 
volumes/size were excluded. Samples that were drawn before arrival of the CGG member or that 
were collected and not appropriately stored were excluded as well. Samples that were collected 
in the wrong sample bottles were not banked and collected samples were carefully annotated 
with clinical information and the database is backed-up and periodically updated. Patient 
information is kept confidential and encrypted in order to eliminate bias and to comply with 
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international standard of study data confidentiality. Samples with incomplete annotation were 
excluded as well. 
2.2. Urine and Blood Sample Collection and Preparation 
 
In this study, both urine and blood samples were collected from patients. Urine was collected by 
voiding into a 50 mL collection tube, or collected directly from a catheter bag. Collected urine 
samples were stored in an ice box and transferred rapidly after collection to a -80⁰C freezer 
facility at the ICGEB within the premises of the Faculty of Health Sciences, University of Cape 
Town. Blood samples were intravenously drawn and collected in a 5ml K2-EDTA bottle and 
stored on ice before being transferred to a -80⁰C freezer facility as described above. Following 
the collection of urine and blood samples, they are processed as described below before 
proceeding to the analytical phases of the study. Quality control checks and assay optimization 
were ensured at every phase of the sample preparation process. Any sample that does not meet 
the standard in terms of sample volume and quality were excluded from further processing. 
2.2.1. Urine Sample Preparation 
 
Urine samples were centrifuged at 2000×g for 30 minutes; to remove cellular debris and particle 
precipitates [199, 200]. The supernatant was collected and protein extraction and digestion was 
performed on it.  
2.2.1.1. Protein Extraction  
 
Other contents of urine, such as lipids, peptides, salts, mucopolysaccharides, and 
oligosaccharides may interfere with the electrophoretic mobility of urinary proteins [201-204]; 
hence there is the need for concentration and purification of urinary proteins before analysis. 
There are various methods for urinary protein extraction including ultrafiltration, and organic 
solvent precipitation using acetone, isopropanol, ethanol, methanol/chloroform, tricholoracetic 
acid (TCA), and occasionally, a combination of these methods. The protein extraction method 
used here was the ultrafiltration method where a series of molecular weight cut-off (MWCO) 
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filters were used to concentrate urine samples. Solutions and reagents required are described 
below in Table 2.2. 
 
Solutions and  Reagents Preparation Description  
10% SDS Add 2.5g of SDS + 25ml of water 
0.5M Tris-(2-Carboxyethyl)phosphine  
(TCEP) (Sigma-Aldrich, St. Louis, MO, 
USA) 
Use as prepared 
0.1M Tris HCl Add 0.78795g of Tris HCl + 50ml of water (pH 8.5) 
0.55M iodoacetamide (IAA) (Sigma-
Aldrich, St. Louis, MO, USA) 
Add 40.7mg of iodoacetamide + 400ul of UA.  Prepare immediately and 
store at in the dark at 5˚C.     
proteomics grade trypsin (Sigma-
Aldrich, St. Louis, MO, USA)* 
2ug aliquot 
1M Tris HCl Add 7.8795g of Tris HCl + 50ml of water (pH 8.5) 
Lysis Solution Add 60ul of 10% SDS + 15ul 1M Tris HCl + 30ul of 0.5M TCEP + 45ul of 
water 
UA Add 24.024g of urea + 50ml of 0.1M Tris HCl 
50mM Ammonium bicarbonate 
buffer (ABC)(Sigma-Aldrich, St. Louis, 
MO, USA) 
Add 98.8mg of NH4HCO3 + 25ml of water.  Store at 5˚C 
Table 2.2. List of Reagents and Solutions used for protein extraction and digestion (* the trypsin to protein ratio is 1:50) 
Steps involved in urinary protein extraction 
1. A 15 ml 50KDa MWCO filter is conditioned 3X with UA. 
2. A 15 ml 3KDa MWCO filter is conditioned 3X with UA. 
3. First run the samples through the 50KDa MWCO filter in a refrigerated centrifuge at 




4. Then concentrate the proteins to about 1mL by running the flow through from the 50KDa 
MWCO filter through a 3KDa MWCO filter. 
5. For steps 3 and 4, you can top up with 15 ml of UA and re-spin. 
6. Then denature the protein concentrate using the lysis solution (75μL lysis buffer/mg 
starting protein) 
7. Incubate at 95⁰C for 3 minutes 
8. Pulsed indirect sonication was the performed for a minute at vibrational amplitude setting 
of 1-2 on a high intensity ultrasonic bath (Analab, Bischheim, France) 
9. Spin at 3500 x g for 10 minutes. 
 
2.2.1.2. Polyacrylamide Gel Electrophoresis 
 
Gel electrophoresis is one of the most widely employed techniques in traditional biochemistry 
and molecular biology to separate and investigate proteins and nucleic acid using an electric 
field. Typically, agarose gels are used to separate nucleic acids while polyacrylamide gels are 
used for proteins; albeit polyacrylamide gels can also be used for shorter fragments of DNA. One 
dimensional (1-D) polyacrylamide gel electrophoresis separates proteins based on their 
molecular weight, while two-dimensional (2-D) polyacrylamide gels further separates proteins 
based on molecular weight and isoelectric pH gradient. One dimensional Laemmli’s Sodium 
Dodecyl Sulfate- Polyacrylamide Gel Electrophoresis (SDS-PAGE) method was employed to 
ensure the presence of proteins, particularly the known urinary proteins like albumin and 
uromodulin in urine sample concentrates. The Dual Xtra Prestained protein standards (Biorad, 
UK) were used as molecular weight markers in the gel. We used 12% acrylamide gels that were 
poured in the lab. The 1X running buffer contained 25mM of Tris-HCl, 200mM of glycine, and 
0.1% (w/v) SDS.Urinary protein content were visualized with Bio-SafeTM Coomasie blue 250G 
(Biorad, UK)  staining after running 50μg, 100μg, 150μg on a 1D-SDS PAGE gel. To improve 
the resolution of the protein bands (especially albumin), lower concentrations of protein (i.e. 
25μg, 20μg, 15μg, 10μg, 5μg, 2.5μg, 1.25μg, and 0.625μg) was loaded on duplicate gels, one 
was stained with Coomasie (Fig. 2.4) and the other was stained using the Pierce™ Silver 
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Staining kit (Fig.2.5). This basic protein gel experiments served as a foundation for my 
proteomics work.  
 
                                              
                                Figure 2.4. Coomasie blue staining of 1D- SDS-PAGE gel of serial dilution of urinary protein   
                                                                 
                                    
                                   Figure 2.5. Silver staining of 1D- SDS-PAGE gel of serial dilution of urinary protein   
2.2.1.3. Bradford Protein Quantification 
 
The Bradford assay is a quick reproducible colorimetric protein concentration assay described by 




































protein components like basic (e.g. arginine) and aromatic residues and shifts its absorption from 
465 to 595 nm. There are 3 forms of the dye viz neutral green, anionic blue and cationic red 
[206]. The dye is doubly charged (red 465nm) in acidic medium but becomes unprotonated 
(595nm blue) when bound to protein components [207]. Detection of this absorption shift using a 
spectrophotometer (cuvette) or microplate reader indicates the concentration of the protein being 
assayed. Detergents are capable of creating interference with the accuracy of this protein 
quantitation method but the use of adequately controlled and optimized experiment may 
eliminate this interference. Common standards used in this assay are bovine serum albumin 
(BSA) and bovine gamma-globulin. The protein standard is diluted serially (2, 1.5, 1, 0.75, 0.5, 
0.25, 0.125 mg/ml) to generate multiple data points for comparative estimation of protein 
concentration. The Bradford protein assay kit used was purchased from Biorad, UK. Protein 
measurements were performed in triplicates and typically CV values were typically found to be 
less than 8%. Outlier samples were excluded from calculations and assay was repeated and re-
measured if the CV values were greater than 10%. The Thermo-Labsystems Multiskan FC 
Absorbance 96-well Plate Reader as well as a clear polystyrene, Corning® Costar® 96-well Flat-
Bottom EIA Plate (Sigma-Aldrich, St. Louis, MO, USA) were used for the Bradford assay. 
Bradford assay gives unreliable results in high concentrations of detergents like SDS, so the 
assay was modified by preparing the protein standards used in the same buffers that were used 
for sample preparation. 
Steps involved in a Bradford assay on a microplate assay 
1. Dilute the Bradford reagent (BioRad, UK) to 1:5 with deionized water in a tube.  
2. Add 200μL of diluted Bradford reagent to into the test wells (standards and proteins of 
unknown concentrations) on the 96 well plate. 
3. If protein is suspected to be too concentrated, it can be diluted x10 using phosphate 
buffered saline (PBS) or water. 
4. Leave a blank well containing only the diluted Braford agent as control. 
5. Add 10 μL of BSA standards (≥4) to the wells. 
6. Then add 10 μL of the unknown proteins to the well. 
7. Then insert into the spectrophotometer reader and read off in a slight agitation mode. 
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8. The data is then extracted in text format and analysed by plotting a standard curve (Fig. 
2.3) to determine the concentration of the unknown proteins. The 595nm values read 
from the microplate reader are plotted on the y-axis, while the concentrations (mg/mL) 
are plotted in the x-axis. The concentration of the unknown protein can be deduced from 
the intercept equation (y=ax+b)) and R2 value shown in the example in Figure 2.6. If any 
dilution was performed, correct the protein concentration result using the original dilution 
factor used. 
                     
                                                     Figure 2.6. Standard curve derived from a Bradford assay. 
2.2.1.4. Bicinchoninic Acid (BCA) Protein Quantification 
 
This is another colorimetric total protein quantification method which is based on a Cu2+ - 
protein complex formation in an alkaline environment. Its advantage over Bradford assay is that 
detergents do not cause interference during the assay. However, reducing agents like 
dithiothreitol (>1mM) may interfere with the assay.  
Steps involved in BCA protein quantification 
1. Add 10 ul of each of the standards (1; 0.5; 0.25; 0.125; 0.0625mg/mL)   to a well in a 96-well 
assay plate. 
2. Add 10 ul of each unknown samples to the plate. 
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3. Working reagent is prepared by adding the BCA Solution (Pierce, ThermoFisher Scientific) to 
the Copper Solution at a ratio 50:1.  
4. 200 μl of working reagent is then added to each well. 
5. Plate is incubated for 45 minutes at room temperature (plate must be covered with a lid or 
parafilm). 
6. Absorbance is read at 560 nm. 
7. Extracted data is then analysed  
2.2.1.5. In-Solution Protein Digestion 
 
Proteins can be digested following quantification with in-solution digestion method. This entails 
the use of organic solvents to aid the precipitation and digestion of proteins into peptides. The 
materials (Table 2.3) and protocol for in-solution digestion are described below. 
 
Solution and Reagent Preparation Description 
6 M Urea in Tris buffer (pH 7.8) 2.0 g of urea in a 15 ml + 1.25 ml of 0.4 M Tris 
stock. Adjust total volume to 5 ml with HPLC-grade 
water (Sigma-Aldrich, St. Louis, MO, USA).  
200 mM iodoacetamide in Tris buffer (pH 
7.8) 
0.037 g of iodoacetamide + 750 μl of HPLC-
grade water.   
Then add 250 μl of Tris stock and vortex.   
200 mM Dithiothreitol (DTT) in Tris buffer 
(pH 7.8) 
0.031 g of DTT + 750 μl of HPLC-grade 
water. The add 250 μl of Tris stock and vortex 
Tris stock (0.4 M, pH 7.8) 12.1 g of Tris base + 200 ml of HPLC-grade 
water. Adjust the pH to pH 7.8 using 6 M HCl. 
Add HPLC-grade water to a final volume of 
250 ml and store at 4°C.   
Trypsin  25 μl of ice‐cold Tris stock + 75 μl of ice‐cold 
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HPLC-grade water. Add solution to trypsin to 
a final concentration of 0.2μg/μL  and store on 
ice 
 
Table 2.3. List of reagents used for in-solution digestion and their preparation description. 
Steps involved in in-solution digestion 
1. After protein precipitation using methanol/ chloroform method, add 100μL of 6M urea. 
2. Vortex the mixture and sonicate on and off for 2 minutes.  
3. Dithiothreitol (5μL) is then added to the sample and vortexed.  
4. Incubate at room temperature for 30 minutes to 1 hour. 
5. Add 20μL of the alkylating agent iodoacetamide and vortex. 
6. Incubate in the dark at room temperature for another 30 minutes to 1 hour. 
7. Dithiothreitol (20μL) is added to the sample again and vortexed.  
8. Incubate at room temperature for 30 minutes to 1 hour. 
9. Dilute the solution with 775μL deionized water and vortex. 
10. Add proteomics grade trypsin (Sigma-Aldrich, St. Louis, MO, USA) (1:50) and digest 
overnight at 37⁰C. 
11. On the next day, stop the reaction by adding acetic acid to adjust the pH to 6.0. 
2.2.1.6. Filter-Aided Sample Preparation (FASP) 
 
Filter aided sample preparation (a.k.a FASP) is a relatively new technique of protein purification 
and digestion using molecular weight cut-off filters as described by Matthias Mann et al [208]. 
To summarize, important steps employed in FASP include: unfavourable low molecular weight 
species removal using urea containing buffer; thiol group carbamidomethylation; digestion of 
proteins with trypsin; and improved peptide elution. 
Steps involved in FASP 
1. Condition a 500μL 10 KDa MWCO (Amicon Ultra®, Millipore-Sigma, USA), with 
500μL with UA and spin at 14,000 x g for 10 minutes and discard flow-through. 
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2. Add 200μL of UA and top up to 500μL with protein sample (100 and spin at 14,000 x g 
for 15 minutes. 
3. Add another 200μL of UA and then repeat spin. 
4. Add 100μL of IAA to filter and agitate gently. 
5. Incubate in the dark for 20 minutes. 
6. Then spin for 10 minutes at 14,000 x g. 
7. Add 100μL of UA and spin at 14,000 x g for 15 minutes. 
8. Repeat step 7. 
9. Add 100 μL of ABC and spin at 14,000 x g for 10 minutes. 
10. Repeat step 9. 
11. Add 40μL of ABC + Proteomics grade Trypsin (Sigma-Aldrich, St. Louis, MO, USA) 
(1:50) and agitate gently. 
12. Incubate in a wet chamber at 37⁰C for 16 to 18 hours. 
13. Spin filters at 14,000 x g for 10 minutes. 
14. Add 40 μL of ABC and repeat spin. 
15. Acidify peptides by adding 0.1% TFA in water until pH is around 2-3 (using a pH test 
strip (Sigma-Aldrich, St. Louis, MO, USA)). 
2.2.1.7. Desalting and Reverse Phase Extraction 
 
Digested peptides were “cleaned up” by desalting/ reverse phase extraction which separates 
compounds based on hydrophobicity. The hydrophobic stationary phase we employed was made 
of C-18 material. In highly aqueous phase, peptides bind to the C-18 column and allow salts, 
impurities and undigested protein fragments to be washed off. However in high organic mobile 
phase, purified peptides can then be eluted for further analysis. Various solid phase extraction 





Steps involved in desalting 
1. As described elsewhere [209], fabricate StageTips by making holes in the lids of 
irradiated 2ml tubes with clean sharp tweezers and inserting irradiated 200µL tip up to 
the hilt. Then place two discs of C18 material in each tip. 
2. Equilibrate C18 with ≥5X C18 bed volumes of 80% HPLC-grade acetonitrile (in 0.1% 
TFA) and spin at 4000 x g for 1min. 
3. Repeat step 2. 
4. Wash the C18 column with ≥5X bed volumes of 2% HPLC-grade acetonitrile (0.1% 
TFA) and spin at 4000 x g for 1min. 
5. Repeat step 4. 
6. Load an equivalent of ≤15μg of peptides onto C18 column. 
7. Wash with 50μL of 2% of HPLC-grade acetonitrile (0.1% TFA) and spin at 4000 x g for 
1min to desalt. 
8. Repeat step 7. (you may store peptides on column at 4⁰C at this stage for future elution) 
9. Elute peptides by adding 50μL of 80% HPLC-grade acetonitrile (0.1% TFA) and spin at 
4000 x g for 1min. 
10. Repeat step 9 twice. 
11. Lyophilize peptides on a SpeedVac (Thermo Fisher Scientific, USA) without heating (or 
low heat). 
12. Re-suspend peptides in peptides in HPLC grade water containing 0.1% formic acid. 
2.2.2. Blood Sample Preparation 
 
Blood samples in Vacuette® K2EDTA venous blood collection set (Greiner Bio-One, North 
Carolina, USA) was centrifuged at 1,500 × g for 15 minutes to separate the plasma from cell 
fraction. The supernatant fraction was carefully removed; and 1.0 μl of plasma was diluted in 




2.3. Mass Spectrometry-based Sample Processing 
 
2.3.1. High Performance Liquid Chromatography (HPLC) 
 
In HPLC, high pressure is introduced to force the analytes through a column for better 
chromatographic separation. HPLC permits column packing with finer chromatographic 
materials thereby improving the surface contact of the solvent with the stationary phase, and 
allows the use of much smaller quantities of analytes. Based on the stationary phase used and the 
relative polarity of solvent, HPLC can be normal phase or reverse phase. Compound separation 
is visualized by the means of a detector and the time taken for compound to travel through the 
column to the detector is known as the retention time. HPLC was performed using the 
specifications described below: 
System specification for HPLC 
1. Place re-suspended peptides in autosampler glass vials (labelled appropriately) and then 
queued up in the autosampler tray of the liquid chromatography system (Dionex 
UltiMate® 3500 RSnano LC systems (Thermo Fisher, San Jose, CA, USA).  
2. Nanoflow ultra-high performance liquid chromatography (UHPLC) was performed 
online on a using a C-18 reverse phase precolumn trap (100μm×5cm; 5μM; 100Ǻ) 
(Separations, South Africa) and analytic column (75 μm×50cm; 5μM; 100Ǻ) 
(Separations, South Africa).  
3. Gradient chromatography was performed at 23⁰C with a flow rate of 300nL/min and 
eluted with a 5-80% gradient of water-acetonitrile for 180 minutes.  
4. The binary mobile phase system was used as follows: buffer A contained water (990µL 
of HPLC grade water with 10µL of acetonitrile) and 0.1% formic acid, while buffer B 
contained acetonitrile (700µL of acetonitrile with 300µL of HPLC grade water) and 0.1% 
formic acid.  
5. Gradient for peptides elution was 5% of B from 0-20minutes and increases to 80% of B 
at 180 minutes.  
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6. After completion of each run, the flow rate was increased to 450nL/minute and 50% B to 
equilibrate the analytic column and then dropped to 300nL and 5% B again prior to the 
next sample run. 
2.3.2. Mass Spectrometry 
 
Mass spectrometry (MS) is an analytical means of measuring the atomic or molecular weight of 
analytes. A mass spectrometer can be regarded as a highly sensitive and sophisticated weighing 
device that measures mass-to-charge (m/z) ratio of compounds. Its development made significant 
progress in the 1990’s and current models have now attained femtomolar sensitivity. Depending 
on the type of mass spectrometer used, ionization of the molecules occurs as an integral part of 
the technique and is coupled with the type of resolution used. In principle, mass spectrometry 
involves placing ionized atoms in a magnetic or electric field and measuring its speed in relation 
to its m/z in a vacuum. Because it separates ions according to their measured m/z, it needs an 
ionization system and a mass analyzer. Two common ionization techniques employed by the 
mass spectrometer to ensure ionization of analytes into the gas phase includes electrospray 
ionization (ESI) and matrix assisted laser desorption and ionization (MALDI). A few commonly 
used mass analyzers are; quadrupole, Orbitrap, Fourier transform ion cyclotron (FTIC), ion trap, 
and time-of-flight (TOF). MS results are usually recorded as a series of peaks known as spectra 
formed by plotting the m/z on the x-axis and relative abundance/ intensity on the y-axis. The 
resolution of the spectra is defined as the width of the peak height typically measured at 50% 
peak height [210], it can be measured at any point. In mass spectrometry, the monoisotopic mass 
refers to the mass determined using the most abundant isotope of each atom in the ion, while the 
average mass is the mass derived from the abundance of all available isotopes of the same ion.  
Higher sensitivity of the MS system can be achieved using a nanospray ESI due to the higher 
surface to volume ratio [211]. There are generally three approaches to the analysis of MS based 
proteomics data which includes matching sequence tags to theoretical databases; de novo 
interpretation of peptide sequences; and assigning correlation scores to experimental-to-
theoretical spectral match [212-214]. Peptide spectral matching scores can be assigned using q-
values which are the minimal false discovery rates (FDR) or posterior error probabilities (PEP). 
The posterior error probability (PEP) score is the local probability that the observed peptide 
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spectral matching (PSM) is incorrect. It is calculated by the ratio of hits from true database vs 
decoy [215, 216]. FDR is the percentage of the global identification by PSM that is expected to 
be false; while the q-value is analogous to the p-value of the FDR that we are willing to accept 
[217-219].  
2.3.3. Tandem Mass Spectrometry (MS/MS or MS2) 
 
Tandem MS which is achieved by using two mass analyzers in tandem and can give better 
insight into peptide sequence and its identity rather than merely depending on its molecular 
weight or m/z value. The first mass analyzer functions as a precursor/parent ion selector for 
fragmentation and the second mass analyzer functions as a fragment/daughter/product ion mass 
analyzer. Two types of mass analyzer may be coupled to a mass spectrometer in which case it is 
referred to as a hybrid e.g. Quadrupole- Orbitrap. Also, the same type of mass analyzer may be 
connected in series for MS2 experiments e.g. Triple Quadrupole. Examples of MS2 scanning 
modes are product ion, neutral loss and precursor ion scanning. There are different patterns of 
fragmentation which can be unimolecular or bimolecular [220]. Unimolecular fragmentation is 
also known as post source decay (PSD) and occurs when a single metastable (highly energetic) 
ion fragments suddenly causing peptide backbone fragmentation (y/b fragments). This type of 
fragmentation is common in MALDI setups due to bombardment of the matrix with a laser 
source [221]. However, MALDI TOF/TOF setups can also give rise to substantial internal 
fragmentation. (x/a or z/c). The bimolecular fragmentation also referred to as collision induced 
fragmentation (CID) occurs when precursor ions acquire sufficient fragmentation energy, due to 
multiple bimolecular events involving bombardment of the selected peptide with an inert noble 
gas in a collision cell, resulting in backbone fragmentation. Another bimolecular fragmentation 
method known as electron capture dissociation (ECD) or electron transfer dissociation (ETD) 
typically generates z/c fragmentation as a result of interaction with an electron donor, resulting in 
chemical fragmentation of the bonds [222, 223]. Traps typically use ETD while FTICs use ECD. 
Tandem mass spectrometry is a vital tool for proteomics which can employ a “bottom-up” 
(shotgun) approach or “top-down” approach. Shotgun proteomics is a discovery proteomics 
approach that determines protein identity from peptides generated from a mixture of digested 
proteins [224, 225]. However “top-down” approaches refer to intact protein analysis by mass 
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spectrometry [226]. There is relative quantitation and absolute quantitation proteomics. Relative 
quantitation is versus a control sample and no conclusions can be reached about concentration of 
the measured analytes. Absolute quantitation is determined using a standard curve to derive a 
measured value. Labelled and label-free methods can be used for relative quantitative proteomics 
which in principle attempts to quantify the identified proteins. Stable isotope labeling by amino 
acids in cell culture (SILAC) is an in-vivo method of labelling [227], while isobaric tag for 
relative and absolute quantitation (iTRAQ) [228], dimethyl labelling [229], and tandem mass 
tags (TMT) [230] are in-vitro approaches. Label free methods typically involve peak intensity 
measurement and MS1 spectral peak integration method using the “top three” approach and 
intensity based absolute quantification (iBAQ) method. Specification for our mass spectrometry 
runs are as described below. 
Specifications of Mass spectrometry runs 
1. QExactiveTM Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo Fisher, San Jose, 
CA, USA) [231] was used for shotgun proteomics analysis in-line with a Dionex 
UltiMate® 3500 RSnano LC systems. 
2. Flow injection analysis of samples introduced from the HPLC system was done with the 
Mass spectra (MS) acquisition resolution of 70,000 at a target value of 3 X 106 or 
maximum integration time of 250 milliseconds.  
3. High-energy collision dissociation (HCD) and normalized collision energy set at 25 was 
used for peptide fragmentation.  
4. Continuous MS2 spectra acquisition resolution was set at 17,500 at a target value of 2 X 
105 ions or maximum integration time of 120 milliseconds.  
5. Automated data dependent full scan cycle was performed with automatic switching 
between MS/MS and MS scans at a scan range of 300-1650 m/z and a maximum 
injection time of 30 seconds.  
6. The top 10 most abundant parent ions selected by the quadrupole during the initial scan is 
further fragmented using in-source HCD with normalized collision energy (NCE) at a 
pressure of 1.2millitorr and a dynamic exclusion time of 90 seconds.  




2.3.4. Proteotypic Peptide Selection 
 
Targeted “hypothesis testing” proteomics focusses on a protein or peptide of interest, hence more 
efficient because they are dependent on adequate knowledge of the protein or peptide of interest 
[232]. Precursor peptide- fragment ion pairs known as “transitions” are used to confirm the 
identity of the targets. Transition selection is often difficult due to various technical and biologic 
factors which can be potentially addressed by using preexisting databases. A unique peptide for a 
target protein that present good MS responses is referred to as a proteotypic peptide [233]. In 
principle, these should be peptides detectable by the mass spectrometer and potentially capable 
of systematic incorporation into the available databases. The success of a targeted proteomics 
experiment is dependent on the successful selection of representative target transitions. 
Predictive machine learning algorithms have been previously suggested to overcome the 
potential bottlenecks of experimental optimization in proteotypic peptide selection [234]. 
Proteotypic peptides were selected prior to PRM assays. During proteotypic peptides selection, 
the following biologic and chemical criteria were considered for the targeted proteomics assay: 
 Selection criteria for proteotypic peptides 
1. The goal was to select at least three transitions per target peptide (potential biomarker). 
2. Shorter unmodified peptides that are unique to a single or specific isoform of the target 
protein with imino acid proline are better targets. 
3. Poorly ionized longer peptides were avoided.  
4.  +2 and +3 charge states were selected for each proteotypic peptide.  
5.  +1 or > +3 were excluded from selection from further assay.  
6. Peptides containing too many units of methionine (M) or tryptophan (W) were excluded 
due to the high propensity of artifactual side chain oxidation.  
7. Based on adjacent sequences, asparagine (N) and glutamine (Q) were carefully 
considered due to possible chemical instability. For instance, N-terminal glutamine can 
change to pyro-glutamate when exposed to acidic treatment. 
8. A maximum of two missed cleavages were permitted for each proteotypic peptide. 
9. The possibility of having missed cleavages are identified to be increase in sequences 
containing two adjacent terminal basic amino acids such as –KR, -KK or -RR. 
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10. Because of low ion current as compared to their tryptic peptide counterpart, non-tryptic 
peptides were generally avoided [233]. Even though they can still be used if we are 
unable to find a good tryptic peptide. 
2.3.5. In-silico SRMatlas Verification 
 
In silico methods play a vital role in confirming the detectability of selected proteotypic peptides 
in previous targeted proteomics assays archived in targeted proteomics repositories. Selected 
reaction monitoring (SRM) is an important targeted proteomics method that permits the 
quantification of detected sets of protein in an unambiguous manner. Optimization and a priori 
characterization of target transition is required in this method [233]. A search for all our selected 
proteotypic peptides was performed against their target protein in the SRMAtlas database 
(http://www.srmatlas.org/). This is a publicly available online-based resource for choosing 
targeted proteomics experimental specifications. This relatively new database is derived from the 
PeptideAtlas projects which permits mining information on peptide transitions for target 
proteins. There is hierarchical integration of deposited data as well as bioinformatics predictions 
in a manner that generates a collection of the most suitable proteotypic peptide for each target 
protein in the proteome. Information contained in the database can also be repositioned in a 
manner that suits individual researcher’s interest. There are two fundamental phases of the SRM 
build, which are firstly optimal peptide selection and secondly optimal transition selection [235]; 
enhanced by the robustness of integrated information from databases like PeptideAtlas SRM 
Experiment Library (PASSEL) [236] and PeptideAtlas Transitions Resource (PATR) [235]  into 
the SRMAtlas database (Fig. 2.7 and Fig. 2.8). PASSEL allows ease of submission of proteomic 
datasets generated from SRM by researchers and facilitates cross-analysis of such datasets. It 
also supports the review and optimization of SRM data collection [236]. PATR stores curated 
lists of transitions collected from community submissions as well as published articles. Peptide 
Atlas Best SRM Transition tool (PABST) algorithm used in PATR is a Peptide Atlas 
functionality that employs diverse sources of information in the production of peptides and 
fragment ions lists for use in SRMs.  The PABST information is compiled into 'builds' that 
permits fast querying via a web interface. Three discrete steps are involved in the PABST build 
process viz; firstly, a list of the top 10 most suitable peptides for each target proteins; secondly, a 
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list of the top 8 potential fragment ions from each selected peptide; and finally the information 
generated is loaded into the Peptide Atlas database for end-user defined queries [237]. 
             
                             Figure 2.7. Integration of the PASSEL databases into the SRM database (adapted from [236]) 
          
                            Figure 2.8. Integration of the PATR database into the SRMAtlas (adapted from [235]) 
The specified setting that was used for the SRM database search is specified below:  
Specified setting for SRMAtlas database verification of potential biomarkers: 
1. Protein accession identification number was filled in. 
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2. Transition source was selected as “ion trap” since an Orbitrap instrument was used. 
3. The specified m/z range selected was 200-2000m/z. 
4. Only b- and y- ions were permitted  
5. Neutral loss MS2 scanning mode was not permitted. 
6. Target database selected for search were Ensembl, IPI and SwissProt. 
7. Default setting were accepted for other parameters 
 
2.3.6. Human Protein Atlas Verification  
 
Biological screening of potential biomarkers was performed using the Human Protein Atlas 
database (http://www.proteinatlas.org/). The database is publicly available online and contains 
images generated from twenty different human cancers, 44 normal human tissue types, and 46 
different human cell lines. The database is organized in a gene-centric manner and information 
regarding genome annotation of human protein-coding genes, protein expression level, as well as 
subcellular localization of protein is made available in this repository.  The most recent version 
launched at the end of 2014 uses antibody profiling and transcriptomics analysis to provide 
information about various proteins in humans. Two important underpinning principles employed 
by the human protein atlas to generate information in a high-throughput manner are the 
improvement on the specificity and non-overlapping epitopes of the antibodies used as well as 
the use of tissue microarrays for immunohistochemical analysis. There are four sub-atlases in the 
human protein atlas viz; the normal tissue atlas, the cancer atlas, the cell line atlas and the 
subcellular atlas (Fig. 2.9). For verification, the cancer atlas and normal tissue sub-atlases were 
used. Normal and cancerous prostate tissue immunohistochemistry was assessed by searching 
either name or gene symbol of the investigated potential biomarkers. Immunohistochemical 
staining of target proteins was compared between normal and cancerous proteins. Proteins with 
differential expression between normal and cancerous tissue were documented as verified 




Figure 2.9. Screenshot of the query page of human protein atlas showing the four sub-atlases (www.proteinatlas.org) which are the normal tissue 
atlas; the cancer atlas, the cell line atlas, and the subcellular atlas. 
2.3.7. Parallel Reaction Monitoring (PRM) 
 
Parallel reaction monitoring is a quantitative high resolution targeted proteomics method. It is 
similar in some respect to selected reaction monitoring (SRM) which targets only a few 
transitions (precursor-product ion pairs) and is typically carried out on a triple quadrupole 
instrument. Parallel reaction monitoring involved the multiplexed/ parallel detection of all 
product ions in a single high resolution mass analysis; using a substitution of the third 
quadrupole mass analyzer with a high resolution and accurate mass Orbitrap or time-of-flight 
mass analyzer. Some advantages of the PRM method over SRM are that multiple transitions can 
be monitored to confirm the identity of the target precursor peptide; ion interference would be 
better tolerated by the full scan without affecting the quality of the spectra because of the high 
resolution of the instrument; less optimization is required in comparison to the SRM setup. On 
the other hand, sensitivity of the PRM would be less compared to the SRM because of the 
optimal duty cycle in SRM which employs an electron multiplier as compared to the trapped 
60 
 
image current detection system used in the Orbitrap instrument, although it has been suggested 
that due to high resolution and accurate mass, PRM may still be a better method for targeted 
survey of transitions [238], while SRM may be more accurate for absolute quantification. PRM 
was carried out on pooled healthy and prostate cancer patients samples using the settings 
described below: 
Settings used for Parallel Reaction Monitoring Assay 
1. PRM runs were performed on a QExactiveTM hybrid Quadrupole- Orbitrap Mass 
spectrometer. 
2.  A spectral library is first created using data from the original shotgun urinary proteomics 
assay. 
3. An isolation list in Skyline (MacCoss Lab software) [239] is then generated. 
4. Precursors are randomized in the isolation list generated to ensure that the following 
precursor m/z value is similar and also a randomized order of +2 and +3 of the precursor 
ions. 
5. Isolation lists are uploaded into the system software connected to the mass spectrometer. 
6. An isolation window of 2m/z units for each precursor ion was used; starting at an m/z of 
80 and final m/z is then automatically derived based on the m/z of the proteotypic peptide 
precursor.  
7. After generation of MS2 data, raw files were imported into Skyline to choose the 
precursors with good signals. 
8. The process is repeated using an isolation list that is ordered differently to ensure that 
interference from multiplexing does not create bias in our inferences [240]. 
9. Relative quantitative analysis was then performed to compare biomarker transitions 
between study groups. 
 
2.3.8. Database Confirmation of Urinary Prostate Cancer Biomarkers 
 
Identified top ranking potential biomarkers that have passed through three levels of stringency 
viz; SRMAtlas database, Human Protein Atlas and Parallel Reaction Monitoring were confirmed 
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in our shotgun urinary proteomics database as well as 14 other publicly available urinary 
proteomics databases.  
2.4. Cancer Antigen Array-based Sample Processing 
2.4.1. Streptavidin Derivatization for Cancer Antigen Array 
 
Streptavidin is a 58.2KDa tetrameric protein that frequently used in immunologic hybridization 
assays. This protein which is purified from Streptomyces avidinii bacterium species [241], 
possesses an extraordinary high non-covalent affinity for vitamin B7 (biotin) with a dissociation 
constant (Kd) of ca. 4 x 10 -14 [242].  The high binding strength makes it an attractive tool in 
molecular biology and nano- or bio-technology. Streptavidin biotin bonds are resistant to 
detergents, organic solvent as well as a wide variation in temperature and pH changes [243]. The 
bond strength remains a subject of research and scientific discussion in molecular biology and 
methods to strengthen and improved its efficacy have been well documented [242, 244-246]. For 
the cancer antigen array experiment, we performed in-house derivatization of a Nexterion-H 
slide with streptavidin. The Nexterion H-Slide demonstrates low intrinsic non-specific binding, 
making assays relatively independent of a blocking step. Its polymer coat has three important 
components, namely: an NHS ester reactive group, a terminal-amino modified amino acid and a 
surface exposed amine-group (Fig. 2.10). The properties of the Nexterion-H slides are as 
described below: 
         
 
                  Figure 2.10. Properties of the polymer coating of Nexterion-H slides (http://www.schott.com/) 
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Properties of the Nexterion H-slides used: 
1. Made in Germany 
2. Contains 25 slides per pack 
3. Thickness is 1.0 ± 0.05mm 
4. Size is 75.6mm x 25mm x 1.0mm (L x W x H) 
5. It is black barcoded 
6. It is hydrogel coated (N-hydroxysuccinimide esters to provide covalent immobilization) 
7. Should be stored at -20⁰C 
The steps involved in the streptavidin derivatization are as follows: 
Streptavidin derivatization protocol: 
1. Slides were thawed for one hour at room temperature. 
2. Streptavidin solution was prepared in 150mM Na2HPO4 buffer at pH 8.5. 
3. Each slide was immersed in 5mL of 1 mg/mL streptavidin solution for one hour at room 
temperature. 
4.  Slides were then removed from the streptavidin solution (reusable). 
5. The slides were washed for one hour in 10mL of 150mM Na2HPO4 buffer (pH 8.5) 
containing 50mM of the blocking agent (ethanolamine). 
6. Each slide was washed thrice for 5 minutes in 10 mL of washing buffer. 
7. It was then washed for 10 minutes in 10 mL of deionized water. 
8. The slides were dried at room temperature by centrifugation at 1000 x g for 5 minutes. 
9. For quality checking, the last slide per batch was incubated in 10μg/mL Cy5-biotinylated 
BSA in PBS and washed in washing buffer, and then scanned on Tecan LS reloaded 
microarray scanner to confirm even spread of streptavidin; and only slides with CV ≤5% 
were used for the assay. 





2.4.2. Cancer-Testis Antigen Protein Microarray Fabrication 
 
Protein microarray technologies have been classified into two major groups, which are functional 
protein microarrays and analytic (protein-detecting) protein microarrays [247, 248]. Protein 
microarrays can be fabricated using recombinant proteins [249-253], reverse capture of native 
proteins [247, 248, 254-258], cDNA expression libraries [259-268] and in-situ expression 
techniques [269-274]. Native proteins are able to retain their post-translational modifications and 
complex structure as compared with recombinant proteins and do not necessitate a cloning 
process. However identifications generated via native proteins are often not reproducible. Using 
cDNA libraries like SEREX [268] is simple, can be combined with robotics and yields a vast 
library of proteins; however generation of truncated cDNA clones from E.coli system, poor 
folding of human proteins in E. Coli and lack of post-translational modifications or protein 
complexes are major drawbacks. In situ systems like Nucleic Acid Programmable Protein arrays 
(NAPPA) [267], in-situ puromycin capture, and protein in-situ arrays (PISA) [270] have the 
advantage that they use eukaryotic cell free system to translate arrayed cDNA to protein; 
however optimization across several cDNAs can be challenging, expressed protein may be 
misfolded, and expression is often not reproducible. An alternative system to overcome all these 
potential limitations is to express recombinant human proteins in “eukaryotic-like” insect cells. 
This would potentially overcome problems with folding, functionalization and reproducibility. It 
is important to note that post-translational modifications in insect cells are not the same as in 
humans. The “CT100+” cancer-testis antigen protein microarray employed in this study is based 
on recombinant protein expression in insect cells that employs the linearized baculovirus genome 
system [275, 276]. The steps involved in microarray fabrication are as listed below: 
Steps in CT100+ microarray fabrication 
1. Crude SF21 insect lysate containing individual, in vivo biotinylated cancer-testis antigens 
were printed on the streptavidin coated Nexterion-H slides using the robotic arrayer, 
Genetix QArray 2.  
2. Biotinylated human IgG and serum were used as positive controls. 




4. On the microarray, each subarray contained biotinylated Cy5-BSA on triplicate spots at 
5, 10 and 15ng/mL.(this is used for slide orientation). 
5. Before printing commences, slides were inspected and confirmed to be free of 
fingerprints and dust particles by microscopy (X40 magnification). 
6. Microarray equipped with 300μM solid pin is employed to print CT100+ replica in a 
4plex format.  
7. Crude lysates were mixed with 40% sucrose and placed in triplicates in the array. Sucrose 
reduces protease release by stabilizing lysosomal membranes. 
8. Positive and negative controls were prepared using lysis buffer containing 20% of 
glycerol, 50mM of KCl, Triton X-100, 25mM HEPES (pH 7.5), 50μM of biotin, 1mM of 
DDT, and supplemented with 20% sucrose. 
 
For the Genetic QArray 2 robotic arrayer, the settings described below were used: 
Settings for robotic arrayer 
1. Row to column pitch was 562 microns. 
2. Arraying pattern was 8 x 8 pins in 4 fields. 
3. Number of stamps per spot was 1 
4. Number of stamps per ink was 1 
5. Stamp time was 0 
6. Print depth adjustment was 150 microns 
7. Inking time was 500 ms. 
8. Water wash used was 60 s and dry time was 0 ms 
9. Number of touch-offs was 0 




2.4.3. CT00+ Cancer Antigen Array Assay 
 
In all, seventy samples were assayed including 3 quality control samples. The quality control 
samples comprised of negative control serum, positive control serum, and a mouse-anti-c-Myc-
Cy3 antibody. The steps involved in the assay are highlighted below: 
Protocol for CT 100 + Antigen array assay 
1. CT 100+ microarray was washed with lysis buffer containing 20% Glycerol, 25mM 
HEPES, 50mM KCl, 0.1% Triton X-100, 1mM Dithiothreitol and 50 μM biotin for 5 
minutes at room temperature. 
2. Repeat step 1 twice. 
3. Slides were dried by centrifugation at 16 x g for two minutes. 
4. Slides were then placed in the automated hybridization station (TECAN HS4800 Pro) to 
isolate each array. 
5. Each microarray was then incubated with diluted sera (1:800 in PBST) at 23⁰C for one 
hour. 
6. After incubation, the microarray is washed with PBST for 5 minutes. 
7. Repeat step 6 twice. 
8. Microarray was then incubated with Cy5-goat anti-human IgG (diluted 1:100 in PBST) 
detection antibody at 23⁰C for 1 hour. 
9. Slides were then washed four times for a minute with PBST. 
10. Rinse with water for 30 seconds. 
11. Individual arrays on the slide were then scanned with 10μm resolution on the Tecan LS 
Reloaded microarray scanner. 
12. Fluorescence is detected at 650 nm. 




2.4.4. Data Extraction from Antigen Array 
 
Information from the TIFF file was extracted using the steps described below: 
Steps for data extraction from TIFF image 
1. The TIFF images generated from the CT100+ assay were initially inspected using simple 
visual analysis to first ensure that the BSA spots (5, 10 and 15μg) were detectible in the 
subarrays of the microarray.  
2. High signals for positive control which is human IgG detected by secondary antibody 
fluorescence was ensured and human anti IgG detected on addition of serum were 
observed in the images. 
3. Arrays that show; speckles, high background, interfering dust particles and protein spot 
coalescing at inspection were excluded. 
4. If array displayed attributes mentioned in step 3, sera was re-assayed on another fresh 
slide. 
5. Data was then extracted using the ArrayPro Analyzer Software version 4.5 (Media 
Cybernetics, Inc, Maryland, USA). 
6. Using a grid, identity of the antigens and control were aligned and encircled on the TIFF 
image. 
7. Raw intensity of the individual spot was measured as mean pixel within the defined 
border to set maximum threshold intensity of 200 pixels. 
8. Local background for each circumscribed spot was measured as adjacent area intensity. 
9. The difference between raw mean intensity and local background was designated as the 
mean net intensity. 
10. Data was extrapolated with ArrayPro Analyzer Software version 4.5 (Media Cybernetics, 
Inc, Maryland, USA). 
11. Then data was filtered and normalized using our in-house developed CT100+ software 
[277, 278]. 




2.5. CT100+ Analysis Programme 
 
The aim of our CT100+ programme was to provide customized normalization and qualitative 
sample clustering using the parameter described in the following sections. 
2.5.1. Spot Homogeneity 
 
Homogeneous signals are expected across all pixels within each spot. A deviation from this 
include what is referred to as the “doughnut effect” which is usually caused by inadequate pin 
height at print run and residual liquid on pin body during pin head immersion in source plate. 
This tends to result in uneven distribution of spots. When slides are inadequately stored and 
handled during the CT100+ assay, dust particles could settle on spot of interest and erroneously 
give a high pixel intensity thus skewing the actual signal on the array surface. Temperature 
increases and decreased humidity may result in printed spot evaporation; while humidity increase 
greater than 75% may result in condensation on the spots and account for unevenness of 
intensity. Coefficient of variation (CV) is employed to evaluate variations between replicates. 
This can be done by measuring the ratio of the mean intensity (%) and the standard deviation of 
all pixel intensities within the spot. Ideally, the CV is not expected to exceed 20%. 
2.5.2. Spot-to-Spot Variation 
 
In principle, signals of triplicate spots are expected to be similar; and spots should be uniform 
across the whole microarray. Practical deviation from this includes a phenomenon known as 
“spot bleeding” whereby two or more closely positioned spots run into each other. This may also 
occur as a result of using inappropriate spotting buffer and may potentially compromise the 
signal of all affected spots. When arrayer pins and printheads are inadequately cleaned between 
print runs, this causes erroneous pin calibration or pin sticking whereby some or all prints may 
fail or may even result in the generation of non-reproducible spots. If the washing step is 
inadequate throughout the assay, this may result in formation of large washing artefacts or 




2.5.3. Signal-to-Noise Ratio 
 
When evaluating multiple spots across arrays, net spot intensity (Foreground intensity minus 
background intensity) is expected to be higher than the neigbourhood or local background. 
Washing artefacts, speckles and dust particles may interfere with this expectation. To potentially 
overcome this, a signal-to-noise ratio ≥2 is accepted (where standard deviation of the background 
pixel is defined as the “noise”) 
2.5.4. Background Variation 
 
When looking at multiple spots on an array, there should be minimal variation in the background 
between neighboring spots. Dust particles may cause variations in recorded background 
intensities across spots on the microarray. 
2.5.5. Pixel Saturation 
 
Saturated pixels above the slide scanner’s reading capacity (limit of detection) should not be 
observed when evaluating multiple spots across the array. The reading capacity of the Tecan 
Reloaded scanner used in our laboratory is ca. 65,000 RFU. If such saturated spots are detected, 
the slide needs to be rescanned at a lower photomultiplier tube (PMT) gain setting until 
saturation is no longer detectible across the array [279]. 
2.5.6. Background Subtraction and Correction 
 
Local background can be smoothened by correcting neigbourhood background. It can be done by 
reducing the noise and artefact effect in the neigbourhood background. This allows for accurate 
calculation of net intensities by removing the corrected neigbourhood background from the 




2.5.7. CT100+ Cancer Antigen Microarray Data Filtering 
 
Quality controls checks are run after background corrections. This entails filtering out of 
defective or noisy array data prior downstream bioinformatics analyses. Filtering improves data 
quality and stringency of analysis. Low quality/ questionable arrays or individual spots are 
flagged. For example spots with foreground intensity close to 65,536 RFU are flagged and 
triplicate spots with high CV vis-à-vis spot intensities can also be flagged. In triplicate spots, if 
one of the spots is flagged, variation in the remaining two spots S1 and S2 can be calculated as 
follows: (| S 1 − S 2|)/(S 1 + S 2). Net signal close to the noise level can be flagged using 2 
standard deviation of the local background pixel intensity as a flag. In principle, negative 
controls on the array can allow filtering of low intensity spots because they depict cross reaction 
of detected antibodies with copurifying SF21 insect cells or the BCCP-tag. In reality antigen-to-
antigen differences in expression level or access to BCCP-tag makes this approach less 
straightforward. A practical approach may be to establish baseline threshold intensity for 
individual antigens across a large healthy sample cohort. 
2.5.8. Custom Microarray Data Normalization Methods 
 
The goal of the normalization workflow is to provide efficient and robust methods of correcting 
technical and systematic bias in array to array and pin to pin discrepancies. This is performed 
bearing in mind the relatively small size of the positive control sample cohort. Assumption is 
made here that the positive controls share a common distribution across the arrays upon which 
they are printed. Hence, a combination of both intensity and quantile normalization modules is 
used to eliminate systematic bias in the composite normalization workflow. The quantile 
approach as described by Bolstad et al 2003 [280], identifies housekeeping spot intensities based 
on their underlying distribution and then reorganizes them based on the step described below: 
Steps involved in the quantile normalization module 
1. Assuming that for a positive control spot i on a chip j, S ij is the intensity. 
2. The positive control spot intensities are loaded into an i x j matrix, represented as X. 
3. The spot intensities are then sorted in each column j of X to get X sort. 
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4. The means across each row i of X sort is then taken to get iX, where  iX is the distribution 
of spot intensities of positive control. 
Total intensity based module described by Quackenbush et al 2001 [281]  takes on the 
assumption that all spots have similar intensity; meaning that intensity sum for all positive 
controls must be constant. This is a scaling method that factors in flagged spots. If any positive 
control spot is flagged, the corresponding spot is flagged across all arrays to minimize 
discrepancies in the number of positive control spot used across the microarray. 
 2.6. Autoantigen Confirmation in Urinary Shotgun Proteomics Database 
All antigens present on the CT100+ platform were searched against our urinary shotgun 
proteomics database. Antigens that were found to have high autoantibody titres were also 
checked in the database to assess if there were any correlations between autoantibody expression 
in blood and urine since most of the potential biomarkers that were discovered from the shotgun 
database were predicted membrane proteins and of extracellular matrix origin. 
2.7. Functional Pathway Analysis  
 
Functional pathway analysis is essential to identify common pathway involvement by the 
potential biomarkers or investigate functional relationship. Enquiry about enrichment for gene 
ontology (GO) categories such as biologic process, molecular function and cellular component 
can be performed on the annotation databases. There are several annotation databases available 
for pathway analysis, a few of which are; the REACTOME, Kyoto Encyclopedia of Genes and 
Genomes (KEGG), molecular signature database (MSigDB), UNIPROT, etc. Functional 
Pathway enrichment analyses were performed on the antigens with high autoantibody titres; 
using a free online gene interaction software GeneMANIA and enrichment was confirmed by 
functional protein association network software STRING (version 9.1). 
2.7.1. GeneMANIA 
 
The GeneMANIA web interface (http://www.genemania.org/) is a user-friendly tool for 
functional pathway analysis of gene sets. Hypotheses can be generated from this interface on 
gene list analysis; gene function and functional assay prioritization of genes; and assigning 
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predictive weights for genes in selected datasets [282].  For each query, GeneMANIA assigns 
weights to data-sets based on how useful they are. Each data-set is represented as a network, and 
each network is assigned a weight based on how well connected the queried genes are to each 
other compared to non-queried genes. The weighting network feature used by GeneMANIA 
identifies and down-weight redundant networks. Annotation or co-annotation based weighting 
may inflate network weights for an organism in the GO categories of biological process, 
molecular function, or cellular process hierarchies. However, high-throughput assays with 
annotation-based schemes are hardly affected by this potential inflation [282]. Gene list is 
entered and organism species is selected and queried against a list of selected datasets (Fig. 
2.11A). Functionally similar genes to the original query list are then displayed in an interactive 
association network based on shared function (Fig. 2.11B).  
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Figure 2.11. GeneMANIA web interface showing (A) the query page where user can input gene list and select search categories and (B) 
interactive functional network generated from query (adapted from [282]) 
2.7.2. STRING 
 
Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) is a web-based resource 
(http://string-db.org) as well as a biological database, for interrogation of protein-protein 
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interaction, and functional pathway analysis [283, 284]. Data sources for STRING include 
curated literature, computational predictions and experimental data in physical interaction and 
curated biologic pathway databases [285, 286]. Data generated on STRING are also weighted 
and confidence scores are assigned to the predicted protein interactions [283]. Protein-mode and 
clusters of orthologous groups (COG)-mode can be used on this web tool. At least three lineages 
of orthologous paralogs are used for each orthologous protein in the COG-mode [287]. STRING 
permits a filtering process for functional genomics interaction by incorporation systems-oriented 
understanding of cellular processes. STRING predicts the specificity and biological 
meaningfulness of protein-protein functional association; and this makes it better than many 
other software. It attempts to predict the full complement of possible interaction for any fully 
sequenced organism, albeit only a subset would be possible in any given cell. The STRING 
database periodically execute interaction prediction algorithms that significantly increasing 
coverage for poorly studied organisms and assigns confidence scoring of coverage and accuracy 
to them. Currently, STRING is based on Adobe Flash Player which allows users to freely 
reposition nodes in, as well as applying clustering algorithm to the network; even while running 
a real time spring-embedded layout algorithm [283]. Most of the associations in STRING are 
derive from genome-based prediction algorithms or by pre-computed interolog transfer. 
Generally, a probabilistic confidence score is used to provide association in STRING. This score 
is derived from separately benchmarked groups of associations against the manually curated 
functional classification scheme of the KEGG database. The sources of interaction in STRING 
database includes: importing known experimental interaction from primary databases; parsing 
pathway knowledge from manually curated databases; automated text-mining of Medline 
abstract or full-text articles; de novo prediction of interactions by algorithms using genomic 
information; and systematically transferring interactions observed in one organism to another 
[286]. Selected gene or protein lists are entered on the query page and organism species is 
selected and queried (Fig. 2.12). Output displayed for network generated includes predicted co-
expression, neigbourhood evidence, occurrence in similar biological pathway, and gene fusion-
fission events (Fig. 2.13). 
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                                    Figure 2.12. Screenshot of STRING query page (http://string-db.org) 
 
Figure 2.13. Example of STRING network visualization showing predicted neigbourhood, occurrence, fusion and coexpression of proteins [286]. 
75 
 
2.8. Bioinformatics and Computational Analyses 
 
Owing to the complexity and huge amounts of data generated in proteomics experiments, various 
computational analyses, algorithms and workflows are needed for systems-level identification of 
biologically significant differences in the proteome. Bioinformatics workflows permits 
systematic integration, management and elucidation of large amount of data generated from high 
throughput omics based experiments, in a seamless manner. Newly emerging software packages 
aim to a supplement basic statistics and overcome the bottleneck often faced by researcher in 
data analysis and experimental inference generation. Some of the computational workflows and 
software used for analyzing the proteomics data are described in the following sections. 
2.8.1. MaxQuant Analysis 
 
MaxQuant, which originates from Matthias Mann’s Group [288], is a C++ based algorithm suite 
for statistical analysis of high throughput mass spectrometry-bases proteomics data. This 
software permits an accurate proteome-wide identification and quantification of proteins from 
the estimated spectral-based peptide masses generated from precursor scans [288]. This feature is 
enable by an integrated search engine know as Andromeda which assigns score-based 
identification to fragment ion, peptides and protein groups. In MaxQuant, proteins sharing the 
same identified peptides together are grouped into one and are called protein groups by the 
protein group assigning algorithm. All the proteins in one protein group have a similar or slightly 
less number of identified peptides [288, 289]. The Andromeda scoring system is based on the 
binomial distribution probability [289]. A binomial experiment requires repeated independent 
trials which can result in just two possible outcomes (i.e. success or failure); and the probability 
of success is the same for every trial. Peptide scoring functions are assigned in binomial 
distribution based probabilistic algorithms by comparing spectral peak characteristics in 
experimental to theoretical target databases. MaxQuant version 1.3.0.5 was used for the analyses 
and the steps followed are as listed below: 
Steps used for Maxquant analysis 
1. Load *raw Xcalibur files generated from the mass spectrometer into Maxquant. 
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2. Set experimental design template 
3. Set experimental parameters using default settings with minor modifications (See 
annexure III for details) 
4. Select number of “threads” for analysis 
5. Run the experiment. 
6. Generate result and Analyse. 
2.8.2. RStudio 
 
R is a free, open source, C++ -based programming language that is highly useful for large-scale 
statistical and graphical computing of high throughput omics data [290]. RStudio 
(www.rstudio.com) is a user friendly application based on the R interface and available as a 
desktop application. Various codes and scripts are already written and deposited as packages in 
the Comprehensive R Archive Network (CRAN) repository (https://cran.r-project.org/). Basic 
data in R can be numeric, logical, integer, complex, list, data-frame or character. RStudio 
software (version 0.98.987.0) was used to analyse and create visualization for our data. A 
summary of the steps used is as highlighted below: 
Steps for Rstudio analysis: 
1. Packages for desired analysis was downloaded from CRAN 
2. Packages were installed. 
3. Working directory was set on the computer. 
4. Experimental dataset was read into RStudio. 
5. R was then used to prepare data prior to analysis. 
6. Final analysis was performed 
2.8.3. Perseus 
 
This is a user-friendly C++ based software platform for downstream computational analysis of 
shotgun proteomics output data, generated from the Maxquant software. Thus, this software is 
capable of completing the Maxquant proteomics analysis pipeline. Numerous independent 
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statistical tools are integrated into the Perseus workflow (available at  
http://www.biochem.mpg.de/5111810/perseus). The software is capable of processes like, 
normalization, data imputation, transformation, t-tests, ANOVA, clustering, correlation, 
enrichment, volcano plots, motif identification, scatter plots etc. System-wide analysis is possible 
because Perseus permits the integration of data from different omics sources. The filtering 
process in Perseus is user-defined. Usually, it is recommended that protein groups with less than 
50% presence among replicates should be removed even though it is possible to adjust this 
percentage to meet various experimental objectives. Perseus (version 1.4.0.20) was used for 
analyses of the data generated from Maxquant analysis as described below: 
 
Steps employed in Perseus analysis 
1. Download and install Perseus software 
2. Load Maxquant result into Perseus. 
3. Select data frame. 
4. Filter data. 
5. Transform data. 
6. Categorical row annotation 
7. Filter based on valid values. 
8. Downstream statistical analysis (correlation, hierarchical clustering etc.) 
2.8.4. InfernoRDN 
 
Previously referred to as DAnTE, InfernoRDN (available at 
https://omics.pnl.gov/software/infernordn) is a Windows-based GUI for R. It is used for 
downstream analysis and visualization of omics based data, with an emphasis on proteomics. 
Various diagnostic plots such as boxplots, Q-Q plots, histograms, principal component analysis, 
peptide-protein rollup plots, correlation plots, heat maps, hierarchical clustering and MA plots 
can be generated on this software. InfernoRDN (version 1.1.5274) was used to create additional 




2.8.5. Preprocessing and Normalization 
 
Raw expression data require preliminary processing prior to proper downstream analysis and this 
is referred to as preprocessing. Noisy data is bound to obscure or bias statistical inference and 
data containing too many missing values may mask the actual biologic meaning of generated 
data, hence filtering steps need to be applied to make data more amenable to statistics. After data 
filtering, simple visualizations like boxplots, histograms and Q-Q plots can be used to assess the 
spread of data. In addition, skewedness (lepto-kurtosis or platy-kurtosis) can be assessed using 
simple histograms. It is important that the distribution of data points follow a normal Gaussian 
distribution to be able to apply parametric statistical tests to it; otherwise a non-parametric 
equivalent can be employed. Normality of data distribution can be tested using Shapiro-Wilk, 
Anderson–Darling or Kolmogorov–Smirnov test [291]. To increase signal-to-noise ratio, data 
normalization is essential and a few examples of normalization methods are; Lowess regression, 
logarithmic transformation, quantile normalization, peptide level ANOVA, etc. On the other 
hand, over-normalization can result in “overfitting” of data. In this study we used logarithmic 
transformation for normalization. 
 
2.9. Statistical Analysis 
 
Definitive downstream statistical analysis was performed en-suite with the computational 
workflows. A few important diagnostic statistical methods used for the proteomics data analyses 




2.9.1. Power Statistics 
 
The ability to detect a statistically significant difference in a population if indeed the difference 
is present is known as the “power”, given by the equation (1 – β), where β is the false negative 
rate (Type II error). It can be demonstrated by applying confidence interval to an effect [292]. 
Power calculation helps in the determination of the sample size needed for the study, depending 
on the size of the effect we are interested in. The higher the power, the higher the confidence in 
the observed difference; however a minimum power of 0.8 is needed. The power calculating 
software G*Power (version 3.1.9.2) (http://www.gpower.hhu.de/en.html) was used for power and 
sample size calculation in this study [293, 294]. 
2.9.2. T-Tests with Bonferroni Correction 
 
T-test is a parametric test for the comparison of two group means. Independent sample t-tests are 
important tools for identifying differential protein expression in proteomics data. Means of each 
protein expression level (dependent variable) is compared in between groups (independent 
variable) to determine statistical significance. Type I errors (due to huge number of 
measurement) can be reduced by applying multiple testing correction. This can be done by 
adjustment of the false discovery rate (FDR) as in Benjamini- Hochberg’s method, or by 
Bonferroni’s correction which maintains family wise error rate (FWER). Independent sample t-
tests with Bonferroni correction was used in this study to identify differentially expressed 
proteins between groups with high level of stringency. T tests were performed on Perseus and 
RStudio and visualized with volcano plots (Fig. 2.14).  
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                                Figure 2.14. Example of volcano plot showing differentially expressed proteins (±2SD) 
 
2.9.3. Analysis of Variance (ANOVA) 
 
This is a parametric method used to test for statistically significant differences in two or more 
group means. This test was employed when comparing more than two group means, as using a t-
test in such scenario would increase the chances of type I error. ANOVA was performed using 
Perseus software, and differentially expressed proteins between PCa, BPH and NC groups were 
identified. 
2.9.4. Kruskal-Wallis Test 
 
This is a non-parametric equivalent of ANOVA for identifying statistically significant 
differences between multiple groups (greater than two). This test was employed for identifying 
statistically significant differences in protein expression between ethnic groups in our PCa 
cohort, since the data was found not to be normally distributed. 
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2.9.5. Venn Diagram Analysis 
 
Venn diagram is a mathematical mode of data representation; whereby circles are used to depict 
association or the lack thereof between different groups know as sets, drawn from a rectangular 
set known as the universal set. This tool is highly useful for preliminary assessment of unique 
and shared elements between study groups. A free online based Venn plotting software known as 
Venny (http://bioinfogp.cnb.csic.es/tools/venny/) was used to perform Venn diagram analyses in 
this study [295]. 
2.9.6. Hierarchical Clustering 
 
Hierarchical cluster of analysis is a pattern detection method in proteomics which can be carried 
out using a bottom-up (agglomerative) or a top-down (divisive) approach. Hierarchical clustering 
data is typically depicted using a dendrogram generated from an iterative process of comparing 
similarity scores assigned to individual proteins in the dataset. Hierarchical clustering can be 
performed to identifying group differences, either by using training sets (supervised) or 
identifying random clustering patterns without the use of training set (unsupervised). 
Unsupervised hierarchical clustering was performed with Perseus on z-scored normalization of 
logarithimized data, using Euclidian distances; and on Cluster Treeview (version 3.0) using k-
mean clustering. 
2.9.7. Principal Component Analysis 
 
Principal component analysis is a multivariate test in which potentially correlated variables are 
orthogonally transformed to linear uncorrelated sets of variables (eigenvectors of the covariance 
matrix) known as principal components. The first principal component always has the largest 
variance and subsequent principal components follow decreasing trend of variance. This analysis 
can be performed in one (1-D or loading plot), two (2-D) or three dimension (3-D) to identify 
presence or absence of clustering of variables within each group. Principal component analysis 




CHAPTER 3: MASS SPECTOMETRY-BASED DISCOVERY OF NOVEL 




PCa has the second highest incidence among cancers [296], and there are established disparities 
in PCa progression based on ethnicity [297, 298]. Even though factors for its aggressive course 
are largely unknown, fusion translocation of TMPRSS2-ERG and AKT hyperphosphorylation 
have been demonstrated as ominous prognostic factors in about 50% of all PCa patients [299]. 
New potential biomarkers of PCa have been described [300-303] in Caucasian populations and 
their significance in African populations remains unclear. Despite its invasiveness, biopsy is still 
the commonest approach to confirmation of the diagnosis of PCa [304]. In addition, tampering 
surgically with a malignant lesion may lead to further seeding of the cancer cells [305]. Prostate 
specific antigen (PSA) and Acid phosphatase (ACPP) are inherently inconsistent in sensitivity 
and specificity [304]; acid phosphatase is not specific for PCa  [72] and PSA testing is plagued 
with inconsistencies [306, 307]. Even when combining TRUS, DRE, and PSA assessment, ca. 
40% of all PCa cases would be diagnosed as localized when they are already extraprostatic 
[308]. Prior to the advent of mass spectrometry based proteomics methodologies, sequencing of 
proteins using Edman degradation was quite laborious and limited in capacity [309]. Differential 
proteomics aims to identify changes in specific proteomes that might correlate with disease 
status, disease progression, and response to cancer therapy. Usefully, proteomics techniques can 
be readily applied to urine specimens containing biomarkers that are directly deposited into the 
genitourinary tract [92]. Clinical proteomics has been used to elucidate the pathogenesis of 
disease; as well as to improve the diagnosis and monitoring of cancer and other infective 
diseases [85, 93, 310-314]. Furthermore, since urine represents a readily available and sterile 
specimen, diagnostic markers identified in urine could provide the basis of noninvasive assays 
for detection, early prevention and control of disease [308]. Ethnic-related biomarker disparity 
studies are lacking in African cohorts. Indeed, in spite of the extensive research on PCa to date, 





3.2.1. Clinical Sample retrieval and preservation 
 
In this study, first-stream urine was collected because it has been reported to contain more 
prostatic secretions in comparison to last-stream or mid-stream urine [301]. Even tough 
expressed prostatic secretion (EPS) generated by massaging the prostate has been reported to 
increase the coverage of biomarker pick-up [315-317], it was not used in this study since we 
were looking for the least invasive approach to diagnosing PCa. Besides, performing a second 
DRE after prior physical clinical examination would be unethical. Full ethical consent was 
obtained from all participants as described earlier in Section 2.1 before sample collection.       
Patients suffering from other comorbidities like hypertension and Diabetes mellitus were 
excluded because the risk of developing essential arterial hypertension rises in older patients and 
has been reported to be higher in African populations [318]. All black African PCa patients in 
our cohort were confirmed to be normotensive.  
              
                          Figure 3.1. Two stage analysis design of mass-spectrometry based biomarker study [319] 
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The research was carried out with strict adherence to the ethical principles for medical research 
as prescribed by the Declaration of Helsinki (DoH) 2008 [197]. PCa patients were graded with 
the Gleason scale [302]. Demographic data such as age, race, as well as the (PSA) level were 
recorded (Table 3.1).  
Sample Number (n) Individual/ pooled Age Race PSA level Gleason Score 
PC1 1 Individual 61 M 7.8 3+3 
PC2 1 Individual 74 M 1.7 3+3 
PC3 1 Individual 71 M 0.4 3+4 
PC4 1 Individual 61 B 3.9 4+5 
PC5 1 Individual 74 M 31.0 3+4 
PC6 1 Individual 61 M 27.4 3+3 
PC7 1 Individual 67 M 185.0 4+5 
PC8 1 Individual 80 B 49.0 3+4 
PC9 1 Individual 70 M 113.0 4+5 
PC10 1 Individual 54 W 9.6 5+4 
PC11 1 Individual 68 M 100.0 4+5 
PC12 1 Individual 80 M 30.1 5+5 
PC13 1 Individual 69 W 5.9 3+4 
PC14 1 Individual 64 W 9.1 2+3 
PC15 1 Individual 81 B 10.5 2+2 
PCa 9 Pooled NA NA 1.7-185.0 (3+3) to (5+5) 
BPH 9 Pooled NA NA 0.7-48.4 NA 
NC 9 Pooled NA NA 1.0-2.6 NA 
DC 9 Pooled NA NA NA NA 
BPH: Benign Prostatic Hyperplasia, PCa: Prostate Cancer, NC: Normal Healthy Controls, DC: Disease 
Control, PC: Individual Prostate Cancer, M: Mixed Ancestry, B: Black, W: White, NA: Not Applicable 
Table 3.1. Clinicopathologic data for individual and pooled samples showed variability in Gleason’s score and serum PSA levels.  
3.2.2. Experimental design and pre-analytic phase 
 
The design of the mass spectrometry based aspect of this study is a two stage design which 
involved initial analysis of pooled samples and subsequent analysis of individual samples. 
Results were then cross validated between experimental stages as well as with other urinary 
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databases. Overlap between protein groups identified were documented and analysed for 
potential biomarkers of prostate cancer as shown in the workflow (Figure 3.1 vide supra). 
Before definitive analysis on the mass spectrometer, several sample preparation and 
optimizations steps were followed to ensure good quality of sample for mass spectrometry 
analysis. At the initial stages of the experimental workflow, proteomic analysis was based on 
urine samples from 36 patients, which were divided into 4 pools (i.e. BPH, NC, PCa, & DC). 
Each group was made up of nine 5ml samples which were all thawed and pooled into a single 50 
mL tube. Upstream pooling as done here reduces the level of statistical variance observed as a 
result of technical errors during the sample processing steps. These pooled samples were 
processed as described in Section 2.2. . Although dynamic range problems are more marked in 
blood serum, high abundance proteins in urine may mask the detection of low abundance and 
often biological significant analytes. Hence, high abundance proteins such as human serum 
albumin, uromodulin (a.k.a Tamm-horsfall protein), and immounoglobulins in the supernatant 
were filtered out using a 50KDa centrifugal molecular weight cut-off (Amicon® Ultra) filter 
unit. After protein quantification and buffer exchange, protein proteolysis was carried out using 
Filter Aided Sample Preparation (FASP) as previously described elsewhere [208]. All organic 
solvents used after tryptic digestion contained 0.1% Triflouroacetic acid (TFA), which is a very 
good ion-pairing agent. Peptide samples were then transferred to StageTips for offline desalting, 
solid phase extraction (SPE), and sample clean-up as described elsewhere [209]. Samples were 
then lyophilized on a Centrivap centrifugal vacuum concentrator and re-suspended to 1μg/μl in 
HPLC grade water (Sigma-Aldrich, St. Louis, MO, USA) containing 0.1% Formic acid (FA) and 
stored at -80⁰C until ready to run on the mass spectrometer. Similar pre-analytic processing was 
performed prior to individual sample analysis. An overview of the workflow for pooled sample 




                                           Figure 3.2. Pooled sample Label-free Urinary Proteomics workflow [319] 
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3.2.3. Ultra-High Performance Liquid Chromatography (UHPLC) 
 
Ultra-high performance liquid chromatography (UHPLC) using a nano-flow system was done 
online on a Dionex UltiMate® 3500 RSNano UPLC systems (Thermo Fisher, San Jose, CA, 
USA) utilysing a C-18 reverse phase precolumn trap (100μm×5cm; 100 Å; 5cm; C-18) with an 
analytic column (75 μm×50cm; 100 Å; 5cm; C-18). Detailed description of the steps involved is 
contained in Section 2.3.1.  
3.2.4. Mass Spectrometry Analysis 
 
A bottom-up (shotgun) proteomics analysis was performed on a QExactiveTM Hybrid 
Quadrupole-Orbitrap Mass Spectrometer (Thermo Fisher, San Jose, CA, USA) in-line with the 
Dionex UltiMate® 3500 RSNano UPLC systems (Thermo Fisher, San Jose, CA, USA). Flow 
injection analysis of samples introduced from the UHPLC system was done using the following 
system specifications as contained in Section 2.3.3.  
3.2.5. Statistical and computational analysis of generated data  
 
The Xcalibur raw* files generated from mass spectrometry experiments were quantitatively 
analysed using the Maxquant software (version 1.3.0.5) default settings with a few minor 
modifications. Carbamidomethylation of cysteine was specified as a fixed modification; and N-
terminal acetylation and oxidation of methionine were selected as variable modification. Enzyme 
specification during the Andromeda search was specified as trypsin/P. Precursor mass tolerances 
and fragment ions mas tolerance were set at 20ppm and 0.5 Dalton respectively in initial scan 
and then set at 6ppm for the main search. Andromeda search engine which is integrated into 
Maxquant suite was used to perform tandem MS search, queries were run against target 
databases such as International Protein Index (IPI human version 3.87). Lower limit cutoff set for 
peptide length was 7 amino acids, and not more than two missed cleavage were permissible. 
Results generated from Maxquant were thereafter imported directly into Perseus software 
(version 1.4.0.20) for further computational analysis and visualization. False discovery rates 
(FDR) used for pooled and individual experiment analysis were 0.01 and 0.001 respectively.  
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3.3.   Results 
3.3.1. Pooled Sample Experimental Findings 
 
We quantitatively analysed raw* files from “pooled” PCa, BPH, NC and DC samples with 
Maxquant software with integrated Andromeda search engine and found a total of 1102 protein 
groups. Of these, 217 (19.69%) were single peptide protein groups and 15 (1.36%) were only 
identified by modification site. There were 41 (3.72%) contaminants and 12 were identified as 
reverse hits. Total identified evidence at peptide level was 32,061 with peptide unique to a 
protein group being 5,069 (90.60%). Identified non-redundant peptides were 5,595 and reverse 
hits were 14. False discovery rates (FDR) were estimated to be 1.10% and 0.25% for protein 
groups and peptides respectively at FDR1 level; and 2.18% and 0.50% at FDR2 level (Table 2). 
FDRs for modified peptides, evidences and msms were 0.25%, 0.09% and 0.07% respectively at 
FDR1 level; and 0.50%, 0.17%, and 0.14% at FDR2 level respectively.  A total of 596 
modifications of peptides were observed which were mainly oxidation of methionine and N-
terminal acetylation. There were no missed cleavages in 87.1%, one in 11.9% and 2 in 0.9% of 
the peptides identified. A summary of our pooled experimental findings is shown below (Table 
3.2). The total ion chromatogram generated from the pooling experiment showed different 
profiles for the different groups PCa, BPH, DC and NC (Figure 3.3); and its even spread 
signifies a stable spray during measurement.  
Pooled Experiment 
PG Peptides 
Parameters Result Parameters Result 
Protein Groups 1102 Identified Evidence 32061 
Single Peptide PG 217 (19.69%) Reverse Hits 28 
Only Identified by site 15 (1.36%) Identified Peptides (non-redundant) 5595 
Contaminants 41 (3.72%) Peptides Unique to a PG 5069 (90.60%) 
Reverse Hits 12 Contaminants 373 (6.68%) 
FDR1 1.1 Reverse Hits (non-Redundant) 14 
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FDR2 2.18 FDR1 0.25 
    FDR2 0.5 
PG: Protein Groups, FDR: False Discovery Rate 
Table 3.2. Maxquant result summary of pooled experiment demonstrates that Protein groups compared with peptide unique to a protein group in 
pooled experiment was approximately 1:5 and level of contaminant was below 5% showing that the results generated were of good quality.  
 
                Figure 3.3. Total ion chromatogram showing differential profile between PCa, BPH, DC and NC both at MS1 and MS2 levels 
 
3.3.2. Data Preprocessing for Statistical Computation 
 
Output files generated from Maxquant for peptides, protein groups, and evidences in text (*.txt) 
format were processed from the “combined” folder of the Maxquant result. Spectral statistical 
analyses were performed on log-2 transformed expression data such as Intensity Based Absolute 
Quantification (iBAQ) values, raw Intensities, and Label free quantitation (LFQ). Depending on 
the total number of missing values per peptide, missing values in peptide expression were either 
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filtered out or imputed with values of intensity from the lower limit of the Gaussian distribution 
of peak intensities [320].  
Computational analysis based on R-studio, involved the use of basic statistical packages (e.g. 
gplots, Knitr, gdata) which were download from the CRAN repository (www.cran.r-project.org/) 
and automatically installed; or manually with a tar.gz files. Following which the “working 
directory” is set and then R is used to read and assess information found in datasets. In this study, 
IBAQ values normalization was first performed by logarithmic transformation (log-2) prior to 
comparison. An initial filtering-out step was carried for proteins with over 50% missing values. 
After cleaning the data in this manner, data spread was then evaluated using box-whisker plots 
(Figure 3.4) and Q-Q plots (Figure 3.5).  
The level of expression of 9 common housekeeping proteins from literature was further 
examined in our pooling experiment and observed that useful β-actin and β-2-microglobulin 
(B2M) where very dependable across all our experimental groups (Figure 3.6). This was also 
demonstrated by expression level in multiple samples as depicted in the protein profile plot 
shown below (Figure 3.7).  
                                                                                 
Figure 3.4. Box- whisker plot to assess the spread of data in each study group (BPH, NC, PCa &DC). On the x-axis are the different pooled 
groups and on the y-axis are log2 -transformed IBAQ values. 
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Figure 3.5. Q-Q plot used to assess data spread in PCa, BPH, DC and NC by comparing the experimental quantiles with theoretical quantiles. On 
the x-axis is the normal theoretical quantile while on the y-axis is the sample quantiles. The data points can be seen to be within acceptable 
distance of the reference line (red). 
Uromodulin or Tamm-Horsefall protein, as expected when renal disease is not present, was 
found to be most abundant in individual and pooled normal healthy (NC) samples in comparison 
to PCa and BPH. In addition, we observed that despite uromodulin’s dominance of the urinary 
proteome, more than 1,500 urinary unique proteins have been previously detected by mass-
spectrometry based methods [321, 322]. Not least, quantitative disease-associated changes in the 
urinary proteome have been previously reported in literature, even when the disease site is 




Figure 3.6. House-keeping protein profile revealed that β2-microglobulin (B2M) and β-actin were stably expressed across all 4 pooled groups. 
Nine common housekeeping proteins from literature were selected. On the x-axis are the housekeeping proteins and on the y-axis are the log2-
transformed IBAQ intensities for the protein groups. 
 
Figure 3.7. Protein profile shows β-actin to be stably expressed across duplicate pooled sample runs. On the x-axis are the pooled sample 
replicates and on the y-axis are log2-transformed IBAQ values. 
3.3.3. Venn Diagram Analyses 
 
Venny, a free online Venn diagram plotting software (link as described earlier) was used to plot 
a 4-way Venn diagram to assess the proteins unique to each, and the degree of overlap between 
them. Up to 63% of the identified peptides were found to be common to at least 3 out of the 4 
pooled group which is in keeping with the reported proportion of the “core proteome” in 
literature [323]. Also from this plot 65, 19, 44 and 42 proteins groups were found to be unique 
NC, PCa, BPH and DC respectively and this unique protein sets represent an excellent niche for 
investigation of potential biomarkers (Figure 3.8). 
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                           Figure 3.8. Venn diagram showing unique and overlapping protein sets in BPH, DC, NC, and PCa 
3.3.4. Intensity- based Absolute Quantification (iBAQ) and MS1 Analysis 
 
IBAQ-based MS1 quantification [324] was carried out on for precursor-ion mass analysis. Using 
this approach, total intensity of protein was normalized by length of peptide. Integration of the 
area under the MS1 peak for the top scoring peptides which were more abundant in the PCa pool 
as compared with DC, NC, and BPH pools were documented. Conversely, peptides found to be 
absent or less abundant were also identified by this method. A total of 20 protein groups were 
found to be potential biomarkers of PCa by this method (Table 3.3).  
Candidate Biomarkers of PCa by MS1 spectral quantification 
More Abundant in PCa (≥2-folds) Less Abundant in PCa (≤2-folds) 
sp|P01023|A2MG_HUMAN Alpha-2-macroglobulin tr|E7EPZ9|E7EPZ9_HUMAN Tenascin-X  
sp|P01024|CO3_HUMAN Complement C3  sp|Q99715|COCA1_HUMAN Collagen alpha-1(XII) 
chain  
sp|P04114|APOB_HUMAN Apolipoprotein B-100 sp|P12109|CO6A1_HUMAN Collagen alpha-1(VI) chain  
sp|P00918|CAH2_HUMAN Carbonic anhydrase 2  sp|P24821|TENA_HUMAN Tenascin  
sp|P08603|CFAH_HUMAN Complement factor H  sp|P12111|CO6A3_HUMAN Collagen alpha-3(VI) chain  
sp|P02649|APOE_HUMAN Apolipoprotein E  sp|P14543|NID1_HUMAN Nidogen-1  
tr|Q32Q12|Q32Q12_HUMAN Nucleoside 
diphosphate kinase  
  
sp|P02775|CXCL7_HUMAN Platelet basic protein   
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OS=Homo sapiens GN=PPBP PE=1 SV=3 
sp|P24666|PPAC_HUMAN Low molecular weight 
phosphotyrosine protein phosphatase  
  
sp|P30041|PRDX6_HUMAN Peroxiredoxin-6    
sp|P19827|ITIH1_HUMAN Inter-alpha-trypsin 
inhibitor heavy chain H1  
  
sp|P37840|SYUA_HUMAN Alpha-synuclein   
tr|G3V2F7|G3V2F7_HUMAN HCG2044781 
(Ubiquitin-conjugating enzyme E2 variant 1) 
  
sp|P04003|C4BPA_HUMAN C4b-binding protein 
alpha chain 
  
                                    Table.3.3. List of more and less abundant protein groups by MS1 spectral quantification  
Even from this initial binary MS1 spectral quantification result, it was observed that that protein 
groups that were found to be less abundant included collagens and other extracellular matrix 
molecules such as Tenascin and Nidogen-1; which made biologic sense because downregulation 
of extracellular matrix molecules is required for the mobility of cancer cells from the surface 
layer through the basement membrane into the lamina propria [325, 326].  
Furthermore, we carried out an independent sample t-test with Bonferroni’s correction for 
multiple testing was performed using iBAQ values that were log-transformed (Figure 3.9). This 
was done to find differential peptide iBAQ values in order to identify differentially expressed 
peptides between PCa and NC. The dependent variables were normalized iBAQ values for 
proteins, while the independent variables were PCa and NC. Using this method, 17 proteins were 
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found to be differentially expressed (±2SD) as shown by Table 3.4. 
 
                      Figure 3.9. Volcano plot of differentially expressed (±2SD) protein groups between PCa and NC 
Candidate Biomarkers of Pca by IBAQ (±2SD) 
P02656 (APOC3_HUMAN) Apolipoprotein C-III variant 1  
P00738 (HPT_HUMAN) Haptoglobin  
P00915 (CAH1_HUMAN) Carbonic anhydrase I  
P01009 (A1AT_HUMAN) Alpha-1-antitrypsin  
P01876 (IGHA1_HUMAN) Ig alpha-1 chain C region  
P02647 (APOA1_HUMAN) Apolipoprotein A1  
P02675 (FIBB_HUMAN) Fibrinogen beta chain  
P02750 (A2GL_HUMAN) Leucine-rich alpha-2-glycoprotein  
P06702 (S10A9_HUMAN) Protein S100-A9  
P07737 (PROF1_HUMAN) Profilin-1 (Epididymis tissue protein Li 184a) 
P19961 (AMY2B_HUMAN) Alpha-amylase 2B  
P30043 (BLVRB_HUMAN) Flavin reductase (NADPH)  
P30740 (ILEU_HUMAN) Leukocyte elastase inhibitor  
P61626 (LYSC_HUMAN) Lysozyme C  
P62937 (PPIA_HUMAN) Peptidyl-prolyl cis-trans isomerase A (Cyclophilin A) 
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P68871 (HBB_HUMAN) Hemoglobin subunit beta  
P69905 (HBA_HUMAN) Hemoglobin subunit alpha  
                                            Table 3.4. List of 17 differentially expressed protein groups by t-test 
Using hierarchical clustering of the protein groups versus pooled PCa, NC, BPH and DC groups, 
a similar molecular signature was found for DC and BPH groups. However, there was a distinct 
signature for NC which was completely different for PCa. The BPH and DC signature looks a bit 
more like the PCa signature as compared with the NC as shown in the heat map presented below 
(Figure 3.10).   
 
                                          Figure 3.10. Hierarchical clustering of PCa, BPH, NC and DC 
Even though it is widely known that prostatitis and some other pathologies of the genitourinary 
tract which formed the DC group in this study can be responsible for false positive in PSA 
results when trying to diagnose prostate cancer; our hierarchical clustering result interestingly 
differentiated them quite clearly, possibly due to the high mass accuracy and resolution of the 
mass spectrometry instrument used. 
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3.3.5. Power Calculation and Sample Size Determination 
 
Power calculation is highly essential in the determination of the extent to which differences 
between the different study-groups could be identified, if indeed they existed. Based on the 
statistics generated from the preliminary pooled sample experiments, we calculated the required 
total number of individual samples (N) needed to attain a statistical power (1-β) of 0.8, and found 
it to be 43 individual samples (Figure 3.11). Individual sample analyses was therefore performed 
on 45 samples comprised of three subgroups (n=15) which were PCa, NC and BPH. DC was 
eliminated because it had similar molecular signature with BPH and technically speaking, BPH 
is also a form of disease control. 
                       
Figure 3.11. Power plot showing that 43 samples were required to attain a statistical power of 0.8. This is a power curve generated automatically 
from G*Power using statistical parameters generated from the initial pooling experiment  
3.3.6. Individual Analysis of PCa, BPH and NC Samples 
 
Using 45 individual samples (PCa (n)=15, BPH (n)=15, NC (n)=15), quantitative analysis was 
performed with Maxquant software with integrated Andromeda search engine. A total of 1,545 
protein groups were identified in all experiments (N=45). Of these, 206 (13.33%) were single 
peptide protein groups and 20 (1.29%) were only identified by modification site. There were 41 
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(2.65%) contaminants and 19 were identified as reverse hits. Total identified evidence at peptide 
level was 122,257 with peptide unique to a protein group being 9,191 (91.99%). Identified non-
redundant peptides were 9,991 and reverse hits were 29. False discovery rates (FDR) were 
estimated to be 1.25% and 0.29% for protein groups and peptides respectively at FDR1 level; 
and 2.46% and 0.58% at FDR2 level. FDRs for modified peptides, evidences and msms were 
0.28%, 0.09% and 0.06% respectively at FDR1 level; and 0.57%, 0.19%, and 0.13% at FDR2 
level respectively (Table 3.5).  A total of 809 modifications of peptides were observed which 
were mainly oxidation of methionine and N-terminal acetylation. There were no missed 
cleavages in 81.6%, one in 16.6% and 2 in 1.8% of the peptides identified. False discovery rates 
(FDR) for proteins, peptides, site and All Ion Fragmentation (AIF) threshold were at 0.01%. 
Maximum peptide Posterior Error Probability (PEP) was at 1%. 
Individual Experiment 
PG Peptides 
Parameters Result Parameters Result 
Protein Groups 1545 Identified Evidence 122257 
Single Peptide PG 206 (13.33%) Reverse Hits 114 
Only Identified by site 20 (1.29%) Identified Peptides (non-redundant) 9991 
Contaminants 41 (2.65%) Peptides Unique to a PG 9191 (91.99%) 
Reverse Hits 19 Contaminants 465 (4.65%) 
FDR1 1.25 Reverse Hits (non-Redundant) 29 
FDR2 2.46 FDR1 0.29 
    FDR2 0.58 
PG: Protein Groups, FDR: False Discovery Rate 
                                                Table 3.5. Summary of individual sample mass spectrometry runs. 
Protein profile plots demonstrated that β-2-microglobulin (Figure 3.12) and β–actin (Figure 





                         Figure 3.12. Protein profile plot demonstrated β-2-microglobulin to be stably expressed across multiple individual samples 
 
                       Figure 3.13. Protein profile plot demonstrates β–actin to be stably expressed across multiple individual samples 
For quality control, three technical replicate samples were randomly selected from the 45 
individual samples and repeatedly injected and then analyzed to assess the accuracy of the mass 
spectrometer. It was observed from this quality control check that the coefficient of variation 
difference ranged from 0.0009 to 0.0026. This high degree of correlation between these replicate 
samples was also observed by scatterplot (Figure 3.14), multivariate principal component 




                                     
      Figure 3.14. High correlation between repeat injection of randomly selected samples (NC11, PC8 and PC15) 
 




Figure 3.16. Correlation between repeat injection technical replicate sample (NC11, PC15 and PC8) demonstrated by Hierarchical clustering 
3.3.7. Urinary Proteome Covered for South African PCa Patients 
 
When the “pooled” and “Individual” proteomics experiments were combined, a total of 1788 
proteins were identified of which 832 protein groups were from PCa samples (Annexure I). This 
identified catalog of proteome coverage discovered in these experiments included reverse 
Identifications (IDs), isoforms, and a few contaminants of potential human origin.  
3.3.8. Potential Prostate Cancer Biomarker Characterization 
 
Individual analysis of patient sample was performed to improve the proteome coverage and to 
increase the number of potential PCa biomarkers to be tested by Parallel Reaction Monitoring 
(PRMs). The relative abundance of MS1 precursor ion spectral count normalized by the iBAQ 
method was compared between PCa, BPH and NC in a binary mode. Using this method, 48 
protein groups were found to be more abundant in PCa and 32 were less abundant as compared 
with NC and PCa. This phase of the individual sample analysis was carried out with stringent 
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visual assessment of performance of peptides across the individual samples. Using label free 
quantification (LFQ) values and iBAQ, differentially expressed proteins were also assessed using 
the Perseus Software (version 1.4.0.20). Logarithmically normalized LFQ and iBAQ values were 
used to perform two independent t-tests with Bonferroni’s correction for “PCa vs BPH” and 
“PCa vs NC” and found differentially expressed proteins between these groups. For further 
validation, a one-way analysis of variance (ANOVA) was performed for BPH, PCA, and NC for 
identification of peptide-level variance between these groups.  In addition, Venn diagrams were 
used to identify overlap between differentially expressed peptides identified by independent 
sample t-test and ANOVA. A total of 157 differentially expressed peptides were found to 
overlap between independent sample t-test and ANOVA. On further stringency increase, by 
lowering the false discovery rate (FDR) from 0.01 to 0.001 using the Perseus software, and 
eliminating elements already found by MS1 spectral quantification; a total of 45 protein groups 
were found unique to differential expression analysis and 28 were found unique to the MS1 
spectral peak integration analysis (Table 3.6). Summing up, 73 protein groups were found to be 




Protein Name MS1 
/LFQ 
PEP Scores 
1 P00915 Carbonic anhydrase 1 LFQ 1.86E-138 
2 P69905 Hemoglobin subunit alpha LFQ 0 
3 B0YIW2 Apolipoprotein C-III LFQ 4.32E-64 
4 P00738 Haptoglobin LFQ 0 
5 P06702 Protein S100-A9 LFQ 0 
6 P30043 Flavin reductase (NADPH) LFQ 1.54E-17 
7 P68871 Hemoglobin subunit beta LFQ 0 
8 Q6GTX8 Leukocyte-associated immunoglobulin-like receptor 1 LFQ 2.64E-304 
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9 B1AVU8 Saposin-D LFQ 3.02E-171 
10 P0CG48 Polyubiquitin-C LFQ 0 
11 P01133 Pro-epidermal growth factor;Epidermal growth factor LFQ 0 
12 Q07654-2 Trefoil factor 3 LFQ 2.52E-61 
13 E9PR17 CD59 glycoprotein LFQ 0 
14 F8W7I2 Prostaglandin-H2 D-isomerase LFQ 0 
15 H9KV70 Neutrophil gelatinase-associated lipocalin LFQ 0 
16 O00187 Mannan-binding lectin serine protease 2 A chain LFQ 0 
17 P04155 Trefoil factor 1 LFQ 9.93E-101 
18 P04406 Glyceraldehyde-3-phosphate dehydrogenase LFQ 2.54E-07 
19 P04430 Ig kappa chain V-I region BAN LFQ 3.46E-120 
20 P04745 Pancreatic alpha-amylase LFQ 0 
21 P05451 Lithostathine-1-alpha LFQ 9.99E-239 
22 M0R1F0 Prostate-specific antigen LFQ 3.13E-101 
23 P07998 Ribonuclease pancreatic LFQ 0 
24 P08123 Collagen alpha-2(I) chain LFQ 7.71E-23 
25 P10153 Non-secretory ribonuclease LFQ 0 
26 P10451 Osteopontin LFQ 0 
27 P11684 Uteroglobin LFQ 2.44E-68 
28 P15309-2 Prostatic acid phosphatase;PAPf39 LFQ 0 
29 P16401 Histone H1.5 LFQ 3.93E-22 
104 
 
30 P17900 Ganglioside GM2 activator LFQ 3.71E-88 
31 P35555 Fibrillin-1 LFQ 0 
32 P35754 Glutaredoxin-1 LFQ 4.25E-97 
33 P36957 Dihydrolipoyllysine-residue succinyltransferase 
component of 2-oxoglutarate dehydrogenase complex, 
mitochondrial 
LFQ 6.86E-52 
34 P60022 Beta-defensin 1 LFQ 6.80E-123 
35 P61626 Lysozyme C LFQ 0 
36 G3V3D1 Epididymal secretory protein E1 LFQ 8.38E-225 
37 P08571 Monocyte differentiation antigen CD14 LFQ 0 
38 P98160 Basement membrane-specific heparan sulfate 
proteoglycan core protein 
LFQ 0 
39 Q03403 Trefoil factor 2 LFQ 8.14E-160 
40 Q14508 WAP four-disulfide core domain protein 2 LFQ 0 
41 Q15828 Cystatin-M LFQ 1.18E-281 
42 Q96PD5-2 N-acetylmuramoyl-L-alanine amidase LFQ 4.42E-138 
43 Q9BZG9 Ly-6/neurotoxin-like protein 1 LFQ 7.06E-298 
44 Q9H299;Q5T123 SH3 domain-binding glutamic acid-rich-like protein 3 LFQ 0 
45 P02652 Apolipoprotein A-II;Truncated apolipoprotein A-II LFQ 0 
46 P07225 Vitamin K-dependent protein S MS1 0 
47 P00739-2 Haptoglobin-related protein MS1 1.27E-292 
48 P00918 Carbonic anhydrase 2 MS1 4.36E-10 
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49 P14543 Nidogen-1 MS1 7.43E-118 
50 P01023 Alpha-2-macroglobulin MS1 0 
51 P08603 Complement factor H MS1 0 
52 P04003 C4b-binding protein alpha chain MS1 3.36E-192 
53 P19823 Inter-alpha-trypsin inhibitor heavy chain H2 MS1 0 
54 F5H4W9 Serum paraoxonase/arylesterase 1 MS1 3.96E-95 
55 H0YAC1 Plasma kallikrein MS1 7.42E-27 
56 P07357 Complement component C8 alpha chain MS1 6.00E-22 
57 P02788 Lactotransferrin MS1 0 
58 P04114 Apolipoprotein B-100;Apolipoprotein B-48 MS1 0 
59 P19827 Inter-alpha-trypsin inhibitor heavy chain H1 MS1 0 
60 P12814 Alpha-actinin-1 MS1 0 
61 P13796 Plastin-2 MS1 0 
62 Q99715 Collagen alpha-1(XII) chain MS1 4.23E-156 
63 P12109 Collagen alpha-1(VI) chain MS1 0 
64 P22105 Tenascin MS1 5.66E-149 
65 P12111 Collagen alpha-3(VI) chain MS1 5.06E-177 
66 P55287 Cadherin-11 MS1 6.06E-150 
67 Q8WZ75 Roundabout homolog 4 MS1 7.90E-124 
68 Q9UBR2 Cathepsin Z MS1 7.84E-50 
69 P54802 Alpha-N-acetylglucosaminidase MS1 1.59E-90 
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70 P15169 Carboxypeptidase N catalytic chain MS1 1.16E-09 
71 P01880-2 Ig delta chain C region MS1 3.40E-60 
72 Q06033 Inter-alpha-trypsin inhibitor heavy chain H3 MS1 1.12E-32 
73 P20742 Pregnancy zone protein MS1 1.05E-240 
LFQ: Label Free Quantification; MS1: Precursor ion spectral peak quantification; PEP: Posterior Error 
Probability; S/N: Serial Number 
                                              Table 3.6. List of discovered potential biomarkers of prostate cancer  
 Unsupervised hierarchical clustering was performed for “protein groups vs PCa and NC 
samples”, and this showed distinct molecular signatures between them (Figure 3.17). 
 
                                             Figure 3.17. Heatmap shows different molecular signature between NC and PCa. 
When BPH samples were included to the hierarchical clustering, it was observed that 4 of the 
BPH samples clustered closer to NC, while three of the PCa samples clustered closer to BPH. 
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These small overlaps warrant further research. Generally, NC, BPH and PCa samples clustered 
distinctly (Figure 3.18). 
 
   Figure 3. 18. Heatmap shows distinct molecular signature between PCa, NC and BPH, with slight overlap between a few samples 
Multivariate testing using principal component analysis for PCa, NC and BPH samples was also 
performed, and this revealed a similar trend with the hierarchical clustering when a 2-D 
(principal components1&2) or a 3-D (Principal components 1,2&3) was performed (Figure 
3.19). It was observed that NC samples clustered more tightly compared with PCa or BPH. By 
these proteomics analyses, there seems to be at least 2 sub-groups of BPH and PCa and possibly 




Figure 3.19. 2-D and 3-D principal component analyses shows separate clustering of peptides in NC (blue) and PCa (pink), even though there 
seems to be 2 distinct subgroups of PCa 
 
 
Figure 3.20. 2-D and 3-D principal component analyses show separate clustering of NC (purple), PCa (yellow) and BPH (green); however some 
overlap can be observed between PCa and BPH. 
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3.3.9. Racial Trends in Potential Prostate Cancer Biomarkers 
The 15 PCa samples in our cohort was carefully analysed for racial trends in potential 
biomarkers identified. In this PCa cohort, nine samples were of Mixed Ancestry or “Coloured” 
origin (PCa_M), three were blacks Africans (PCa_A) and the last three were Caucasians 
(PCa_A). Even though Q-Q plots (Figure 3.21), histograms (Figure 3.22), Boxplots (Figure 
3.23) and Shapiro-Wilk test (p value > 0.05) indicated that these samples were normally 
distributed, we could not identify any racial biomarker between these three racial groups with 
statistical significance both by ANOVA and non-parametric Kruskal-Wallis test; this is possibly 
because our sample size is underpowered to decipher the true between-group differences.  
              Figure 3.21. Q-Q plots of all 15 PCa samples show normal distribution of all samples in relation to the reference line 
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 Figure 3.22. Histograms of all 15 PCa samples demonstrating a Gaussian distribution of all samples. A range of log2-transfromed IBAQ 
intensities were plotted on the x-axis, while the probability is plotted on the y-axis. 
 
                              Figure 3.23. Boxplot showing normal distribution of all 15 PCa samples in the cohort 
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The “numeric-venn” function in Perseus Software was further used to identify protein groups 
that are unique to preprocessed and filtered protein groups. Even though this method is a binary 
approach without considering relative expression, we identified that MAN1A1 (Mannosyl-
oligosaccharide 1,2-alpha-mannosidase IA) and SLAIN1 (SLAIN motif-containing protein 1) 
were found to be unique to PCa_A; and GP1BA (Platelet glycoprotein Ib Alpha chain; 
Glycocalicin), PSMF1 (proteasome inhibitor P131 subunit), MYOC (Myocilin) , FABP6 
(Gastrotropin), and Ig Heavy chain V-III region ZAP were found to be unique to the PCa_M. 
There were no protein groups found unique to the PCa_C group by this approach (Table 3.7).  
PCa_A PCa_M PCa_C 
MAN1A1 GP1BA  
SLAIN1 PSMF1  
 MYOC  
 FABP6  
 Ig Heavy chain V-III region ZAP  
                                        Table 3.7. List of proteins unique to racial groups by numeric Venn analysis 
Further analysis was carried out on the 45 and 28 potential biomarkers identified by iBAQ/LFQ 
analysis and MS1 spectral analysis respectively. For each of these 2 sets of potential prostate 
cancer biomarkers, 4-way Venn analysis with protein groups in PCa_A, PCa_M and PCa_C was 
performed to identify potential ethnic-based biomarker trend. Thirty-seven (37) out of 45 
differentially expressed potential biomarkers were shared by the 3 racial groups. HPT 
(Haptoglobin) was shared by PCa_C, and PCa_M. AMY1 (Alpha-amylase 1), PTGDS 
(Prostaglandin-H2 D-isomerase), REG1A (Lithostathine-1-alpha), OSTP (Osteopontin), and 
SAP3 (Ganglioside GM2 activator) were found unique to PCa_C. ODO2 (Dihydrolipoyllysine-
residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex) was only 
found in PCa_A (Figure 3.24).  
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          Figure 3.24. Venn diagram showing overlap between differentially expressed potential biomarkers and the 3 racial groups 
Nine (9) out of the 28 potential biomarkers by MS1 spectral analysis were shared by the 3 racial 
groups.  PON1 (Serum paraoxonase/arylesterase 1) and C4BPA (C4b-binding protein alpha 
chain) were found to be unique to PCa_A. KLKB1 (Plasma kallikrein heavy chain), ITIH3 
(Inter-alpha-trypsin inhibitor heavy chain H3), ITIH2 (Inter-alpha-trypsin inhibitor heavy chain 
H2), and COL6A1 (Collagen alpha-1(VI) chain) were observed to be common to PCa_C and 
PCa_M. PLSL (Plastin-2), ACTN1 (Alpha-actinin-1), COL6A3 (Collagen alpha-3(VI) chain), 
and TENX (Tenascin-X) were common to PCa_A and PCa_M. HPTR (Isoform 2 of 
Haptoglobin-related protein), PZP (Pregnancy zone protein), PROS (Vitamin K-dependent 
protein S), IGHD (Isoform 2 of Ig delta chain C region), and CBPN (Carboxypeptidase N 
catalytic chain) were unique to PCa_M (Figure 3.25). 
                         
Figure 3.25. Venn diagram showing overlap between 28 potential biomarker by MS1 spectral analysis and three racial groups  
113 
 
3.4.  Discussion 
 
It is well reported that the urinary proteome is far less complex as compared with plasma, serum, 
cell or tissue proteomes [327, 328]. As performed initially here, pooling reduces the level of 
biologic variability among individuals and minimizes the experimental runs needed, as well as 
reduces the total cost of experiments [329]. Furthermore, it also permits for method development 
and optimization; and avoidance of sample wastage [330]. However, it is unable to provide 
adequate basis for good biological inferences concerning the types of samples being compared. 
This strategy can generate useful comparative information about pooled samples themselves, 
albeit unable to provide adequate information about the individuals in the population from which 
the pools were drawn [329]. Biologically independent replicate sub-pooling can improve the 
information derived from pooling experiments [329]. Considering that proteome composition 
within and between individuals varies with disease state, diet, time of the day, and possible 
environment or ethnicity [331-334]; it is necessary to statistically normalize proteomics data to 
increase the signal to noise ratio. Various normalization methods have been reported [320, 335-
337], but great caution must be exercised to avoid over-fitting of data [335].  
 As observed in this study, up to 63% of the peptides were shared by at least 3 out of the 4 
pooled groups. Previous studies have reported the measurable “core proteome” in proteomics 
experiment to be similar [323, 338] . The advent of high resolution, accurate mass (HRAM) mass 
spectrometers with mass accuracy less than 10ppm has drastically improved quantification of 
integrated MS1 peak intensities, even in a label-free experimental setup [339-341]. Heretofore, 
MS2 spectral counting methods were more appealing to proteomics researchers due to the 
inherent inaccuracies of MS1 signals quantification on lower resolution instruments [342, 343]. 
It is now known that MS2 spectral counting is highly data dependent and true abundance level of 
peptides can be easily saturated [341]. MS2 signal saturation is a consequence of ion packeting; 
particularly when ions are present at high concentrations [344]. This affects the accurate 
quantitation of proteins due to the fact that a huge number of ions are reaching the detector at the 
same time, particularly ions from high abundance proteins [344]. (A figure illustrating the 
essential differences between MS1 and MS2 quantitation is presented in Annexure VI) The 
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statistical power of 0.8 as we have used in this study is the minimum acceptable level for 
proteomics experiments in keeping with literature [345],.  
Disease related and normal human urinary proteomes have be characterized by various studies 
[116, 321, 323, 346-353]; detecting between 124 to 1823 proteins. Two landmark researches 
recently described a comprehensive draft of the human proteome using several fetal and adult 
human tissues, cell lines, and body fluids. Between 17, 294 - 18,097 of the over 20,000 annotated 
genes in the human genome were identified in these studies [323, 352]. These aggregations of 
data from several studies have expedited the development of the proteome databases. However 
there remains a dearth of proteome catalog constituents from African-based studies, particularly 
a urine-based proteome. Hence, we established a draft physiologic urinary proteome of a 
Southern African human cohort, in addition to PCa specific urinary proteome.  
Previous studies have employed smaller cohort of patients in comparison this study [317, 354]. 
Validation of proteins generated from mass spectrometry based experiments with real-time 
qualitative PCR (RTqPCR) as performed by some studies [354] could potentially interfere with 
downstream statistical inferences because transcriptomics does not always correlate accurately 
with proteomics and vice versa due to factors like posttranslational modifications and 
translational control [355]. 
From the individual sample analysis, distinct clustering of PCa, BPH and NC with minor 
overlaps in a few BPH and PCa samples may indicate underlying disparity between molecular 
and histopathologic classification. It was particularly interesting to note that a subset of BPH 
patients were similar to NC patients, and some PCa patients looked more like BPH patients, 
based on their urinary proteomes. This further buttresses the fact that molecular signatures may 
be more reliable for classification than phenotypic characterization. In addition, this disparity 
may point to the fact that some prostate cancers may originate from a prior BPH state and may 
have a different prognostic indication. However, these observed differences in PCa urinary sub-
proteomes require further research. 
Many of the candidate biomarkers discovered in this study have been previously described in the 
literature as playing a role in cancer, including prostate cancer (Table 3.8). For instance, 
Pregnancy Zone Protein (PZP), which is a homologous inhibitor of alpha-2 macroglobulin, is 
able to cleave prostate specific antigen at Lys145-lys146 to form “nicked PSA”. This cleavage 
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does not inactivate PSA but limits recognition of PSA epitopes by commercial ELISA kits. Also, 
Trefoil Factor 3 (TFF3) overexpression has been reported to increase ERG-mediated cellular 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Subcellular characterization of these potential biomarkers shows that most were predicted as 
secreted, cell membrane, and extracellular proteins. Many inflammatory molecules were found to 
be upregulated in PCa as well. This was not strange as inflammation is an emerging hallmarks of 
cancer [25]. Also, cluster of differentiation (CD) family molecules and other proteins derived 
from leukocytes such as neutrophil gelatinase-associated lipocalin 2 (LCN2) have been reported 
in human urinary proteomes previously [321, 351, 353, 357]. In an NF-kB dependent manner, 
the renal tubular enzyme LCN2 has been previously reported to be upregulated in PCa cells 
[358]. Individualized medicine is quite challenging in the Low and middle income countries 
(LMICs) who carry up to 80% of the global cancer burden, but receives only about 5% of the 
world’s spending on cancer [132]. Even though several prostate cancer genetic biomarkers are 
known [359, 360], the journey to finding newer proteomic biomarkers has been a difficult one 
[361-364]. One big challenge is how to improve the reliability of PSA in order to avoid false 
positives and overtreatment [365]. Novel potential diagnostic biomarkers discovered in this study 
may complement the efficacy of PSA or its parameters. Several factors including epigenetic 
modification [366] of the androgen receptors, epithelial-mesenchymal transition [367] and 
cancer stem cells [368] may play fundamental roles in aggressive progression of PCa. High 
throughput technologies have resulted in the emergence of novel PCa biomarkers like 
Circulating Tumour Cell (CTC) telomerase activity [369].  
This study requires large scale, multiplatform, and multicenter clinical validation. However, it 
demonstrated the efficacy of urinary proteomics in the identification of novel potential 
biomarkers of prostate cancer. It also established a draft physiologic and prostate cancer specific 
urinary proteome for a South African population. Although racial trends within the PCa cohort 
was not established by differential expression, ethnic-related biomarker variations identified by 
the methods described in this study warrants further study.   
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CHAPTER 4: TARGETED PROTEOMICS PREVALIDATION AND IN-SILICO 




PCa is responsible for the highest number of cancer deaths in African men [370]. Despite this, it 
receives inadequate public health attention due to the concurrent high burden of Malaria, 
Tuberculosis, and HIV/AIDS. PSA has resulted in overdiagnosis and overtreatment due to its 
poor negative predictive value and specificity [371]. PCa disparity in Africa needs to be 
addressed. Even though some promising molecular biomarkers of PCa such as the TMPRSS2-
ERG fusion gene, E-Cadherin, PCA3, PTEN and EZH2 have been discovered [372], these have 
not been well research or validated in African populations. 
The process of validating multiple potential biomarkers generated from high throughput 
discovery shotgun proteomics can be very tasking. This validation gap prevents a glut of 
promising discovery phase potential biomarkers from making it to clinical utility [373-376]. 
Given the status quo, the use of preexisting experimental databases as an adjunct to actual high 
throughput systems biology experiments, offers a promising option to improve the prevalidation 
of potential biomarkers of interest and expedite the biomarker pipeline processes. Cancer 
proteomics research databases can be grouped into five classes [377], viz tumour antigen, 
gene/protein expression, protein interaction/ pathway, gene mutation and SNP, and cancer-
associated genes databases. Several proteomics databases have emerged for translation of 
systems biology data into useable diagnostic and therapeutic tools; such as the Max-Planck 
Unified database (MAPU) [378], CancerResource [379], PepSeeker [380], Global Proteome 
Machine Database (GPMDB) [381], Yale Protein Expression Database (YPED) [382], Genome 
Annotating Proteomic Pipeline (GAPP) [383], NeXtProt [384], Tranche [385], and Proteomic 
Identifications database (PRIDE) [381]. In addition, various reports have emphasized the 
importance of mining proteomics data repositories for clinical research, functional genomics, and 
understanding of post-translational modifications [386-391]. 
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The Peptide Atlas Project (http://www.peptideatlas.org) [392, 393] is a proteomic database that 
permits high throughput, in-silico identification of tandem mass spectrometry based peptides, 
which are algorithmically mapped to the eukaryotic cell genome.. This database allows the 
robust in-depth interrogation of information deposited in a centralized repository of targeted 
proteomics assays [393, 394]. The PeptideAtlas database possesses capabilities for large scale 
quantitation and compilation of proteotypic peptides (PTPs) and proteins across multiple 
experiments [394]. PeptideAtlas has recently initiated a new repository known as the 
PeptideAtlas SRM Experiment Library (PASSEL) which collects single reaction monitoring 
(SRM) experiments and allows researchers access and submit targeted SRM proteomics datasets 
[236]. This database is also useful for optimizing transitions (which are parent-fragment ion 
pairs) for each peptide using SRMCollider software in conjunction with a new SRM database 
known as the SRMAtlas [395]. Furthermore, new data independent acquisition (DIA) mass 
spectrometry methods such as SWATH that combine high throughput data collection with 
consistent reproducibility can be more accurately reproduced by using this approach. SRMAtlas 
has established many integrated data builds, for instance N-Glycoproteome recapitulation across 
different datasets for different cancer types have been demonstrated by SRMAtlas [396]. 
Certainly, databases such as  SRMAtlas, PASSEL and PeptideAtlas are effective web-based 
resources for the verification of potential biomarkers [397].  
Another valuable online resource is the Human Protein Atlas (http://www.proteinatlas.org/), 
which creates an atlas of ca. 400,000 high quality images of localization characteristics and 
expression level of over 700 human proteins in 20 and 48 different cancerous and normal human 
tissues respectively, using antibody-centered proteomics [398]. Information included in the 
database includes western blots, immunohistochemistry and fluorescent digital imaging of 
tissues. Rigorous recombinant affinity purification with careful antibody design of protein 
epitope signature tags (PrESTs) was carried out [398, 399]. Antibodies used in this database are 
only those with reduced sequence homology to any other proteins of human origin and also 
increased tissue specificity. Stringent quality assurance was followed for assigning 
bioinformatics validation scores to proteins when comparing literature- to experiment-based 
information [398]. This database offers a promising approach to biologic screening and 
verification of potential biomarkers to assess tissue specificity and to provide a preliminary in-
silico differential expression profile of biomarkers between normal and cancerous tissues.  
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A triple quadrupole (QQQ) mass spectrometer is traditionally described as the workhorse of 
targeted Single Reaction Monitoring (SRM). In a QQQ, the first and third quadrupoles are mass 
filters, and the second quadrupole is a collision cell [233]. This setup allows for accurate 
identification and quantitation of transitions and it is good for targeting and absolute 
quantification of analytes. However assays on this instrument requires intensive optimization for 
each transition and there is limited capacity for multiplexing. In addition, expensive synthetic 
peptides are often required as standards for quantitative assays. However, Parallel Reaction 
Monitoring (PRM) in principle has overcome some of the setbacks experienced with SRM 
assays, albeit PRMs are better for survey mode of targeted proteomics rather than quantitation. 
Using a high resolution, high mass accuracy instrument such as the hybrid Quadrupole-Orbitrap 
mass spectrometer (QQ-Orb), PRM can be performed for multiplexed analysis of peptide 
transitions. This instrument has a modus operandi that is somewhat similar to the QQQ in some 
respects, and allows for a simultaneous highly multiplexed quantitation and identification of 
multiple transitions. The basic difference between the QQQ and the QQ-Orb is that the third 
quadrupole is replaced by an Orbitrap [238, 400]. With remarkable improvement in instrument 
resolution and mass accuracy, PRM has been demonstrated to provide comparable performance 
metrics with SRM in terms of dynamic range, precision, and linearity [401]. 
This study demonstrates intermediate in-silico verification and potential biomarker prevalidation 
of potential PCa biomarkers using parallel reaction monitoring. The approach used here could 
potentially improve the potential biomarker validation pipeline and improve the number of 





4.2.1. Sample Cohort and Experimental Design 
 
From Chapter 3, a total of 73 potential biomarkers of PCa were discovered, as well as nine 
biomarkers that demonstrated racial trends [319]. To prevalidate these 82 potential urinary 
biomarkers of prostate cancer, in-silico verification and PRM prevalidation was carried out on 
pooled samples of PCa (n=15) and NC (n=15), derived from the same cohort (Table 3.1). Every 
PCa patient that participated in this study had localized primary disease (≤TNM Stage III) 
without metastasis. Before PRM, in-silico approaches were employed to streamline the list of 82 
discovered potential biomarkers for top ranking candidate biomarkers. This was followed by 
retrospective confirmation of top ranking biomarkers in the discovery shotgun urinary 
proteomics database we generated as well as 14 other publicly available proteomics databases 
(Figure 4.1). 
 




4.2.2. Biologic Screening with Human Protein Atlas  
 
Initial biological screening of the potential biomarkers was done by assessing the performance of 
target biomarkers in the Human Protein Atlas database. A detail of immunohistochemical 
procedure used for the Human Protein Atlas has been well described elsewhere [398].  In 
summary, specialized tissue microarrays (TMAs) optimized with serial antibody dilutions were 
used. Recipient TMA blocks had both negative and positive controls arrayed on it. Citrate buffer 
(pH 6.0) and autoclave method was used for antigen retrieval. Diaminobenzidine (DAB) was 
used to develop the immunohistochemical slides and they were counterstained with hematoxylin. 
Slides were scanned with an automated scanner; and then annotated and scored by certified 
pathologists. Immunohistochemical staining of cancerous and normal prostate tissue was 
assessed by searching either the name or the gene symbol of the protein of interest. Target 
mRNA expression level in normal and cancerous prostate tissue, as well as human cell lines were 
assessed; even though it is widely known that mRNA may not correlate with protein expression. 
Subcellular localization of target proteins is documented in this database as well. Considering 
that a large proportion of the discovered potential biomarkers were predicted to be of 
extracellular matrix and membrane protein origin, stromal staining was assessed in determining 
presence or absence of biomarkers. Differential staining of the identified potential biomarkers 
between normal and cancerous prostate tissue was used as a surrogate marker for performance 
and prostate tissue specificity. Expression of potential biomarkers in normal and cancerous 
prostate tissue or cell lines both at the mRNA or protein level was used as stringency criteria to 
streamline candidates for further targeted proteomics. In-silico verification with Human Protein 
Atlas and SRMAtlas were used to increase the stringency for potential PCa biomarker prior to 
targeted PRM prevalidation 
4.2.3. Peptide Selection 
 
To establish that target peptides are unique and specific for a particular protein in targeted 
proteomics, a set of proteotypic peptides (PTP) need to be selected. Successful selection of such 
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peptides is heavily dependent on their fragmentation pattern during tandem mass spectrometry. 
Proteotypic peptides were selected as described in Section 2.3.4. 
 4.2.4. In-Silico Verification of PTPs 
 
In silico verification of selected peptides was performed using the SRMAtlas database. This 
database is a compilation of high quality SRM experiments for quantitation and identification of 
proteins. Over 170,000 peptides from the human proteome have been identified by this database 
with ca. 99.9% coverage for human proteins (http://www.srmatlas.org/). The presence of targeted 
proteomics evidence of previous peptide assay in this database increases confidence in the 
potential using such peptides as PTPs in this study. Selected proteotypic peptides for our 
potential biomarkers were verified in the SRM database using the setting described in Section 
2.3.5.  
4.2.5. Biomarker Prevalidation with Parallel Reaction Monitoring (PRM)  
 
After in-silico biologic screening of potential biomarkers with the Human Protein Atlas database 
and target PTP verification using the SRMAtlas; top ranking biomarkers were prevalidated with 
parallel reaction monitoring on a QExactiveTM Mass spectrometer in line with Dionex 
UltiMate® 3500 RSnano UPLC system (Thermo Fisher, San Jose, CA, USA). This initial 
targeted PRM experiment is aimed at evaluating the selected “best flying” PTPs prior to 
definitive targeted proteomics. Steps involved in PRM are described in Section 2.3.7, and results 
generated were analysed using Skyline which is an open source analysis tool for targeted 
proteomics [239]. Because this was a preliminary survey type of targeted proteomics experiment, 
and observed mean retention time range for each selected PTP varied remarkably (Figure 4.2), 
the experiments were not scheduled. Singly injected samples were used as it was observed in 
previous experiments that there was very little variation in transitions detected in multiply 
injected peptides from the same urine samples (Figure 4.3). Besides, the high resolution and 




                      Figure 4.2. Bar graph demonstrating variability in mean retention time range in selected proteotypic peptides 
 
Figure 4.3. Stacked bar graph showing low variations in peak area of transitions detected in multiple peptide injection. Each sub-section of one 
bar in this stacked bar graph is the area under the curve (AUC) of a single transition which can be easily compared between different groups. 
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4.2.6. Ultra-High Performance Liquid Chromatography 
 
The same liquid chromatography gradients and column dimensions used in shotgun discovery 
proteomics experiments were used for PRM. Pooled urinary peptides from 15 prostate cancer 
and 15 normal healthy control participants at 50ng/μl (in HPLC grade water containing 0.1% 
(v/v) Formic acid) were subjected to Nanoflow UHPLC in-line on a Dionex UltiMate® 3500 
RSnano UPLC system (Thermo Fisher, San Jose, CA, USA) equipped with a 75μm×50cm; 5 
μm; 100Å C-18 resin packed analytic column and a 100μm×5cm; 5μm; 100Å C-18 resin packed 
pre-column. Gradient chromatography was carried as described in Section 2.3.1. 
4.2.7. Quadrupole-Orbitrap Analyses 
 
A QExactiveTM Hybrid Quadrupole-Orbitrap Mass Spectrometer (Thermo Fisher, San Jose, CA, 
USA) was used for parallel reaction monitoring. This instrument combines accurate mass 
Orbitrap detection with high resolution quadrupole precursor ion selection. A spray current of 
0.1μA, an ionization voltage of 1.86kV, an S-lens RF level of 50.0, and a capillary temperature 
of 320⁰C was used for the nano-electrospray ionization source. An unscheduled 4-plex tandem 
mass spectrometry targeted methodology was used at a mass spectra acquisition resolution of 
35000. All Ion Fragmentation (AIF) full scan mode was used with positive polarity at a scan 
range of 79 to 1945 m/z, charge exclusion z = 2, and maximum time per peptide of 30 
milliseconds. A total scan time of 140 milliseconds and required cycle time was 2 second. A 
fixed automatic gain control (AGC) value of 5 × 𝐸6 was used. In-source High-energy Collision 
Dissociation (HCD) with Normalized Collision Energy (NCE) set at 27eV was used for peptide 
fragmentation. Acquisition method comprises of targeted PRM scan events directed at the +2 and 
+3 PTP precursor charge states. For each precursor, an isolation window of 2m/z units was used 
at a starting m/z of 80 and followed by automatic derivation of final m/z from the charge state 
and PTP precursor m/z. Upon generation of MS2 data from PRM experiments, raw data files 
were imported into Skyline to determine precursors with good signals and high concordance of 
charge states in terms of retention time and intensity. With the isolation list, this process is 
repeated using a different order to ascertain that multiplexing interferences did not bias generated 
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results. Further quantitative analyses were performed to compare biomarker transitions between 
pooled normal and PCa samples.  
4.2.8. Database Verification of Candidate Biomarkers 
 
Candidate biomarkers that were observed to have good performance by human protein atlas, 
SRMAtlas and parallel reaction monitoring were identified. These biomarkers were further re-
confirmed using the previous shotgun urinary proteomics database. Their differential expression 
in PCa, BPH and normal healthy controls were assessed in this database. In addition, their 
performance was also confirmed in 14 other publicly available urinary proteomics databases to 
assess their ability to differentiate between PCa, BPH and normal healthy states. 
 
4.2.9. Functional Network Association Analysis 
 
Top ranking potential biomarkers by this approach in addition to well established PCa pathways 
like PTEN and ETS was performed using GENEMANIA (http://www.genemania.org/). 
Predicted interaction between these top ranking biomarkers with pre-exisiting PCa pathogenesis 







4.3.1. Screening of Candidate Biomarkers 
 
Even though three proteotypic peptides were targeted for each biomarker, a few biomarkers had 
less than 3 identified peptides. Hence, a total of 235 proteotypic peptides were selected (Table 
4.1). These 235 selected proteotypic peptides were characterized with posterior error probability 
(PEP) scores, peptide length (PL), retention time ranges, charge states, and modification status. 
They were further characterized with results from biologic screening with Human Protein Atlas 
(HPA) and SRMAtlas verification. Using the features described in Table 4.1, the list of 82 
potential biomarkers were tailored down to a list of 32 top ranking potential biomarkers found 
most suitable for targeted proteomics analysis (Table 4.2). Higher priority was given to peptides 
with 2+ and 3+ charges in comparison to 1+ or >3+ charges. Medium sized peptides were 
preferred to longer ones. Peptides with a narrower range of retention time were preferred over 
those with wider retention time window. We found 115 (48.9%) of our 235 PTPs were not 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Protein Name Gene 
Name 














BLVRB 15 TVAGQDAVIVLLGTR Very high 
(++) 
high (+) Yes no no  
Prostatic acid 
phosphatase 
ACPP 12 SPIDTFPTDPIK high (+) high (+) no no no  
N-acetylmuramoyl-L-
alanine amidase 




Yes Yes Yes Good 
Epididymal secretory 
protein E1 
NPC2 16 EVNVSPCPTQPCQLSK high (+) very high 
(++) 
Yes no no  
Glutaredoxin-1 GLRX 21 DCIGGCSDLVSLQQSGELLTR Very high 
(++) 
high (+) Yes no no  
CD59 glycoprotein CD59 16 TAVNCSSDFDACLITK low (-) high (+) Yes Yes no  
Trefoil factor 3 TFF3 11 VDCGYPHVTPK high (+) low (-) Yes Yes no  
Non-secretory 
ribonuclease 
RNASE2 17 YAQTPANMFYIVACDNR high (+) low (-) Yes Yes no  
Prostate-specific antigen KLK3 12 LSEPAELTDAVK high (+) low (-) Yes Yes no  
Proactivator 
polypeptide;Saposin 
PSAP 11 GCSFLPDPYQK high (+) high (+) no no no  
Vitamin K-dependent 
protein S 
PROS1 8 HCLVTVEK Very high 
(++) 
low (-) Yes Yes Yes Good 
Haptoglobin-related 
protein 
HPR 10 VTSIQHWVQK Very high 
(++) 
low (-) Yes Yes Yes Good 
Nidogen-1 NID1 10 EDLSPSITQR high (+) very high 
(++) 




PON1 16 IFFYDSENPPASEVLR Very high 
(++) 
high (+) Yes no no  
Plasma kallikrein KLKB1 14 IAYGTQGSSGYSLR Very high 
(++) 
high (+) Yes no no  
Lactotransferrin LTF 12 LADFALLCLDGK Very high 
(++) 
high (+) Yes no no  
Inter-alpha-trypsin 
inhibitor heavy chain H1 





CPN1 9 IVQLIQDTR Extrememly 
high (+++) 
high (+) Yes Yes Yes Good 
Inter-alpha-trypsin 
inhibitor heavy chain H3 




no no no  
Pregnancy zone protein PZP 10 SLFTDLVAEK Extrememly 
high (+++) 
high (+) Yes Yes Yes Good 
Alpha-actinin-1 ACTN1 14 FAIQDISVEETSAK Extrememly 
high (+++) 
low (-) Yes Yes Yes Good 
Plastin-2 LCP1 9 NEALIALLR high (+) low (-) Yes Yes no  
Collagen alpha-1(XII) 
chain 
COL12A1 12 ITVDPTTDGPTK Very high 
(++) 
high (+) Yes no no  
Tenascin TNC 16 CECDDGFTGADCGELK Very high 
(++) 
high (+) Yes no no  
Cadherin-11 CDH11 12 FFTINPEDGFIK low (-) high (+) Yes Yes no  
Cathepsin Z CTSZ 12 NVDGVNYASITR Very high 
(++) 
high (+) Yes no no  
Alpha-N-
acetylglucosaminidase 





Yes no no  
Proteasome inhibitor 
PI31 subunit 




no no no  
Heat shock protein HSP 
90-beta 




no no no  
Myocilin MYOC 21 SGEGDTGCGELVWVGEPLTLR Very high 
(++) 
low (-) Yes Yes Yes Good 
SLAIN motif-containing 
protein 1 













no no no  
    Total number of 
Biomarkers 
25 13 7  
Level 1 Stringency: any difference in expression 
Level 2 stringency: Favour low (-) / high (+) and "Extrememly" 
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Level 3 stringency: Greater than  2 unit of difference + Favour "Extremely" 
PL= Protein Length 
Table 4.2. List of top ranking 32 biomarker PTPs with increasing level of stringency based on various parameters [402] 
 
4.3.2. In-Silico Screening with Human Protein Atlas 
 
Initial screening of all 82 potential biomarkers with the human protein atlas yielded differential 
immunohistochemical staining patterns between normal and cancerous prostate tissues. Primary 
focus was on the top ranking 7 PTPs (Table 4.2), in addition to five other PTP that were shown 
to have good signals by PRM assays. A snapshot of differential immunohistochemical staining 
for all top 12 biomarkers confirmed by PRM is documented in Annexure II. Vitamin K-
dependent protein S (PROS1) demonstrated moderate immunohistochemical staining of prostatic 
tissues, but demonstrated low staining of normal prostate tissue (Figure 4.4).  
  
           Figure 4.4. Differential staining pattern for Vitamin K-dependent protein S between prostate cancer and normal prostate tissues 
N-acetylmuramoyl-L-alanine amidase (PGLYRP2) showed heavy staining ductal acinar cells 
with a non-specific staining of PCa stromal tissues, whilst there was low staining of normal 
prostate tissues for this biomarker. For prostate cancer tissues, Haptoglobin related protein 
(HPR) stained lightly positive, but no staining was observed for normal prostate tissues (Figure 




          Figure 4.5. Differential staining pattern for Haptoglobin-related between prostate cancer and normal prostate tissues 
Carboxypeptidase N catalytic chain (CPN1) stained positively in both cancerous and normal 
prostate; but this staining was stronger for prostate cancer. PCa was found to stain positive for 
Alpha-actinin-1 (ACTN1), but this biomarker stained negative in normal prostate. Pregnancy 
zone protein (PZP) stained positive in prostate cancer but negative for normal prostate tissue; 
albeit light staining of the stromal of normal prostate tissues was observed. It was found that 
Myocilin (MYOC) stained positive for PCa and negative for normal prostate tissues. In addition 
to these seven top ranking biomarkers, the following five potential protein biomarkers described 
hereafter had good transition signals during the PRM. Using the human protein atlas, Prostatic 
acid phosphatase (ACPP) was unable to immunohistochemically distinguish between normal 
tissue and PCa; showing diffuse positivity in prostatic epithelium under both conditions with 
mild stromal stains in PCa (Figure 4.6).  
 
               Figure 4.6. Differential staining pattern for prostatic acid phosphatase between prostate cancer and normal prostate tissues 
To a reasonable extent, Prostate-specific antigen (KLK3) was able to distinguish between normal 
and cancerous prostate tissues. KLK3 stained positive in PCa, but negative in normal prostate 
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epithelium (Figure 4.7). The staining pattern observed for Nidogen-1 (NID1) was non-specific 
both for normal and cancerous prostate tissues.  
 
            Figure 4.7. Differential staining pattern for prostatic-specific antigen between prostate cancer and normal prostate tissues 
Although higher levels of luminal and stromal staining was observed for normal as compared 
with cancerous prostate tissues. Cathepsin Z (CTSZ) stained positive in PCa but negative for 
normal prostatic tissues. Besides MYOC, one other race-based potential biomarker with good 
signal in our PRM was Slain motif-containing protein 1 (SLAIN1) which stained remarkably for 
PCa tissue but stained mildly for stromal tissues in normal prostate tissue. 
4.3.3. Evaluation of Biomarkers using SRMAtlas Database 
 
Selected 32 top ranking potential prostate biomarkers were carefully searched with the 
SRMAtlas. The Best out of 3 proteotypic peptide for each of the top ranking potential biomarker 
was verified in the SRMAtlas database. This database automatically ranks the best b- and y- ion 
transitions making it easy to identify the “best flying” transitions to target. Mass detection at Q1 
and Q3 were reported. The amino acid following the C-terminus (Fol-AA) and the one before the 
N-terminus (Pre-AA) were demonstrated. Sequence specific retention times (SSRT) for 
hydrophobicity and relative intensities (RI) of peaks in the collision induced dissociation (CID) 
spectra were shown. Also reported in the SRMAtlas database was frequency of peptide mapping 
(N-Map) to proteins in target proteomes. Weighting of predicted vs empirical suitability score 
results in the reported adjusted suitability score (AdjSS) of transitions. SRMAtlas results for 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 4.3.4. Parallel Reaction Monitoring Prevalidation 
 
Preliminary targeted PRM experiments were performed to potentially corroborate the in-silico 
biomarker screening results and identify high confidence potential biomarkers before proceeding 
to large scale, multi-platform hypothesis testing using targeted proteomics experiment. Although 
ELISA is widely acclaimed to be the gold standard for protein quantification, its use can 
sometimes be limited by the availability of high quality antibodies. Targeted proteomics has been 
shown to demonstrate performances similar to ELISA assays [403-405]. The focus for parallel 
reaction monitoring was on the high ranking proteotypic peptides detected from biologic 
screening and in-silico verification of potential biomarkers. Transitions from this experiment 
were identified with good quantifiable peak area under curve (AUC) (Figure 4.8).   
 
 
Figure 4.8. Quantitation of target transition of potential biomarkers by parallel reaction monitoring. All peaks within the vertical bracket 





Differential expression was observed for N-acetylmuramoyl-L-alanine amidase (PGLYRP2) 
showing a higher expression in PCa as compared to normal controls. This expression difference 
is more remarkable in the +2 charge state as compared to the +3 charge state. Replicate 
comparison of peak AUC showed difference majorly in y-type ions for +3 charge states while a 
single b-type ion expressed difference in the 2+ charge state. There was greater than 2 fold of 
difference in peptide transitions between PCa and normal controls for Vitamin K-dependent 
protein S (PROS1). Transition ions of the b-type were observed to be higher for both +2 and +3 
charge states in PCa in comparison to normal controls. The same trend was found for 
Haptoglobin related protein (HPR) which had more than a 3-fold difference in AUC between 
normal control and PCa regardless of charge states with b-ions expressed differentially for both 
+2 and +3 charges. Carboxypeptidase N catalytic chain (CPN1) transitions were differentially 
expressed with +2 peptide transitions being lower in normal control and higher in PCa. However, 
a greater AUC was found for CPN1 in normal controls compared to prostate cancer +3 charge 
states with y-ion dominance. Pregnancy Zone Proteins (PZP) demonstrated greater AUC signals 
in the normal controls as compared with PCa for both +2 and +3 charges; and were 
predominantly y-type ions. In normal controls, Alpha-actinin-1 (ACTN1) was more highly 
expressed in comparison to PCa in the +3 charge state. Five y-ions fragments were detected in 
the +2 charge state for NC which was not detected at all in the +3 charge. Similarly, detected 
transitions for Myocilin (MYOC) in normal controls were higher than those found in PCa; with 
mostly b-type and y-type ions being responsible for the difference in the +2 and +3 charge states 
respectively. Better signals were found for prostatic acid phosphatase (ACPP) in normal controls 
as compared to PCa, with y-ion fragment predominance. Prostate-specific antigen (KLK3) 
showed higher transition signals for PCa in comparison to normal controls, albeit the difference 
was not great. Replicate comparisons of peak AUC showed differential signals with mixed b- 
and y-ion fragments. The performance of Nidogen-1 (NID1) in parallel reaction monitoring 
assay was spectacular, demonstrating over 6-fold difference between normal control (higher) and 
PCa transitions for both +2 and +3 charge states. Replicate comparison for NID-1 showed y-ions 
more differentially detected. Cathepsin Z (CTSZ) had higher in transition signal for normal 
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control as compared to PCa for both +2 and +3 charge states.  No transitions were detected for 
CTSZ in the +3 charge states while y-ions dominated both charge states. The race-based 
biomarker slain motif-containing protein 1 (SLAIN1) showed significant differential expression 
between PCa and normal controls. For SLAIN1, PCa had over 2-fold difference in transition 
signals in comparison to normal controls. 
4.3.5. Confirmation of Candidate Biomarkers in Databases 
 
The top 12 potential biomarkers were re-assessed retrospectively in the data from the previous 
shotgun urinary proteomics experiments that was performed. Frequency of occurrence of the top 
ranking biomarkers was assessed in this database as well as 14 other publicly available urinary 
proteomics databases. In the previous shotgun urinary proteomics data from our PCa cohort, it 
was observed that HPR, PROS1, SLAIN1 and PZP were reliable biomarkers of PCa (Figure 
4.9). PZP, PROS1, and HPR were observed only in PCa but found absent in BPH and normal 
control. Greater than 2-fold of difference in expression was found for SLAIN1 in PCa as 
compared with normal control and BPH. NID1, CTSZ, ACPP and KLK3 were also moderately 
good biomarkers of PCa because of their higher expression in normal controls compared with 
BPH and PCa. NID1 was highly observed in normal controls, slightly present in BPH, but not 




Figure 4.9. Confirmation of top ranking potential biomarkers in shotgun urinary proteomics data. On the x-axis are the top ranking potential 
biomarkers and on the y-axis are the log2-transformed IBAQ values 
KLK3 and ACPP were both highly observed in BPH and normal controls as compared with PCa. 
CTSZ was observed as highest in NC, slightly present in BPH but completely absent in PCa. All 
other top ranking biomarkers queried did not demonstrate a clear-cut pattern in their frequency of 
occurrence. They either demonstrated similar pattern of expression across PCa, BPH and normal 
control or similar expression in normal control and PCa. These top ranking 12 potential 
biomarkers of PCa were further queried against 14 other publicly available urinary proteomics 
databases to assess the degree of concordance with our urinary proteomics database. Six PCa, 2 
BPH, 6 healthy (NC), and 1 multiple condition (MC) urinary databases were used (Table 4.4). 
PGLYRP2 was absent in PCa, MC and BPH databases but was present in 5 (83.3%) of the NC 
databases. PROS1 was found in 4 (66.7%) of the NC databases, but found absent in all BPH, MC 
and PCa databases. Three (50%) of the PCa databases demonstrated HPR as well as one (16.7%) 
of the NC databases. MC and BPH databases were not found to demonstrate the presence of 
159 
 
HPR. CPN1 was observed to be present in 5 (83.3%) of the NC and 2 (33.3%) of the PCa 
databases, whilst absent in MC and BPH databases. PZP was noticed to be absent in BPH, NC 
and PCa databases, albeit found in the MC database. ACTN1 was observed in 3 (50%) of the NC 
databases and absent in the BPH, MC and PCa databases. MYOC was found in 2 (33.3%) of the 
NC and not present in MC, BPH and PCa databases. ACPP was observed in 5 (83.3%) of the NC 
and 3 (50%) of the PCa databases; it was also present in the MC and BPH databases. KLK3 was 
observed in 5 (87.3%) of the NC and 1 (16.7%) of the PCa databases; while absent in MC 
databases but present in BPH. NID1 was found in 6 (100%) of the NC databases and absent (0%) 
in PCa, MC and BPH databases. CTSZ was found in 4 (66.7%) of the NC and 1 (16.7%) of the 
PCa databases; whilst absent for both BPH and MC databases. None of the 14 databases 









































































































































































































































































































































































































































































































































































































































































































































































































































4.3.6. Functional network association 
 
Functional genetic pathway analysis was performed using GENEMANIA for the 12 top ranking 
biomarkers in addition to PTEN and ETS genes which are well established to be involved in PCa 
pathogenesis. A network with a predicted coexpression of 79.19%, physical interaction of 
17.26%, co-localization of 2.73% and shared protein domain of 0.83% was generated (Figure 
4.10). 
         





Targeted validation of potential biomarkers generated from hypothesis generating shotgun 
proteomics experiments needs rigorous assay optimization and careful planning [314, 375, 406]. 
Unfortunately, the expanding number of discovered candidate biomarkers for many diseases, 
does not tally with clinically applicable or approved disease biomarkers [406, 407]. Some reports 
have suggested the establishment of standards for biomarker discovery and validation of 
candidate biomarkers for clinical use [116, 375, 408]. An essential requirement of the validation 
phase of the biomarker pipeline is the availability of numerous clinical samples that are 
randomized [406]. An orthogonal approach was used in this study to screen 82 potential 
biomarkers that were previously discovered for prostate cancer in our South African cohort 
[319]. Database searching using in-silico approaches is rapidly becoming an crucial adjunct to 
high-throughput systems biology [409-411], although there are some limitations to its use [412]. 
Over half (51.5%) of our selected proteotypic peptides were shown to have been previously 
assayed by targeted SRM on an ion trap instrument. This coverage indicates that the selected 
PTP were reliable. Another subset (47.7%) has not been reported previously in targeted 
proteomics assays and can be added to this database. Close to 80% coverage has been previously 
reported when comparing experimental transition identification to in-silico identification [234], 
indicating the prospects in-silico method application in the biomarker pipeline.  
Finding differentially expressed urinary biomarkers in the Human Protein Atlas database 
confirms their tissue specificity. Due to its vast coverage (11,200 unique proteins) of differential 
immunoproteomics profile of normal vs cancerous tissue, as well as its tissue-specific expression 
profiles; the human proteomics atlas has been branded as a vital tool for histopathologic 
assessment [413] and biomarkers discovery [414]. This database has contributed huge 
proteogenomic information to the development of the Human Proteome Project [415, 416]. An 
important caution for immunoproteomics evaluation of potential biomarkers is avidity and 
sequence specificity of the antibody when targeting a specific variant; this may lead to non-
specific binding. Another down side to antibody proteomics is the fact that it is may be 
dependent on commercial availability of the specific antibody; many of which are not 
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variant/isoform specific [417, 418]. However, we found the use of this database quite helpful in 
sorting out biomarkers of PCa in our cohort.  
Considering the fact that all product ions are concurrently available with minimum interference 
during the full scan duration, PRM is reliable for multiplexed targeted proteomics even without 
foreknowledge or prior selection of target transition. This drastically reduces optimization time 
and effort for every single target transition, albeit poor transition signals may be caused by the 
stochastic nature of ion selection in PRM. Conversely, a duty cycle of nearly 100% as seen in the 
QQQ instrument which uses electron multiplier-based detection offers a better sensitivity 
compared to Orbitrap instrument image current-based detection [419]. This brings to 
consideration, the inherent tradeoff between the sensitivity and high mass accuracy between 
PRM and SRM experiments [238, 401, 419]. PRMs are typically used in the screening/survey 
mode of targeted proteomics experiments, whilst SRM may be more suited for absolute/ precise 
quantitation of analytes across samples [419].  In this study, we used PRM as a screening tool for 
the 32 top ranking potential biomarkers generated by in-silico database screening.  
The frequency of detection of the 12 top ranking potential biomarkers of prostate cancer was 
confirmed retrospectively and differential expression was observed in the previous urinary 
shotgun proteomics experiments.  Putative biomarkers of prostate cancer like KLK3 and ACPP 
were found in PCa, normal control and BPH urinary databases. This indicates that these putative 
biomarkers are specific for prostate disease and not exclusive to PCa. SLAIN1, a Race-based 
potential biomarker was more observed in PCa compared to NC and BPH, although no 
information was found for it in the SRMAtlas. This may be accounted for by the paucity of 
targeted proteomics data emanating from African PCa studies. Good biomarkers observed by 
database reconfirmation were PROS1, HRP, SLAIN1, PZP, and NID1. Notably, NID1 was 
observed only in the healthy urine samples; indicating a fairly constant performance across both 
in-silico and experimental biomarker analyses. The high level of co-expression (79.19%) as well 
as physical interaction (17.26%) of shared protein domains found in the network association and 
pathway analysis of the 12 top ranking biomarkers with PTEN and ETS pathways requires 
further study. Using a pragmatic penultimate screening approach prior to definitive large scale 
targeted proteomic validation, this study identified a panel of 12 top ranking potential biomarkers 
of PCa in a South African cohort of patients.  
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CHAPTER 5: CANCER ANTIGEN MICROARRAY -BASED DISCOVERY OF NOVEL 




Among cancers in Africa, PCa has the highest incidence, mortality and 5-year prevalence as 
reported by the WHO/IARC GLOBOCAN 2012 database [32]. The basis for PCa disparity in 
Africa is poorly understood, although higher levels of serum testosterone [176, 420], androgen 
receptor variations [176, 421, 422], dietary factors [423, 424], familial [193] and genetic 
mutations [193, 425-427] have been previously suggested. More reliable novel biomarkers of 
PCa are needed in Africa considering that PSA as a blood-based biomarker is neither able to 
differentiate benign from malignant prostate disease [428] nor distinguish aggressive from 
indolent phenotypes of the disease [98, 429]. Another blood-based biomarker, prostatic acid 
phosphatase (ACPP), is poorly sensitive for localized PCa [71, 430]. In addition, ACPP can be 
found in extraprostatic tissue as well, making it a poor clinical biomarker for PCa [72, 431]. 
Derivatives of prostate-specific antigen such as free-to-bound PSA ratio [432], velocity, density, 
doubling time, proPSA, kallikrein-marker panels and Prostate Health Index (PHI) have been 
observed to improve the prognostic and diagnostic value of PSA [432, 433]. In addition, 
TMPRSS2:ERG translocation has been shown to be prognostic marker for PCa aggression in 
Western studies [432]. Another blood-based predictor that has been used to predict prostate 
cancer distant metastasis is circulating tumour cells (CTCs) [74]. Urinary levels of 
TMPRSS2:ERG fusion, PCA3 are also some of the emerging biomarkers for stratification of 
PCa risk [74, 432]. Clearly, a combination of good clinical assessment and reliable PCa 
biomarkers would offer more benefit in the diagnosis and management of PCa. For example, PHI 
and PSA isoforms have been combined with the use of multiparametric-MRI targeted prostate 
biopsy; and has improved the stratification of PCa risk in comparison to urinary biomarkers or 
PSA alone [434]. 
An emerging miniaturized technology for multiplexed high-throughput discovery of molecular 
pathways, cancer biomarkers, and immunotherapeutic targets is the protein microarray 
technology [435]. Seeing that a vital that hallmark of natural immunity and cancer is the 
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production of autoantibodies [436]. Various forms of protein microarrays exist, including bead 
based arrays, antibody arrays, reverse phase protein arrays, microspot ELISA array, and pathway 
arrays systems. Various platforms exist for the formulation of protein microarrays such as glass 
slides, membranes, and beaded platforms [435]. This technology is potentially capable of 
detecting variations in antibody response to immunization and can identify target antibodies in 
large cohorts of individuals [437]. The fact that a target subset of the proteome can be 
functionally interrogated in a systems-oriented manner, the consistency of the technical layout of 
the array  and economy of ligand or reaction quantity permits meaningful comparison and 
quantitation of protein microarray results across huge datasets [438]. Many authors have shown 
that antibody-antigen microarray platforms used is beneficial for early diagnosis of cancer and 
discovery of biomarkers [257, 439-443].  
Cancer-Testis antigens (CTAs) are a heterogeneous family of tumour associated antigens 
(TAAs) that are solely found naturally in adult ovarian and testicular germ cells as well as 
placental embryonic/trophoblast membranes; and pathologically in cancers [277, 444-446]. The 
fact that these antigens are only found in cancer or gonadal germline tissues makes them an 
attractive target for immunotherapy and diagnosis of cancer. In-depth understanding of these 
tumour specific and very immunogenic antigens is currently evolving, although over a hundred 
of CTAs have been described in scientific literature [446, 447]. Cancer-testis antigens have been 
reported previously with variable expression in melanomas, cancers involving the lung, prostate, 
breast, bladder, colon, kidneys; as well as malignancies involving the hematologic and 
lymphoreticular systems [447]. The theranostic possibilities of cancer-testis antigen for 
urological malignancies were explored in a review by Kulkarni et al [448], who examined the 
cancer-testis antigens as therapeutic targets and diagnostic biomarkers in an array of urologic 
malignancies including renal, prostate, testicular germ cell and bladder malignancies. 
Analysis of serum for humoral adaptive response to cancer using protein microarray technology 
is a promising scientific approach to achieve a bidirectional outcome of potential diagnostic 
biomarker and vaccine target identification. Using protein microarrays to identify cancer-specific 
humoral immune responses; vaccine targets and potential CTA biomarkers were found for non-
small cell lung cancer [449], as well as pancreatic and ovarian cancer [437]. Cancer testis antigen 
have been previously described as potential biomarkers of aggression [450, 451], progression of 
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disease [452], staging [453] and biochemical recurrence [454] of PCa. As an emerging 
technology, protein microarrays are not without their challenges. For instance, pH alteration may 
render capture molecule unstable, and they may demonstrate variable specificity for their target 
antigens. These problems can be compounded by dynamic range issues found with the plasma 
proteome. Additionally, in post-translationally modified protein, non-active conformations of the 
arrayed proteins may affect exposure of the desired epitope [435]. Furthermore, many of the 
bioinformatics data analysis software for protein microarrays were adapted from genomic 
microarray computational workflows, which may not necessary be amenable for variations in 
individual unique immune response as observed in antigen microarrays [435, 437]. 
Despite the developments in protein microarray technology, there is a dearth of literature on the 
cancer-testis antigen expression pattern in any African PCa cohort. In addition, racial disparities 
in CTA expression in a heterogeneous cohort of PCa patients are under-explored. Hence, a novel 
blood-based approach to identification of immunotherapeutic target and potential PCa 
biomarkers using a protein microarray comprised of CTAs and a cocktail of putative TAAs was 
described in this this study. In addition, racial distribution of TAAs and CTAs were explored in 






5.2.1. Characterization of patient and sample cohort 
 
Blood samples (N=67) were collected in our cohort over a period of 2 year period from benign 
prostatic hyperplasia (BPH) (n=32), PCa patients (PCa) (n=20), and individuals who were 
symptomatic but were suffering from other genitourinary diseases or screened negative for 
malignancy or BPH with histopathologic assessment (DC) (n=15). Clinicopathologic and 
demographic data of all 67 participants were documented (Table 5.1). The mean ages for PCa, 
BPH and DC were 68.95, 67.75, and 58.3 respectively; while the median ages for these groups 
were 68, 68, and 61 respectively.  The mean PSA values for PCa, BPH and DC were 158.61, 
8.67, and 4.63 respectively; while the median PSA values for these groups were 27.52, 4.87, and 
3.7 respectively. Blood was collected and processed as described in Sections 2.1 & 2.2 
respectively. 
Code Diagnosis Age PSA level Race Group Gleason Score 
PC1 CANCER 61 11.6 MA 6 
PC2 CANCER 71 5.1 MA 7 
PC3` CANCER 61 100 B 9 
PC4 CANCER 74 31 MA 7 
PC5 CANCER 61 16.4 MA 6 
PC6 CANCER 67 350 MA 9 
PC7 CANCER 80 39.4 B 7 
PC8 CANCER 68 1091 MA 9 
PC9 CANCER 69 5.9 W 7 
PC10 CANCER 64 9.1 W 6 
PC11 CANCER 64 1.1 W 6 
PC12 CANCER 76 195 W 10 
PC13 CANCER 74 1.5 MA 6 
PC14 CANCER 66 34 MA 9 
PC15 CANCER 76 315 MA 6 
PC16 CANCER 62 17.05 MA 7 
168 
 
PC17 CANCER 63 24.05 MA 7 
PC18 CANCER 71 2.9 W 9 
PC19 CANCER 74 184 W 10 
PC20 CANCER 77 738 B 8 
BPH1 BENIGN 72 3.6 MA NA 
BPH2 BENIGN 64 2.8 MA NA 
BPH3 BENIGN 70 5.4 W NA 
BPH4 BENIGN 61 2.9 MA NA 
BPH5 BENIGN 75 3.7 MA NA 
BPH6 BENIGN 58 19.5 W NA 
BPH7 BENIGN 70 48.4 MA NA 
BPH8 BENIGN 68 5.7 MA NA 
BPH9 BENIGN 69 7.1 MA NA 
BPH10 BENIGN 56 5.03 MA NA 
BPH11 BENIGN 53 1.24 W NA 
BPH12 BENIGN 63 4.7 W NA 
BPH13 BENIGN 86 10.6 B NA 
BPH14 BENIGN 56 9.6 MA NA 
BPH15 BENIGN 75 7.3 B NA 
BPH16 BENIGN 61 4.5 B NA 
BPH17 BENIGN 81 25.8 B NA 
BPH18 BENIGN 64 6.6 B NA 
BPH19 BENIGN 74 2.6 B NA 
BPH20 BENIGN 57 3.64 MA NA 
BPH21 BENIGN 69 3.3 MA NA 
BPH22 BENIGN 70 1.2 W NA 
BPH23 BENIGN 75 0.83 W NA 
BPH24 BENIGN 65 27 B NA 
BPH25 BENIGN 68 5.8 MA NA 
BPH26 BENIGN 62 1.4 W  NA 
BPH27 BENIGN 78 0.1 B NA 
BPH28 BENIGN 66 3.6 W NA 
BPH29 BENIGN 68 0.75 B NA 
BPH30 BENIGN 70 9.1 MA NA 
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BPH31 BENIGN 77 37.1 MA NA 
BPH32 BENIGN 67 6.43 MA  NA 
DC1 NFM 44 0.7 MA NA 
DC2 NFM 74 7.8 MA NA 
DC3 NFM 62 3.7 MA NA 
DC4 NFM 52 NA MA NA 
DC5 NFM 34 NA B NA 
DC6 NFM 63 6.3 MA NA 
DC7 NFM 67 5.9 MA NA 
DC8 NFM 65 3.4 MA NA 
DC9 NFM 59 18.9 MA NA 
DC10 NFM 69 0.4 MA NA 
DC11 NFM 61 8 MA NA 
DC12 NFM 76 7 B NA 
DC13 NFM 56 0.9 MA NA 
DC14 NFM 35 NA B NA 
DC15 NFM 58 6.5 MA NA 
PSA= Prostate-specific antigen; MA= Mixed Ancestry; W= White; B= Black; NFM= Negative 
for malignancy 
                                                  Table 5.1. Clinicopathologic information on all participants 
 
5.2.2. Nexterion H-slide microarray derivatization 
 
The specifications of the Nexterion® Slide H (SCHOTT GmBH, Jena, Germany) used as well as 
its streptavidin derivatization protocol is described in details in Section 2.4.1. Derivatized slides 
were stored at -20⁰ C until use. 
5.2.3. Quality check for streptavidin-derivatized slides 
 
Quality check (QC) was carried out to make sure that streptavidin is homogeneously spread on 
the Nexterion H-slides. For the QC assessment, the last slide of every batch derivatised was 
incubated with 10 μg/ml Cy5-biotinylated BSA in PBS, washed in washing buffer and then 
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scanned using the Tecan LS ReloadedTM microarray scanner (Tecan Group Ltd, Männedorf, 
Germany). Only slides with CV ≤ 5% across the slide surface were used for the assay. 
5.2.4. Fabrication of CT100+ Antigen Microarray 
 
Genetix QArray2 robotic arrayer (Genetix Ltd., New Milton, UK), a high throughput microarray 
printer was used to print antigen-containing crude insect lysates on the streptavidin-coated 
Nexterion H-slides as described in Section 2.4.2. Heterologous expression with Escherichia coli 
(E.coli) has been generally fraught with expression problems like defects in folding, absence of 
posttranslational modifications (PTMs), and protein solubility [278]. Therefore, Spodoptera 
frugiperda SF21 insect cells were used to express the human antigens of interest because this 
method presents a simple eukaryotic-like expression system that preserves PTM and native 
protein folding better [438]. Full details of the optimized insect expression system and lysate 
preparation have been well documented in previous works [277, 278, 438]. The physical origin 
of ligand binding assay system is comprised of spatially-defined array of immobilised, purified 
cancer-testis antigens printed on a surface which permits capture of cognate autoantigens in 
serum sample. Through fluorescently labelled anti-human IgG, which are captured on the 
microarray surface, anti-CT antigen expression is then detected. Biotinylated human IgG and 
biotinylated human serum were used as positive control and a crude cell lysate containing the 
BCCP-tag alone with no recombinant fusion partner was the negative control.  
5.2.5. QC in Microarray Fabrication 
 
Each slide was carefully inspected prior to the printing process. Quality checks were used to 
confirm that there were no forms of contaminants like fingerprints or dust particles on the slide. 
The Qarray2 arrayer has a 300 μM solid pins to print replicate CT100 arrays in a 4-plex format. 
An equal volume of 40 % sucrose was mixed with lysates and spotted in triplicates for each 
array. The settings for microarray printing are as described in Section 2.4.2. After printing, slides 
were stored in storage buffer (Blocking buffer with 50 % glycerol) at -20 °C until when the 




5.2.6. CT100+ Microarray Assay 
In total, 70 serum samples were assayed, 3 of which were used for the purposes of quality 
control. These quality controls included negative control serum, positive control serum, and a 
mouse-anti-c-Myc-Cy3 antibody. The positive control which was derived pooled multiple cancer 
sera showed reactivity to a number of antigens on the array, whereas the negative control which 
were pooled from normal healthy patients’ sera showed no reactivity to antigens on the 
microarray. The anti-c-myc-Cy3 assay was used to confirm that all the 123 individual antigens 
(Table 5.2) were successfully immobilised to the array during printing with layout shown below 
(Figure 5.1). The steps involved in the CT100+ assay are described in Section 2.4.3. 
List of 123 antigens printed on the CT100+ antigen microarray platform 
123 NY-ESO-1 ORF2 MAGEA3 p53 M133T THEG 
MAGEA4 v2 BAGE2 TPTE 97 p53 L344P 
MAGEA4 v3 BAGE3 TSGA10 98 CYP3A4 
MAGEA4 v4 BAGE4 TSSK6 99 CYPR 
MAGEA5 BAGE5 TYR 100 EGFR 
MAGEB1 CCDC33 XAGE-2 101 5T4/TPBG 
MAGEB5 CEP290 XAGE3a v1 102 XAGE1B 
MAGEB6 COL6A1 XAGE3a v2 103 SOX2 
MART-1/MLANA COX6B2 ZNF165 104 ACVR2A 
MICA CSAG2 AKT1 105 ACVR2B 
NLRP4 CT47.11 CDK2 106 ITGB1 
NXF2 CT62 CDK4 107 MAP9 
NY-CO-45 CTAG2/ NY-ESO-2 CDK7 PIM1 
NY-ESO-1 CXorf48.1 FES TKTL1 Isoform a 
OIP5 DDX53 FGFR2 SPATS1 isoform 1 
p53 MMA1 MAPK1 DPPA2 
PBK FTHL17 MAPK3 SOX1 
RELT GAGE1 PRKCZ ROPN1A 






                                                        






   
                                                         Table 5.2. List of 123 antigens printed on CT100+ microarray 
On each slide, individual arrays were scanned using the Tecan LS Reloaded microarray scanner 
with 10 μm resolution, and fluorescence was detected. The images were then saved as a 16-bit 
Tagged image file (TIF) format (Figure 5.2). Any sample that shows spot merging of Cy5-
biotin-BSA channels was re-assayed afresh. 
 
 
SGY-1/ GAGE4 SRC POU5F1 
SILV GAGE5 CALM1 NANOG 
SPAG9 GAGE6 CDC25A BORIS B0 
SPANXA1 GAGE7 CREB1 DPPA4 
SPANXB1 GRWD1 CTNNB1 DPPA3 
SPANXC HORMAD1 p53 S6A GDF3 
SPANXD LDHC p53 C141Y CTAG2 / LAGE-1b / LAGE-1L 
SPO11 LEMD1 p53 S15A CAMEL 
SSX1 LIPI p53 T18A p53 S392A 
SSX2a MAGEA1 p53 Q136X MAGEA2 
SSX4 MAGEA10 p53 S46A SYCP1 




         Figure 5.1. Layout of CT100+ microarray with each slide printed in a 4-plex format which is further subdivided into 8 subarrays  
.  




5.2.7.  Data extraction from TIFF images 
 
The TIFF files generated from scanning were inspected visually inspection as a form of 
preliminary quality assessment. The triplicate BSA spots at 5, 10, and15 μg/ml were confirmed 
to be visibly present within each subarray of the microarray. Human IgG which detected by 
fluorescently labelled secondary antibody as well as human anti-IgG which were detected only 
on the addition of plasma or serum to the slide were employed as positive controls to evaluate 
image signal intensity. Each microarray was further visually assessed for high background, 
presence of interfering dust particles, excessive speckling, and evidence of protein spot 
coalescing; and such slides were excluded. If any of the microarrays demonstrated the 
aforementioned properties, the assay was repeated form the sera in a fresh slide until the anomaly 
is corrected. Array-Pro 4.5 (Media Cybernetics, Inc., Maryland, USA) was used for data 
extraction. A grid with the identity of each antigen and control was positioned such that it 
encircled each control and antigen on the TIFF image. Further protocol for TIFF image data 
extraction is documented in Section 2.4.4. Once the data was extrapolated by the ArrayPro 
Analyzer Software version 4.5 (Media Cybernetics, Inc, Maryland, USA), it was filtered and 
normalized using an in-house developed software (CT100+ programme) with additional data 
analysis. 
5.2.8. CT100+ programme and data normalization 
 
One of the main goals of the CT100+ programme was to resolve some of the bottlenecks of 
normalization, class comparison and qualitative clustering of protein microarray data. The 
current programme developed in-house [278]  aims to address various parameters as discussed 
herein. For quality control, technical variations between triplicate signals from spot to spot 
should be identical. Multiple spots may bleed into each other due to proximity of the spots as 
well as the use of the wrong buffer at a specific spot. Another issue is that the spotting pin may 
get stuck during print runs or due to wrong calibration and artefact formation due to inadequate 
cleaning of print-heads between runs. Homogeneous pixel intensity is expected from individual 
spot signals across spot surface. Improper handling and storage conditions as well as pin height 
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errors may result in “doughnut effects”, high intensity spots, uneven spot intensity, and printed 
spot evaporation. Homogeneity was estimated by measuring the percentage mean intensity and 
coefficient of variation (CV) within a spot; and spots that fall short of the expected quality are 
repeated. 
5.2.9. Background signal intensity normalization and data filtering  
 
There should be minimal variation in the background signal across array spots. Improper 
handling, dust particles, poor storage and presence of artefacts can result in high background 
signal at a print spot. This reduction in signal to noise ratio (SNR) makes it difficult to identify 
genuine signals (net spot intensity) because there is no distinct difference in the intensity of the 
high background noise and the actual foreground signal intensity. For QC, only SNR of less than 
2 is acceptable for further statistical evaluation. Spots across the array should not contain 
saturated pixels as this can affect the scanner reading. When there is a faulty array the whole 
process of sample preparation, microarray printing and CT100+ assay is repeated. If this high 
signal still persists after repeat assays, automatic gain control (AGC) is used to ensure that the 
signal lies within the reference range of 200-65,550 RFU. If AGC signal is still too strong after 
this, the measurement may go into the non-linear range of the platform; hence the antigen is 
flagged automatically. The same scanner was used for all the slides throughout this study. 
Further QC was performed to filter out noise and array defects before bioinformatics evaluation. 
The data quality is improved by filtering because poor quality and disputable spot or arrays can 
be easily detected. Spots with saturation levels beyond our saturation cutoff were excluded from 
further analysis as well as triplicate spot intensity with high CV. When this occurs, the spot with 
the high intensity is excluded and analysis is carried out on the remaining two spots (S1 and S2). 
The variability is now defined by the equation (|S 1 − S 2|)/(S 1 + S 2). Before data analysis, 
normalization was carried out using a customized composite normalization method for antigen 
arrays. This method is robust enough to accommodate a relatively smaller number of positive 
controls to inter-spot and inter-array spot variation. An assumption that there is equal distribution 
of intensity in all positive controls across array was made. Based on this proviso, a combination 
of quantile normalization and total intensity normalization was carried out to eliminate 
systematic bias on the array. In the quantile normalization workflow, the Cy5-labelled positive 
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controls were assumed to share similar distribution across arrays. Through this distribution, 
baseline “house-keeping” intensities across arrays were defined. The data was then reorganized 
to accommodate outlier spots in the positive control dataset. In the total intensity normalization 
workflow, summation of all the positive controls on each array is presumed to be constant. If a 
“house-keeping” positive control spot intensity is deemed to be an outlier, this method of 
normalization ensures that the same spot is regarded as such across all arrays. 
5.2.10. Differential and linear statistical analysis 
 
Following the preprocessing statistical step with the CT100+ programme, spot intensities were 
compared between BPH, PCa, and DC groups and a set of top ranking antigens in each group 
using linear fold over cut-off differences in relation to the interquartile values per array for each 
group were identified. For differential expression and multivariate analysis, background-
corrected raw intensity data for the 67 samples were then loaded into the Perseus Software 
(version 1.4.0.20) followed by logarithmic normalization, data filtering and further analyses. 
Differentially expressed antigen between PCa, BPH and DC were identified (FDR = 0.01) using 
an independent sample t-test with Bonferroni correction for multiple testing. In addition, 
unsupervised hierarchical clustering was carried out to identify unique antigen signatures for 
PCa, BPH and DC. Multivariate testing, using principal component analysis (PCA) was also 
performed to see how the group clustered along each principal component. Unsupervised 
hierarchical clustering was also performed using k-mean clustering on Cluster (Version 3.0) 
software in conjunction with Java TreeView (version 3.0) software. Futhermore, the top ranking 
50 antigens were assessed with a 3-way Venn diagram plotted using the software known as 
Venny (as described earlier), a freely available Venn diagram plotting resource. Antigens unique 
to DC, PCa, and BPH were identified and compared with those identified by differential and 
linear expression analyses. The top ranking 20 antigens with the highest signal intensities in PCa, 
BPH and DC were also analysed. Racial variation in PCa antigen expression was examined and 
high ranking antigen expressions in Mixed Ancestry, Africans, and Caucasians in our PCa cohort 
were identified. The presence of potential antigen biomarkers of PCa was also confirmed in the 
previous shotgun urinary PCa proteomic data [319]. 
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5.2.11.  Functional pathway analysis 
 
Functional Pathway enrichment analyses of highly expressed antigen by differential expression, 
linear expression, and Venn diagram analysis were performed using the GeneMANIA software 
(http://www.genemania.org/), a free online gene interaction pathway analysis tool. Functionally 
enriched pathways and genes were then further confirmed using the STRING (version 9.1) 




5.3.  Results 
 
5.3.1. Linear analysis for potential biomarkers 
 
Given that most approaches to protein microarray analysis are modified from gene microarrays 
and considering that statistical methods for protein microarrays are currently evolving; absolute 
quantification of antigen for standardized comparison between different individuals can be quite 
challenging. A series of 67 patients’ sera were analyzed for autoantibody response to 123 
Antigens, composed primarily of a cocktail of CTAs and a few other TAAs. A union of all 
identified potential biomarkers by linear, Top 20, Venn diagram, and differential expression 
analysis yielded a total of 41 antigens with differential autoantibody response in our prostate 
cancer cohort (Table 5.3).  
S/N Potential PCa 
antigen Biomarkers 
Analyses High/ Low 
autoantibody 
titre in PCa 
Ethnic 
Distribution 
1. DPPA4  Differential  & Venn High MA 
2. CEACAM1 Isoform 1 Differential High CA 
3. NY-ESO-1 Differential & Top 20 High MA 
4. FGFR2 Differential, Venn & Shotgun High CA 
5. RAF Differential High MA 
6. ZNF165 Differential High  
7. TKTL1 (Isoform a) Differential High IA 
8. MAPK3 Differential & Top 20 High CA* 
9. CAMEL Differential & Top 20 High MA 
10. LDHC Differential , Venn & Top 20 High  
11. BORIS BO Venn High  
12. SPANXA1 Linear & Venn High MA 
13. ROPN1A Linear & Top 20 High MA* 
14. p53 S392A Venn High  
15. p53 L344P Differential High IA 
16. p53 C141Y Top 20 High MA 
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17. p53 K328R Differential High MA 
18. p53 S15A Linear & Top 20 Low MA* 
19. p53 T18A Top 20 High MA* 
20. CDK2 Differential High IA* 
21. MAGEA11 Differential High CA 
22. FES Differential & Top 20 High  
23. OIP5 Differential & Top 20 High MA* 
24. SSX2A Differential High  
25. GAGE5 Differential Low IA 
26. MAGEB5 Differential & Top 20 Low CA 
27. EGFR Differential Low  
28. CCDC33 Differential Low CA 
29. CSAG2 Differential & Venn Low CA 
30. DDX53 Differential & Venn Low IA 
31. CT47.11 Differential & Venn Low IA 
32. p53 Differential & Venn Low  
33. p53 Q136X Differential & Venn Low  
34. MAGEB6 Differential Low CA 
35. PBK Differential Low IA* 
36. CAML1 Shotgun High IA* 
37. COL6A1 Shotgun High IA* 
38. GAGE1 Linear & Top 20 High MA 
39. PRKCZ Linear & Top 20 High MA 
40. p53 S46A Linear & Top 20 low MA 
41 MAGEB1 Linear & Top 20 Low  
MA= Mixed Ancestry; IA= Indigenous African; CA= Caucasian African; S/N= Serial number; 
*=Significant 
   Table 5.3. List of 41 antigens with differential autoantibody response in prostate cancer using linear, differential and Venn diagram analysis. 
 
It was observed that the positive control sera showed reactivity to many of the antigens on the 
array (Figure 5.3), whereas the negative control sera showed no reactivity to antigens on the 
microarray (Figure 5.4).  
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                            Figure 5.3. Bar graph demonstrating that positive control sera showed reactivity to antigens on the array 
                   
                   Figure 5.4. Bar graph demonstrating that negative control sera showed no reactivity to antigens on the array 
The anti-c-myc-Cy3 assay was used to ensure that individual antigens were successfully 
immobilised to the array during printing (Figure 5.5). All spots demonstrated in Figure 5.5 are 
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not of the same intensity because all 123 recombinant proteins are expressed to different degrees 
in the insect lysate and biologic processes like rate of degradation is not similar for all proteins 
on this array. They are linked to biotin and cMyc (positive control) to confirm their presence on 
the array. Albeit all signals are not discernible by naked eyes, the signals of the apparently 
invisible spots are read off by the ArrayPro Analyzer software and scored. (a bar graph of the c-
Myc assay can be found in Annexure IV)  
     
                                       Figure 5.5. TIFF image showing successful immobilization of antigens on the array 
 
For prostate cancer samples, higher autoantibody titres were found to ROPN1, GAGE1, PRKCZ, 
and SPANXA1 relative to other antigens (Figure 5.6); while two mutant p53 antigens, p53 S46A 




           Figure 5.6. Radar plot showing ROPN1, PRKCZ, SPANXA1 and GAGE1 having higher autoantibody titer in prostate cancer 
 
              Figure 5.7. . Radar plot showing p53 S46A and p53 S15A having higher autoantibody titer in disease control sera 
MAGEB1 and PRKCZ were the antigens found to have the highest autoantibody titres in BPH 




        Figure 5.8. Radar plot showing MAGEB1 and PRKCZ having higher autoantibody titer in benign prostatic hyperplasia sera 
There was a general variation in mean autoantibody response to TAAs, observed between PCa, 
BPH and DC samples (Figure 5.9).  These highly differentially expressed autoantibodies were 
confirmed by ranking the autoantibody responses based on to their mean signal intensities and 
selecting the “top 20” intensities in each of the three categories for further analysis (Table 5.4). 
By using this approach, p53 S46A and SPANXA1 were not found for DC and PCa groups 
respectively, possibly due to the fact that this method focuses on the signal strength and not 




                        
                          Figure 5.9. Radar plot showing difference in autoantibody response signals between PCa, BPH and DC 
 
 PCa  BPH  DC  
Antigens  Mean Intensity Antigens  Mean Intensity Antigens  Mean Intensity 
PRKCZ  1048.3 PRKCZ  907.0 DDX53  813.5 
p53 S15A  938.8  MAGEB1  846.6 MAGEB1  778.1  
OIP5  849.1 GAGE2A  778.3 PRKCZ  757.3 
MAPK3  846.2 GAGE1  766.9 GAGE4  668.6 
MAGEB1  820.3  CCDC33  764.3 GAGE1  650.7 
NY-ESO-1  816.6 GAGE5  734.1  GAGE6  648.4 
ROPN1A  810.2 LEMD1  715.9  p53 S15A  616.0 
p53 C141Y  702.5 OIP5  686.0 OIP5  600.2  
P53 T18A  692.5 CTNNB1  625.9 MAPK3  598.9 
p53 S46A  692.0 GAGE7  612.5 MAGEB5  584.3 
LDHC  690.8 RAF  604.4 MAGEA2  583.7 
CDC25A  683.8 MAGEB5  591.6  PBK  570.5 
CTNNB1  678.2 MAGEA10  569.4 p53 Q136x  568.3 
CAMEL  665.2 GAGE6  558.6  CALM1  565.1 
GAGE1  653.9 CDC25A  555.1 LEMD1  560.5 
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p53 S6A  632.3 p53 S15A  551.1 MAGEB6  551.1 
XAGE3av1  632.0 p53 C141Y  535.9  MAGEA10  545.2 
GAGE6  629.7 CREB1  526.4 CT47.11  540.9 
FES  607.1 GAGE4  500.3 P53 T18A  532.4 
MAGEB5  600.1 MAGEA2  496.2 NY-ESO-1  529.9 
                                 Table 5.4. List of top ranking 20 antigens in PCa, BHP and DC by mean intensities 
A third method of linear analysis which does not have intensity components was carried using a 
three-way Venn diagram for the “top 50” autoantibody responses ranked by mean pixel intensity. 
This analysis revealed that 25 (50%) of the antigens were common to PCa, BPH and DC groups, 
9 (18%) of the antigens were only common to PCa and BPH. There were 6 (12%) antigens only 
common to BPH and DC, whilst only 4 (8%) antigens were common to PCa and DC. In total, 12 
(24%), 15 (28%), and 10 (20%) antigens were found unique to PCa, DC and BPH respectively 
(Figure 5.10). 
                                     
                              Figure 5.10. Three-way Venn diagram showing overlap in “Top 50” antigens by mean intensities 
Interestingly, 6 (50%) of the 12 antigens found unique to PCa were found highly expressed by 
linear and differential expression analyses. These 6 antigens were LDHC, FGFR2, SPANXA1, 
p53 S392A, DPPA4, and BORIS BO. Similarly CSAG2, which was one of the 10 antigens found 
unique to BPH, was also observed to be differentially expressed between PCa and BPH. Wild-
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type p53, DDX53, CT47.11 and p53 Q136X (a mutant p53) were found among the 15 antigens 
unique to DC (Table 5.5).  
 
                       Table.5.5. Venn diagram analysis showing autoantigens common to linear and differential analyses results 
 
5.3.2. Differential expression analysis for Potential biomarkers 
 
Perseus Software (version 1.4.0.20), Cluster (Version 3.0) and TreeView (Version 3.0) were 
employed for further bioinformatics analysis and visualization of the protein microarray data.  
Using an independent sample t-test with Bonferroni correction for multiple testing on the 
background corrected raw intensity data post-normalization; DPPA, NY-ESO-1, CEACAM1 
isoform1, GAGE5, P53 L344P, EGFR, MAGEB5, CSAG2 and CCDC33 were differentially 









Using the same test for PCA vs DC, 8 differentially expressed (±2SD) antigens were identified 
including; P53 L344P, GAGE5, DPPA4, wild-type p53, ZNF, RAF, CT47.11, and DDX53 
(Table 5.7).  
 
                                             Table 5.7. Differentially expressed antigens between PCa and DC by t-test 
Given that BPH is technically speaking, a form of disease control as well, all benign samples 
were further combined i.e. DC & BPH, and differentially expressed antigens between Benign 
and Malignant samples were explored. A total of 17 TAAs were found with higher autoantibody 
titres in PCa in comparison to benign conditions, whilst 6 antigens were found with lower 




                                         Table 5.8. Differentially expressed antigens between PCa and benign by t-test 
Initial unsupervised hierarchical clustering of all antigens using either Perseus or Cluster 
revealed moderate molecular signature overlap between DC, PCa, and BPH (Figure 5.11). This 
overlapping patter was also observed in multivariate testing using principal component analysis 
(PCA), which revealed that individuals in distinct groups clustered haphazardly with other 





                                 




Figure 5.12. Overlap in molecular signature by multivariate test using 1D (left) and 3D (right) principal component analysis [455] 
However, when the top ranking 10 TAAs with the highest autoantibody titres and presence in the 
20 PCa samples were analysed, distinct grouping patterns were identified for BPH, PCa, and DC 




Figure 5.13. 1D (top left), 2D (top right), and 3D (bottom) principal component analysis of top 10 TAAs with highest titres in PCa [455] 
 




For the hierarchical clustering analysis, 17 (85%) out of the 20 PCa patients clustered together, 
whilst two PCa patients (PC11 & PC2) clustered with DC and one PCa patient (PC15) clustered 
separately, albeit closer to the BPH clusters. The two PCa samples that clustered with DC were 
re-evaluated and observed to have relatively lower PSA levels than other PCa cases. PC15 had a 
very high PSA level (315ng/mL), in spite of a moderate total Gleason score of 6. All BPH 
samples clustered distinctly together, while 13 (86.7%) of the 15 DC samples clustered together. 
Two of the DC samples (DC5 & DC15) clustered with PCa. On re-assessment of these samples, 
DC5 was found to be of a younger age (34 years) and of Africa ethnicity (Black), however his 
PSA level was not available; DC15 was a 58 year old patient with a PSA level of 6.8ng/mL and 
of Mixed-Ancestry ethnicity. 
5.3.3. Racial variations in autoantibody response to potential TAA biomarkers 
 
To determine if there was any variation in autoantibody response to TAAs between PCa patients 
drawn from three major ethnicities of which our cohort was composed; differences in 
autoantibody response to TAAs between the racial groups were evaluated. There were 6 from 
Caucasian African (White), 3 samples from Indigenous African (Black), and 11 from Mixed-
Ancestry (Coloured) PCa patients. All the 41 potential antigens biomarkers were examined in 
our PCa patient cohort. We observed variation in autoantibody response to TAAs between the 
Caucasian African (PCa_C), Indigenous Africans (PCa_B) and Mixed Ancestry (PCa_M) 
prostate cancer patients (Figure 5.15).  
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Figure 5.15. Variations in autoantibody response to 41 candidate TAA biomarkers in Caucasian, African and Mixed-Ancestry PCa patients 
The mixed ancestry population had the highest autoantibody expression, which included DPPA4, 
NY-ESO-1, CAMEL, RAF, SPANXA1, GAGE1, ROPN1A, OIP5, PRKCZ and a subset of 
mutant p53 antigen including p53 T18A, p53 S15A, p53 S46A, p53 C141Y, and p53 K328R. 
From these 14 antigen, OIP5, p53 S15A, ROPN1A, and p53 T18A had the highest autoantibody 
response in PCa_M as compared with PCa_C or PCa_B. There were eight highly expressed 
autoantibodies for PCa_C in comparison to PCa_M or PCa_B, which included MAGEB6, 
CSAG2, MAGEB5, CCDC33, MAGEA11, FGFR2, MAKP3, and CEACAM1 Isoform 1. 
MAPK3 was found to be significantly more expressed in PCa_C as compared with others. Nine 
antigens were observed to have a higher autoantibody titer in PCa_B, which included PBK, 
DDX53, CT47.11, GAGE5, CALM1, COL6A1, CDK2, p53 L344P and TKTL Isoform a. 
Among these, COL6A1, PBK, CALM1 and CDK2 were found with the highest autoantibody 
titer in PCa_B.  
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5.3.4.  Functional pathway analysis of potential PCa antigen biomarkers 
 
The possibility of differentially expressed TAAs and CTAs being involved in a common or 
multiple biologic pathways was investigated to better understand and explore functional 
pathways in prostate cancer pathogenesis. Gene names or symbols for potential TAA biomarkers 
for prostate cancer were uploaded into GENEMANIA (http://www.genemania.org/) and 
bioinformatics enrichment analysis for the GO terms cellular component, molecular function and 
biological process was automatically carried out. Functionally clustering the “biological process” 
as the major Gene Ontology (GO) term for enrichment in the differentially expressed antigens 
revealed that they act via analogous signaling pathways involving: fibroblast growth receptor, Fc 
receptor, ERBB, epidermal growth factor receptor, neurotrophin, and ERK1/ERK2. These 6 
signaling pathways were found similar to the lists of differentially expressed antigen between 




                                                    Table 5.9. Top ranking biologic processes between PCa and DC 
 
When the antigens unique to PCa using the Venn diagram analysis were queried on 
GeneMANIA, cellular processes involved in reproduction were the major pathways involved 
(Table 5.11). Similarly, cellular process involved in reproduction was also one of the top 25 
pathways common to “PCa vs all controls”. To be able to determine whether this was the true 
picture at the protein expression level, we queried the same complement of genes using STRING 
(version 9.1) functional protein association network software.  
 




                                              Table 5.11. Top ranking biologic processes in PCa by Venn diagram analysis 
By this approach, similar molecular signaling pathways were found involved both at the gene 
and protein expression level. (Table 5.12).  
                                  Table 5.12. Top ranking biologic process top ranking TAA biomarkers using STRING software 
Network generated from STRING demonstrated that CDK2, TP53, PBK, MAPK3, EGFR and 
CEACAM1 were strongly linked TAAs by neighborhood evidence (Figure 5.16). Although 
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some CTAs were not observed to be interacting physically with this TAA network, the 
possibility of their co-expression or predicted linkage is plausible. Furthermore, CTAG1A, 
GAGE1, CTAG2 and SSX7 were observed to be linked by neighborhood evidence. Co-




                            Figure 5.16. STRING Protein network interaction between top ranking prostate cancer TAA 
 
5.3.5.  Verification of TAAs in urinary shotgun proteomics data 
 
The presence of TAA and CTA expression in urine of PCa patients in our cohort was assessed. 
Previously acquired urinary shotgun proteomics data [319] was assessed for  the presence of all 
antigens on the CT100+ antigen array. Of the 123 antigens on the array, only 11 (8.9%) antigens 
were found in the urine of prostate cancer patient in our cohort. These included MAPK1, 
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FGFR2, COL6A1, CALM1, SOX1, SRC, LIP1, CEACAM1 isoform 1, RELT, ITGB1 and 
EGFR (Table 5.13). Further focusing on antigens without splice variants in the shotgun data, 
only 5 (4.5%) antigens namely COL6A1, RELT, CALM1, FGFR2 and ITGB1 were found in this 
database.  
 
                                          Table 5.13. Verification of TAAs in shotgun urinary proteomics data 
Initial classification of the antigens identified based on their differential expression both in the 
shotgun proteomics experiment and on the cancer antigen array showed that out of these 5 
antigens, only FGFR2, COL6A1, and CALM1 demonstrated promise for use as biomarkers of 





5.4.  Discussion 
 
It is becoming evident that autoimmunity plays an important role in the process of 
carcinogenesis. Three plausible hypotheses for the origin of autoimmune response in cancer are: 
firstly, when cancer cells die, their content and membrane remnants are exposed,  driving an 
autoimmune response in the body; secondly, cancer cells may carry aberrant immunogenic 
glycoproteins on their membranes which are displayed as Major Histocompatibility Complex 
(MHC) I molecule for antigen presentation to cytotoxic T Cells; thirdly, cancer cells or the 
remnants thereof may be engulfed by macrophages or antigen presenting cells and displayed as 
MHC II molecules for antigen presentation to T-helper cells.  
In this study, a novel cancer antigen microarray platform was employed to evaluate serum 
autoantibodies to TAAs as potential biomarkers and immunotherapeutic targets for PCa in our 
South Africa cohort. Protein detection in serum ranges from fractions of a picogram to the gram 
range and on stimulation, their abundance can increase by as much as 10,000 folds. Owing to 
wide variations in the size and abundance of proteins present in serum [456], it is vital to 
evaluate the dynamic range and sensitivity of the microarray used in this study. Earlier protein 
microarray platforms were fraught by narrow dynamic range and low sensitivity for analytes of 
interest [457, 458]. However, remarkable improvement in dynamic range of newer protein 
microarrays and their sensitivity in the femtomolar range have increased their relevance [458]. 
Using a two-step linearity and dynamic range assay as described in previous work [277], a linear 
response in dynamic range of over 3 orders of magnitude was demonstrated. In addition, using a 
noise threshold of 2 standard deviations (of the background), a detection limit of ca. 1:1,000,000 
serum dilution was observed, which corresponded to an autoantibody titer of about 190pg/mL 
[277].  
Autoantibodies are more stable in serum than proteins or polynucleotides which may be rapidly 
degraded soon after their release by tumour cells [459].  Autoantibodies are capable of remaining 
in the blood long after the removal of antigenic stimulus [460], and they represent a promising 
measurable biosensor that can be correlated with different disease and health states; albeit we 
recognize the fact that autoantibody response between individuals is dynamic. Hence, 
measurement of autoantibody response to TAAs is a better approach than the direct measurement 
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of serum autoantigen.  Due the detection of a few of the arrayed TAAs in our previous shotgun 
urinary proteomics data, we assumed that it is plausible that an increased autoantibody titer may 
be indirectly associated with increased urinary expression of the autoantigen.  
Even though, the renal glomerular filtration barrier was anecdotally suggested to prevent the 
passage of macromolecules such as proteins due to a smaller pore size in comparison to serum 
protein size [461], there is overwhelming literature evidence for the presence of pathogen-
specific antigens in urine [313, 462-471]. Suggested barriers to protein filtration include pore 
size, charge selectivity, shape of protein and potential for downstream tubular reabsorption [472, 
473]. Although, it was reported that the human nephron size selectivity is about 50KDa [474]; 
the molecular weight of the overlapping TAAs detected in urine in this study ranged from 39-
140KDa. This alludes to the possibility of an alternative mechanism such as shape/ structure 
might explain their presence in urine. In addition, it is plausible that detected overlapping TAAs 
in urine from shotgun proteomics data may be short proteolytic fragments or “degradome” of 
longer proteins. Emerging evidence suggests that low molecular mass proteins/antigens are able 
to pass through this filtration barrier and are concentrated in the proximal tubule of the kidney 
[474]; and then sequestered in the renal lymph nodes and dendritic cells. Such antigens stimulate 
PDL1-mediated apoptosis of antigen presenting T-cell. Hence there is physiologic 
hyporesponsiveness, inactivation or clonal deletion of cytotoxic T-cells against circulating 
innocuous proteins/antigen [474-476]. It is therefore plausible that that the low overlap between 
serum and urinary antigen stems from a combination of lability of serum antigens, renal filtration 
barrier, dendritic cells/ renal lymph node sequestration, inter alia. It therefore seems reasonable 
that urinary cancer antigen testing, just like pathogen-specific antigen testing may become more 
routinely used in clinics for cancer diagnosis. 
Many antigens on our platform have been specifically documented to be dysregulated in PCa, 
albeit all are cancer-associated. For instance, promoter methylation of GAGE1 has been reported 
in PCa cell lines [477], while ROPN1 has been found to be expressed in a subset of acute 
myeloid leukemia (AML) patients [478]. SPANXA1 a member of the SPANX-A/D cluster of 
SPANX gene located on Xq27 [479] has been found highly expressed in cancer as well. 
Recently, a splice variant of PRKCZ has also been shown to be an emerging biomarker of 
malignant prostatic epithelium as well as PCa cell lines [480].  
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It is unclear why immunoreactivity of BPH sera to PRKCZ was high in our cohort; possibly 
indicating a malignant biotransformation potential of BPH. In addition, MAGEB1, which also 
had a high BPH sera immunoreactivity in our study was previously found to exhibit low 
immunoreactivity to PCa after administration of Lenalidomide (a thalidomide analogue) to PCa 
patients in a randomized phase II trial [481]. Generally p53 missence mutations were found more 
frequently in PCa and BPH sera, while wild-type p53 was found more commonly in DC. Two 
missence mutations p53 S15A and p53 S46A found in DC have been previously reported to be 
responsible for inactivation of constitutive phosphorylation of p53 [482] and dysregulation of 
apoptotic target genes, cell cycle, senescence as well as suppression of ERK activation [483, 
484], respectively. Phosphorylation of p53 S46 appears to be important for maintaining genomic 
stability of cells after DNA damage and its high autoantibody response in our DC sera may 
indicate that a follow-up should be directed at patients who, despite presenting with symptom of 
prostate disease, screened negative histopathologically. There is evidence that anti-p53 (auto) 
antibodies isolated from cancer patients are sometimes unable to recognize wild-type p53; and 
most commercial antibodies and vaccines are directed to the p53 terminal domain epitopes which 
is similar in both wild-type and mutant p53 rather than the “core” DNA-binding domain where 
most of the mutations occur [485]. These observations support the idea that differential signals to 
p53 variants on our array are real. We found considerable overlap between potential antigen 
biomarkers of PCa identified by different analyses, notably BORIS BO which was unique to PCa 
in our 3-way Venn diagram analysis has been reported recently to correlate at mRNA level with 
prostate cancer aggression and is potentially able to activate the androgen receptor genes [453].  
Class comparison of differentially expressed antigens in this study showed that DPPA4, a 
nuclear chromatin associated embryonic stem cell protein was more upregulated in PCa sera 
compared to BPH and DC. Expression of DPPA4 has been reported in PCa cell lines but its role 
in somatic cancer is largely unknown [486]. Higher titer of NY-ESO-1 antigen in PCa serum in 
comparison to BPH and DC demonstrates that this antigen which is known to generate 
autoantibody response in many human cancers, could be a part of diagnostic antigen biomarker 
panel for PCa. We found the autoantibody response to CSAG2 antigen to be lower in our PCa 
sera in comparison to BPH, albeit previous reports did not find any difference in CSAG2 gene 
expression between PCa and normal prostate tissue [454]. GAGE5 antigen which had a low 
expression in our PCa sera compared to BPH and DC was reported not to be significantly 
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expressed by SKOV-3 human ovarian cancer cell lines [487]. Differential antigen expression 
detected in this study represents a potential niche for diagnostic biomarker and PCa 
immunotherapeutic target detection for African populations.  
Variation in antigen expression was observed here between indigenous African, Mixed Ancestry 
and Caucasian PCa patients in our cohort. Notably, ROPN1A, OIP5 and two mutant p53 
antigens (S15A & T18A) were highly expressed in PCa patients of Mixed Ancestry origin. 
Mutation of Thr18 to alanine in p53 using site-directed mutagenesis has been reported to result 
in the reduction of thioredoxin reductase expression, DNA damage, increased expression of p21, 
and increased production of reactive oxygen species [488]. In a report by Lee et al [489], OIP5 
has been described as a targetable CTA for colon and gastric cancer using cell lines and cancer 
tissues. MAPK3 was found to be significantly highly expressed in Caucasian patients in our 
cohort in comparison to Indigenous Africans or Mixed Ancestry PCa patient. We observed that 
CSAG2, even though previously reported to be highly expressed in prostate cancer [450], was 
generally higher in our BPH as compared with PCa sera. However, focusing on our PCa data 
alone we observed that CSAG2 was higher in the Caucasian sera, as compared with other racial 
groups. This difference is possibly due to the population from which these samples were drawn 
and the fact that formalin fixed paraffin embedded (FFPE) sections were used in previous studies 
[450]. In addition, our cohort may not be large enough to conclude that CSAG2 is lower in 
African PCa patients as compared to their Caucasian counterparts. Hence, this observation 
warrants further studies using samples drawn from Africa PCa patients’ populations. We also 
found COL6A1, CALM1, PBK and CDK2 to be highly expressed in Indigenous Africa PCa 
patients in comparison to Caucasian and Mixed Ancestry PCa patients in our cohort. PBK and 
CSAG were found to correlate significantly with histopathologic progression using Gleason’s 
score in the same study [450]. Taking advantage of racial variation in TAA antigen expression 
may be a plausible approach to PCa theranostics in the future.  
It was evident from pathway analysis that the strong link between CDK2, MAPK3, EGFR, 
CEACAM1, PBK, OIP5, FGFR and TP53 seem to play crucial roles in the pathogenetic 
mechanism of PCa development. In addition, other networks such as CTAG2, GAGE1, SSX7 
and CTAG1A; as well as TKTL1 and LDHC need further study vis-à-vis PCa pathogenesis. It is 
also noteworthy that some of the potential serological TAA biomarkers of PCa were also 
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identified in our previous urinary shotgun discovery proteomics data [319]. This observation 
makes sense because the majority of our potential urinary biomarkers were predicted membrane 
and intercellular matrix/space proteins and the process of cancer development involves 
disruption of cell-cell contact and discohesive tendencies of the normal prostate epithelial 
architecture. 
 As demonstrated in a previous study using CT100+ cancer antigen array platform [277], results 
generated were comparable to an independently generated ELISA assay. Hence, an interesting 
approach to antigen array result validation is to use a multiplexed mini-array of fully validated 
biomarker subsets for in-vitro clinical immunodiagnostics. A panel of antigens on the full array 
to which autoantibody response is found can be miniaturized for point-of-care (POC) 
diagnostics. Such mini arrays have been previously used for confirmatory identification of 
differential autoantibody response signature for Hepatocellular [490], Ovarian [491], Breast 
[492], and Colon [493] cancer. The cohort of differential autoantibody response signature 
discovered for prostate cancer in the current study could serve as a primer for its 
immunodiagnostic mini-array fabrication. 
In this study, potential serologic diagnostic biomarkers and immunotherapeutic targets for PCa 
were explored in sub-Saharan Africa (SSA), a sub-continent where infection plays a pivotal role 
in cancer pathogenesis [494, 495]. It is envisaged that cancer vaccination would play an 
important role in reduction of the cancer burden in SSA. Emerging cancer immunotherapy 
techniques such as checkpoint blocking antibodies [496] and genetically engineered T-cells 
[497] are beginning to take center stage, although great attention needs to be paid to possible side 
effects of their use. There are various novel vaccination-based therapies currently in the pipeline 
for different stages of PCa [498], but several bottlenecks need to be addressed to bring these to 
routine clinical utility [10]. This study serves as a foundation for further immunological prostate 
cancer theranostic research in Africa and development of point-of-care (POC) tools for timely 





CHAPTER 6: CONCLUSION AND RECOMMENDATIONS 
 
This study provides better insight into various aspects of prostate cancer biology, diagnosis and 
treatment in Southern African subjects using proteomics methodologies. Without fractionation, 
this study identified close to 1,800 protein groups, which is close to some of the largest urinary 
proteome coverages identified in Western studies (even with fractionation) [322]. Even though, 
no study so far has directly proved the causal relationship between prostate cancer and BPH, 
studies have shown that BPH often co-exist with PCa at diagnosis and increases the potential for 
diagnosis of incidental cancers [499]. In a 27 year Danish follow-up study of over 3 million men, 
BPH was found to increase the risk of PCa incidence and mortality by up to three and eight fold 
respectively [500], albeit the authors disclaimed causality relationship between the BPH and 
PCa. Other studies have suggested similar immunologic [501] and molecular [502] pathogenesis 
of BPH and PCa, but did not establish causality relationship between the two. The observation of 
proteomics overlap in this study provides further evidence for malignant biotransformation 
potential of BPH. The observed overlap may also point to the disparity between 
histopathological and molecular level of diagnosis; suggesting that treatment should not be solely 
based on histopathologic classification.  
Because of the vastness of its database, the Human Protein Atlas has been recommended as a 
very effective proteomics tool for biomarker discovery [414], clinical biomarker studies [503], 
and also an important tool for pathologic studies [413]. SRMAtlas on the other hand, has also 
been described as essential for in-silico prediction of the best target transitions for biomarker 
validation [504], because its database contains a compendium of MS-detectable transitions for a 
host of target peptides. In addition, SRMatlas has been found beneficial as adjunct in biomarker 
discovery and validation for various diseases [505-508]. More than half of the selected 
proteotypic peptides have been previously assayed, and have adequate information in the 
SRMAtlas database. This indicates that using SRMAtlas prior to definitive targeted validation is 
a reasonable target transition screening method.  
Even though, cancers due to environmental exposure are on the decrease in high-income nations, 
it is reported that such cancers are on the increase in low and middle income countries [509].  
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Chronic infection has been linked with cancer development and Africa bears a great burden of 
such infection-related cancers in comparison to other regions of the world [510-514]. Chronic 
infection is known to lead to the development of Burkitt’s lymphoma (EBV), Kaposi sarcoma 
(HHV8), hepatocellular carcinoma (HBV), gastric cancer (H.Pylori) and cervical cancer (HPV). 
In addition, Acquired Immunodeficiency Syndrome (HIV) has been known to be associated with 
the development of various cancers. It seems plausible that immunotherapy and vaccine 
development may play an important role in cancer control in Africa. Several studies have shown 
a link between infection to PCa [515-517], but none has established causal relationship yet.  
Similar to what was found in the urinary shotgun proteomics, some of the autoantibody 
signatures overlapped between BPH and PCa. For instance, PRKCZ which has been previously 
described as highly upregulated in PCa [480], was also detected as upregulated in BPH in this 
study. This further alludes to the potential precursor relationship between BPH and PCa. BORIS 
BO which we identified as a potential biomarker of PCa has been recently identified as a marker 
of androgen receptor activation as well as aggressive progression in prostate cancer [453]. High 
autoantibody titres to putative CTA biomarkers of PCa such as NY-ESO-1, DPPA4 and 
ROPN1A in this study indicate that our panel of differentially expressed autoantigen is reliable. 
In addition, the link between CDK2, MAPK3, EGFR, CEACAM1, PBK, OIP5, FGFR and TP53 
by functional network analysis needs further elucidation. These pathways seem to be highly 
related for prostate carcinogenesis in the African population. The higher autoantibody expression 
level to CTAs observed in the mixed ancestry population in comparison to men of African or 
Caucasian descent warrants further studies. 
This study identified novel non-invasive potential urinary and serological biomarkers of PCa in a 
heterogeneous cohort of South African patients. Draft physiologic and PCa-specific urinary 
proteomes were established for our South African cohort. Ethnic trends were identified in 
potential urinary and serologic biomarkers signatures which may ameliorate the development of 
ethnic-tailored biomarkers for PCa diagnosis and management in South Africa. Based on these 
preliminary findings, it is recommended that more global funding should be directed towards 
cancer research in Africa. Not least, further research should be directed towards understanding 
the potential role of prostate cancer immunotherapy in African patients. It is also suggested, that 
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Io
ns
 o
f 
a 
pa
rti
cu
la
r 
m
/z
 w
hi
ch
 a
re
 k
no
w
n 
as
 p
re
cu
rs
or
 i
on
 a
re
 f
ur
th
er
 s
el
ec
te
d 
fo
r 
fr
ag
m
en
ta
tio
n 
an
d 
da
ug
ht
er
/fr
ag
m
en
t/p
ro
du
ct
 io
ns
 a
re
 c
re
at
ed
 b
y 
hi
gh
er
 c
ol
lis
io
n 
en
er
gy
 d
is
so
ci
at
io
n 
(H
C
D
), 
co
lli
si
on
-in
du
ce
d 
di
ss
oc
ia
tio
n 
(C
ID
), 
ph
ot
od
is
so
ci
at
io
n,
 io
n-
m
ol
ec
ul
e 
re
ac
tio
n,
 o
r o
th
er
 fr
ag
m
en
ta
tio
n 
pr
oc
es
s. 
Th
e 
io
ns
 g
en
er
at
ed
 in
 th
is
 m
an
ne
r a
re
 th
en
 se
pa
ra
te
d 
an
d 
de
te
ct
ed
 in
 th
e 
ne
xt
 st
ag
e 
of
 m
as
s s
pe
ct
ro
m
et
ry
 (M
S2
). 
(P
ic
tu
re
 a
da
pt
ed
 fr
om
 h
ttp
://
pr
ot
eo
m
ic
sn
ew
s.b
lo
gs
po
t.c
o.
za
/) 
